PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25708226-3 2015 Olaparib, a highly potent PARP inhibitor, has recently been the approved for ovarian cancer therapy by the FDA and European commission in patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer with BRCA1 or BRCA2 mutations. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 26-30 25757679-0 2015 Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 18-24 25888415-0 2015 Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. olaparib 152-160 poly(ADP-ribose) polymerase 1 Homo sapiens 106-134 25888415-0 2015 Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. olaparib 152-160 poly(ADP-ribose) polymerase 1 Homo sapiens 136-140 25888415-1 2015 INTRODUCTION: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has been found to have therapeutic potential for treating cancers associated with impaired DNA repair capabilities, particularly those with deficiencies in the homologous recombination repair (HRR) pathway. olaparib 14-22 poly(ADP-ribose) polymerase 1 Homo sapiens 26-54 25888415-1 2015 INTRODUCTION: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has been found to have therapeutic potential for treating cancers associated with impaired DNA repair capabilities, particularly those with deficiencies in the homologous recombination repair (HRR) pathway. olaparib 14-22 poly(ADP-ribose) polymerase 1 Homo sapiens 56-60 25483710-0 2015 BRCA1, PARP1 and gammaH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. olaparib 107-115 poly(ADP-ribose) polymerase 1 Homo sapiens 7-12 25483710-0 2015 BRCA1, PARP1 and gammaH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. olaparib 107-115 poly(ADP-ribose) polymerase 1 Homo sapiens 7-11 25483710-1 2015 Olaparib (AZD-2281, Ku-0059436) is an orally bioavailable and well-tolerated poly(ADP-ribose) polymerase (PARP) inhibitor currently under investigation in patients with solid tumors. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 77-104 25483710-1 2015 Olaparib (AZD-2281, Ku-0059436) is an orally bioavailable and well-tolerated poly(ADP-ribose) polymerase (PARP) inhibitor currently under investigation in patients with solid tumors. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 106-110 25483710-1 2015 Olaparib (AZD-2281, Ku-0059436) is an orally bioavailable and well-tolerated poly(ADP-ribose) polymerase (PARP) inhibitor currently under investigation in patients with solid tumors. olaparib 10-18 poly(ADP-ribose) polymerase 1 Homo sapiens 77-104 25483710-1 2015 Olaparib (AZD-2281, Ku-0059436) is an orally bioavailable and well-tolerated poly(ADP-ribose) polymerase (PARP) inhibitor currently under investigation in patients with solid tumors. olaparib 10-18 poly(ADP-ribose) polymerase 1 Homo sapiens 106-110 25483710-1 2015 Olaparib (AZD-2281, Ku-0059436) is an orally bioavailable and well-tolerated poly(ADP-ribose) polymerase (PARP) inhibitor currently under investigation in patients with solid tumors. olaparib 20-30 poly(ADP-ribose) polymerase 1 Homo sapiens 77-104 25483710-1 2015 Olaparib (AZD-2281, Ku-0059436) is an orally bioavailable and well-tolerated poly(ADP-ribose) polymerase (PARP) inhibitor currently under investigation in patients with solid tumors. olaparib 20-30 poly(ADP-ribose) polymerase 1 Homo sapiens 106-110 25584654-4 2015 To demonstrate the proof of principle of this approach, we engineered NP formulations of two chemosensitizers, the PI3-kindase inhibitor wortmanin (Wtmn) and the PARP inhibitor olaparib. olaparib 177-185 poly(ADP-ribose) polymerase 1 Homo sapiens 162-166 25750175-5 2015 Very promising is also the observed improvement of PFS in recurrent OC in patients when combining cediranib with the PARP inhibitor olaparib without giving additional chemotherapy. olaparib 132-140 poly(ADP-ribose) polymerase 1 Homo sapiens 117-121 25878361-6 2015 This synthetic lethal approach, while rooted in ideas from invertebrate genetics, has been inspired most strongly by the successful use of PARP inhibitors, such as olaparib, in the clinic to treat BRCA defective cancers. olaparib 164-172 poly(ADP-ribose) polymerase 1 Homo sapiens 139-143 25884663-5 2015 Therefore, we assessed the radiosensitizing effect, and the underlying mechanism of combination treatment with PARP inhibitor olaparib and PI3K inhibitor PI-103 in BRCA-proficient TNBC cells. olaparib 126-134 poly(ADP-ribose) polymerase 1 Homo sapiens 111-115 25757679-1 2015 Olaparib (Lynparza ; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biologic activity in ovarian cancer as well as other solid tumors. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 42-48 25757679-1 2015 Olaparib (Lynparza ; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biologic activity in ovarian cancer as well as other solid tumors. olaparib 10-18 poly(ADP-ribose) polymerase 1 Homo sapiens 42-48 25757679-1 2015 Olaparib (Lynparza ; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biologic activity in ovarian cancer as well as other solid tumors. olaparib 21-28 poly(ADP-ribose) polymerase 1 Homo sapiens 42-48 25531448-2 2014 We show that targeting PARP by the small molecule inhibitors, Olaparib (AZD-2281) or PJ34, reduces proliferation and lowers the apoptotic threshold of GBM cells in vitro and in vivo. olaparib 62-70 poly(ADP-ribose) polymerase 1 Homo sapiens 23-27 25139258-0 2015 PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma. olaparib 15-23 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 25139258-2 2015 We have previously shown that the oncolytic adenovirus dl922-947 induces extensive DNA damage, therefore we hypothesized a synergistic antitumoral effect of the PARP inhibitor olaparib in association with dl922-947. olaparib 176-184 poly(ADP-ribose) polymerase 1 Homo sapiens 161-165 25531448-2 2014 We show that targeting PARP by the small molecule inhibitors, Olaparib (AZD-2281) or PJ34, reduces proliferation and lowers the apoptotic threshold of GBM cells in vitro and in vivo. olaparib 72-80 poly(ADP-ribose) polymerase 1 Homo sapiens 23-27 24826054-9 2014 Pro-caspase-3 and PARP degradation was induced by paclitaxel and enhanced by olaparib in a dose-dependent manner. olaparib 77-85 poly(ADP-ribose) polymerase 1 Homo sapiens 18-22 25028150-0 2014 Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells. olaparib 57-65 poly(ADP-ribose) polymerase 1 Homo sapiens 14-19 25028150-5 2014 We showed that responders are radiosensitized by Olaparib because their DSB-repair is switched to PARP1-dependent end-joining (PARP1-EJ), as evident by (i) the significant increase in the number of residual gammaH2AX foci following irradiation with 3Gy and treatment with Olaparib, (ii) the enhanced enrichment of PARP1 at the chromatin after 3Gy and (iii) the inhibition of end-joining activity measured by a specific reporter substrate upon Olaparib treatment. olaparib 49-57 poly(ADP-ribose) polymerase 1 Homo sapiens 98-103 25028150-5 2014 We showed that responders are radiosensitized by Olaparib because their DSB-repair is switched to PARP1-dependent end-joining (PARP1-EJ), as evident by (i) the significant increase in the number of residual gammaH2AX foci following irradiation with 3Gy and treatment with Olaparib, (ii) the enhanced enrichment of PARP1 at the chromatin after 3Gy and (iii) the inhibition of end-joining activity measured by a specific reporter substrate upon Olaparib treatment. olaparib 49-57 poly(ADP-ribose) polymerase 1 Homo sapiens 127-132 25028150-5 2014 We showed that responders are radiosensitized by Olaparib because their DSB-repair is switched to PARP1-dependent end-joining (PARP1-EJ), as evident by (i) the significant increase in the number of residual gammaH2AX foci following irradiation with 3Gy and treatment with Olaparib, (ii) the enhanced enrichment of PARP1 at the chromatin after 3Gy and (iii) the inhibition of end-joining activity measured by a specific reporter substrate upon Olaparib treatment. olaparib 49-57 poly(ADP-ribose) polymerase 1 Homo sapiens 127-132 25028150-5 2014 We showed that responders are radiosensitized by Olaparib because their DSB-repair is switched to PARP1-dependent end-joining (PARP1-EJ), as evident by (i) the significant increase in the number of residual gammaH2AX foci following irradiation with 3Gy and treatment with Olaparib, (ii) the enhanced enrichment of PARP1 at the chromatin after 3Gy and (iii) the inhibition of end-joining activity measured by a specific reporter substrate upon Olaparib treatment. olaparib 272-280 poly(ADP-ribose) polymerase 1 Homo sapiens 127-132 25028150-5 2014 We showed that responders are radiosensitized by Olaparib because their DSB-repair is switched to PARP1-dependent end-joining (PARP1-EJ), as evident by (i) the significant increase in the number of residual gammaH2AX foci following irradiation with 3Gy and treatment with Olaparib, (ii) the enhanced enrichment of PARP1 at the chromatin after 3Gy and (iii) the inhibition of end-joining activity measured by a specific reporter substrate upon Olaparib treatment. olaparib 272-280 poly(ADP-ribose) polymerase 1 Homo sapiens 127-132 25028150-5 2014 We showed that responders are radiosensitized by Olaparib because their DSB-repair is switched to PARP1-dependent end-joining (PARP1-EJ), as evident by (i) the significant increase in the number of residual gammaH2AX foci following irradiation with 3Gy and treatment with Olaparib, (ii) the enhanced enrichment of PARP1 at the chromatin after 3Gy and (iii) the inhibition of end-joining activity measured by a specific reporter substrate upon Olaparib treatment. olaparib 272-280 poly(ADP-ribose) polymerase 1 Homo sapiens 127-132 25028150-5 2014 We showed that responders are radiosensitized by Olaparib because their DSB-repair is switched to PARP1-dependent end-joining (PARP1-EJ), as evident by (i) the significant increase in the number of residual gammaH2AX foci following irradiation with 3Gy and treatment with Olaparib, (ii) the enhanced enrichment of PARP1 at the chromatin after 3Gy and (iii) the inhibition of end-joining activity measured by a specific reporter substrate upon Olaparib treatment. olaparib 272-280 poly(ADP-ribose) polymerase 1 Homo sapiens 127-132 25028150-6 2014 This is the first study which directly demonstrates the switch to PARP1-EJ in tumor cells and its contribution to the response to Olaparib as a radiosensitizer, findings which could widen the scope of application of PARPi in tumor therapy. olaparib 130-138 poly(ADP-ribose) polymerase 1 Homo sapiens 66-71 25286857-4 2014 Here, the high-resolution crystal structures of the human TNKS2 PARP domain in complex with 16 various PARP inhibitors are reported, including the compounds BSI-201, AZD-2281 and ABT-888, which are currently in Phase 2 or 3 clinical trials. olaparib 166-174 poly(ADP-ribose) polymerase 1 Homo sapiens 64-68 24650937-2 2014 PARP trapping is drug-specific, with olaparib exhibiting a greater ability than veliparib, whereas both compounds are potent catalytic PARP inhibitors. olaparib 37-45 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 24650937-5 2014 For camptothecin, both PARP inhibitors showed highly synergistic effects due to catalytic PARP inhibition, indicating the value of combining either veliparib or olaparib with topoisomerase I inhibitors. olaparib 161-169 poly(ADP-ribose) polymerase 1 Homo sapiens 23-27 24650937-6 2014 On the other hand, for temozolomide, PARP trapping was critical in addition to catalytic inhibition, consistent with the fact that olaparib was more effective than veliparib in combination with temozolomide. olaparib 131-139 poly(ADP-ribose) polymerase 1 Homo sapiens 37-41 24694947-1 2014 In preclinical and clinical studies, olaparib and veliparib are the most represented PARP inhibitors (PARPi), which mainly target homologous DNA damage repair pathway-deficient cancer cells. olaparib 37-45 poly(ADP-ribose) polymerase 1 Homo sapiens 85-89 25526472-7 2014 Following treatment with the PARP1 inhibitor olaparib, the viability of cells with different XRCC2 levels was determined; cell cycle distribution and apoptosis were analyzed using flow cytometry. olaparib 45-53 poly(ADP-ribose) polymerase 1 Homo sapiens 29-34 25374341-2 2014 This study aimed to translate that observation into a clinical trial to assess the efficacy and tolerability of olaparib, a PARP inhibitor, in patients with advanced Ewing sarcoma (EWS) progressing after prior chemotherapy. olaparib 112-120 poly(ADP-ribose) polymerase 1 Homo sapiens 124-128 25062913-5 2014 We show that Olaparib, but not Veliparib and HYDAMTIQ, is able to induce a specific conformational drift of the WGR domain of PARP-1, which stabilizes PARP-1/DNA complex through the locking of several salt bridge interactions. olaparib 13-21 poly(ADP-ribose) polymerase 1 Homo sapiens 126-132 25062913-5 2014 We show that Olaparib, but not Veliparib and HYDAMTIQ, is able to induce a specific conformational drift of the WGR domain of PARP-1, which stabilizes PARP-1/DNA complex through the locking of several salt bridge interactions. olaparib 13-21 poly(ADP-ribose) polymerase 1 Homo sapiens 151-157 25062913-6 2014 Fluorescence anisotropy assays support such a mechanism, providing the first experimental evidence that HYDAMTIQ, a potent PARP inhibitor with neuroprotective properties, is less potent than Olaparib to trap PARP-1/DNA complex. olaparib 191-199 poly(ADP-ribose) polymerase 1 Homo sapiens 208-214 25033374-5 2014 Maintenance therapy with olaparib, a poly ADP ribose polymerase inhibitor given post-platinum therapy for recurrent disease, has led to a prolongation in PFS, particularly, in patients with a BRCA mutation. olaparib 25-33 poly(ADP-ribose) polymerase 1 Homo sapiens 37-63 25120693-5 2014 The effect of AZD2281 on XRCC2 and PARP1 expression was investigated in the five cell lines using quantitative polymerase chain reaction and western blot analyses. olaparib 14-21 poly(ADP-ribose) polymerase 1 Homo sapiens 35-40 25144364-0 2014 Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib. olaparib 105-113 poly(ADP-ribose) polymerase 1 Homo sapiens 0-29 25144364-0 2014 Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib. olaparib 105-113 poly(ADP-ribose) polymerase 1 Homo sapiens 31-36 25144364-8 2014 ALDH+ cells from BRCA1-mutated HCC1937, which had the highest level of PARP1 overexpression, displayed resistance to olaparib, a specific PARP1 inhibitor. olaparib 117-125 poly(ADP-ribose) polymerase 1 Homo sapiens 71-76 25144364-8 2014 ALDH+ cells from BRCA1-mutated HCC1937, which had the highest level of PARP1 overexpression, displayed resistance to olaparib, a specific PARP1 inhibitor. olaparib 117-125 poly(ADP-ribose) polymerase 1 Homo sapiens 138-143 24770870-8 2014 Finally, the clinically relevant PARP inhibitors olaparib and veliparib also exhibited hypersensitivity in both pol beta(-/-) and Xrcc1(-/-) BER-deficient cells. olaparib 49-57 poly(ADP-ribose) polymerase 1 Homo sapiens 33-37 25074383-0 2014 The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2"-deoxycytidine lesions. olaparib 19-27 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 24895135-3 2014 In the present study we observed that the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and veliparib sensitize the myeloid leukemia cell lines ML-1 and K562, the ovarian cancer line PEO1, non-small cell lung cancer line A549, and a majority of clinical AML isolates, but not normal marrow, to TRAIL. olaparib 88-96 poly(ADP-ribose) polymerase 1 Homo sapiens 42-69 24895135-3 2014 In the present study we observed that the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and veliparib sensitize the myeloid leukemia cell lines ML-1 and K562, the ovarian cancer line PEO1, non-small cell lung cancer line A549, and a majority of clinical AML isolates, but not normal marrow, to TRAIL. olaparib 88-96 poly(ADP-ribose) polymerase 1 Homo sapiens 71-75 24521039-1 2014 We report the antitumor effects of nitric oxide (NO) releasing derivatives of the PARP-1 inhibitor olaparib (1). olaparib 99-107 poly(ADP-ribose) polymerase 1 Homo sapiens 82-88 24219164-4 2014 We evaluated the effect of a PARP Inhibitor (AZD2281) on the TE-series ESCC cell lines. olaparib 45-52 poly(ADP-ribose) polymerase 1 Homo sapiens 29-33 24625059-0 2014 Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells. olaparib 23-31 poly(ADP-ribose) polymerase 1 Homo sapiens 35-63 24625059-0 2014 Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells. olaparib 23-31 poly(ADP-ribose) polymerase 1 Homo sapiens 65-69 24625059-4 2014 We examined the anti-tumor activity of olaparib, a PARP inhibitor, and its correlation between the sensitivity and status of PTEN in endometrial cancer cell lines. olaparib 39-47 poly(ADP-ribose) polymerase 1 Homo sapiens 51-55 24625059-14 2014 CONCLUSIONS: Our results suggest that olaparib, a PARP inhibitor, is effective on certain endometrial cancer cell lines. olaparib 38-46 poly(ADP-ribose) polymerase 1 Homo sapiens 50-54 22454224-13 2014 CONCLUSIONS: This study has indicated for the first time that the PARP inhibitor olaparib has substantial antitumor and anticancer stem cell activity in breast cancer cell lines of nonfamilial origin. olaparib 81-89 poly(ADP-ribose) polymerase 1 Homo sapiens 66-70 22454224-1 2014 BACKGROUND: Although the poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor olaparib is known to have potent antitumor activity in BRCA-related breast cancer cells, a limited number of preclinical and clinical studies have shown antitumor activity of olaparib in non-BRCA-related breast cancer. olaparib 93-101 poly(ADP-ribose) polymerase 1 Homo sapiens 77-81 22454224-1 2014 BACKGROUND: Although the poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor olaparib is known to have potent antitumor activity in BRCA-related breast cancer cells, a limited number of preclinical and clinical studies have shown antitumor activity of olaparib in non-BRCA-related breast cancer. olaparib 268-276 poly(ADP-ribose) polymerase 1 Homo sapiens 77-81 24675890-6 2014 Furthermore, treatment of tumor cells with PARP1 inhibitor AZD2281 can compromise doxorubicin-induced PTEN suppression and enhance the inhibitory effect of doxorubicin. olaparib 59-66 poly(ADP-ribose) polymerase 1 Homo sapiens 43-48 24841718-5 2014 Significant correlation was found between ATM protein expression and sensitivity to the PARP inhibitor olaparib, with NUGC4 being the most sensitive. olaparib 103-111 poly(ADP-ribose) polymerase 1 Homo sapiens 88-92 24038812-0 2014 Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors. olaparib 46-54 poly(ADP-ribose) polymerase 1 Homo sapiens 30-34 24038812-3 2014 We evaluated the PARP inhibitor, olaparib, in combination with chemotherapy using in vitro and in vivo pediatric solid tumor models. olaparib 33-41 poly(ADP-ribose) polymerase 1 Homo sapiens 17-21 24145016-1 2013 Olaparib is an inhibitor of poly ADP ribose polymerase 1 (PARP-1). olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 28-56 24145016-1 2013 Olaparib is an inhibitor of poly ADP ribose polymerase 1 (PARP-1). olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 58-64 24070777-7 2013 Instead, we show that inhibiting repair of single-strand DNA breaks with the poly(ADP-ribose) polymerase (PARP) inhibitor, Olaparib, enhances nitrofuran toxicity in melanoma and neuroblastoma cells. olaparib 123-131 poly(ADP-ribose) polymerase 1 Homo sapiens 77-104 24222661-8 2013 Two key observations were made when estrogen levels were dropped: (i) the serum concentration of olaparib was significantly increased, resulting in sustained PARP inhibition at the tumor bed; and (ii) the homologous recombination pathway was compromised, as evidenced by decreased Rad51 protein expression and function. olaparib 97-105 poly(ADP-ribose) polymerase 1 Homo sapiens 158-162 24252502-5 2013 RESULTS: When ATM-depleted cells and their relative controls were treated with olaparib (a competitive PARP-1/2 inhibitor) and iniparib (a molecule originally described as a covalent PARP-1 inhibitor) a different response to the two compounds was observed. olaparib 79-87 poly(ADP-ribose) polymerase 1 Homo sapiens 103-109 24070777-7 2013 Instead, we show that inhibiting repair of single-strand DNA breaks with the poly(ADP-ribose) polymerase (PARP) inhibitor, Olaparib, enhances nitrofuran toxicity in melanoma and neuroblastoma cells. olaparib 123-131 poly(ADP-ribose) polymerase 1 Homo sapiens 106-110 23619942-6 2013 Olaparib (AZD2281, KU-0059436), as one of the best understood Poly-(ADP-ribose) polymerase (PARP) inhibitor targeting DNA repair mechanisms, caused more and more attention. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 62-90 23979918-6 2013 We found that the PARP inhibitor AZD2281 (olaparib) increased DNA damage, cell-cycle arrest, and apoptosis in nasopharyngeal carcinoma cells challenged with ionizing radiation or temozolomide. olaparib 33-40 poly(ADP-ribose) polymerase 1 Homo sapiens 18-22 23979918-6 2013 We found that the PARP inhibitor AZD2281 (olaparib) increased DNA damage, cell-cycle arrest, and apoptosis in nasopharyngeal carcinoma cells challenged with ionizing radiation or temozolomide. olaparib 42-50 poly(ADP-ribose) polymerase 1 Homo sapiens 18-22 23619942-0 2013 Olaparib: a promising PARP inhibitor in ovarian cancer therapy. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 22-26 24204199-7 2013 PARP1 inhibition with olaparib preferentially radiosensitized ERG-positive cells by a factor of 1.52 (+-0.03) relative to ERG-negative cells (P < .05). olaparib 22-30 poly(ADP-ribose) polymerase 1 Homo sapiens 0-5 23810467-0 2013 A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. olaparib 61-69 poly(ADP-ribose) polymerase 1 Homo sapiens 23-50 23619942-6 2013 Olaparib (AZD2281, KU-0059436), as one of the best understood Poly-(ADP-ribose) polymerase (PARP) inhibitor targeting DNA repair mechanisms, caused more and more attention. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 92-96 23619942-6 2013 Olaparib (AZD2281, KU-0059436), as one of the best understood Poly-(ADP-ribose) polymerase (PARP) inhibitor targeting DNA repair mechanisms, caused more and more attention. olaparib 10-17 poly(ADP-ribose) polymerase 1 Homo sapiens 62-90 23619942-6 2013 Olaparib (AZD2281, KU-0059436), as one of the best understood Poly-(ADP-ribose) polymerase (PARP) inhibitor targeting DNA repair mechanisms, caused more and more attention. olaparib 10-17 poly(ADP-ribose) polymerase 1 Homo sapiens 92-96 23619942-6 2013 Olaparib (AZD2281, KU-0059436), as one of the best understood Poly-(ADP-ribose) polymerase (PARP) inhibitor targeting DNA repair mechanisms, caused more and more attention. olaparib 19-29 poly(ADP-ribose) polymerase 1 Homo sapiens 62-90 23619942-6 2013 Olaparib (AZD2281, KU-0059436), as one of the best understood Poly-(ADP-ribose) polymerase (PARP) inhibitor targeting DNA repair mechanisms, caused more and more attention. olaparib 19-29 poly(ADP-ribose) polymerase 1 Homo sapiens 92-96 23315029-0 2013 Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. olaparib 78-86 poly(ADP-ribose) polymerase 1 Homo sapiens 63-67 23315029-1 2013 Olaparib (AZD2281) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor with antitumour activity in cancer patients with BRCA1/2 germline mutations and in patients with homologous recombination deficiency. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 30-57 23315029-1 2013 Olaparib (AZD2281) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor with antitumour activity in cancer patients with BRCA1/2 germline mutations and in patients with homologous recombination deficiency. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 59-63 23315029-1 2013 Olaparib (AZD2281) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor with antitumour activity in cancer patients with BRCA1/2 germline mutations and in patients with homologous recombination deficiency. olaparib 10-17 poly(ADP-ribose) polymerase 1 Homo sapiens 30-57 23315029-1 2013 Olaparib (AZD2281) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor with antitumour activity in cancer patients with BRCA1/2 germline mutations and in patients with homologous recombination deficiency. olaparib 10-17 poly(ADP-ribose) polymerase 1 Homo sapiens 59-63 23840564-7 2013 While wild type SLX4 and all the other variants fully rescued the sensitivity to mitomycin C (MMC), campthothecin (CPT), and PARP inhibitor (Olaparib) the p.W823* SLX4 mutant failed to do so. olaparib 141-149 poly(ADP-ribose) polymerase 1 Homo sapiens 125-129 23512992-0 2013 RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib. olaparib 73-81 poly(ADP-ribose) polymerase 1 Homo sapiens 58-62 23512992-3 2013 We found that cell lines sensitive to a novel oral PARP inhibitor, olaparib, had low levels of RAD51C expression using microarray analysis, and we therefore hypothesized that low expression of RAD51C may hamper the DNA repair process, resulting in increased sensitivity to olaparib. olaparib 67-75 poly(ADP-ribose) polymerase 1 Homo sapiens 51-55 23512992-3 2013 We found that cell lines sensitive to a novel oral PARP inhibitor, olaparib, had low levels of RAD51C expression using microarray analysis, and we therefore hypothesized that low expression of RAD51C may hamper the DNA repair process, resulting in increased sensitivity to olaparib. olaparib 273-281 poly(ADP-ribose) polymerase 1 Homo sapiens 51-55 24063698-0 2013 Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. olaparib 41-49 poly(ADP-ribose) polymerase 1 Homo sapiens 26-30 23634208-0 2013 A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. olaparib 98-106 poly(ADP-ribose) polymerase 1 Homo sapiens 75-80 23634208-7 2013 In a further screen for resistance to the clinical poly(ADP-ribose) polymerase (PARP) inhibitor olaparib we recovered multiple Parp1 mutants. olaparib 96-104 poly(ADP-ribose) polymerase 1 Homo sapiens 51-78 23634208-7 2013 In a further screen for resistance to the clinical poly(ADP-ribose) polymerase (PARP) inhibitor olaparib we recovered multiple Parp1 mutants. olaparib 96-104 poly(ADP-ribose) polymerase 1 Homo sapiens 80-84 23634208-7 2013 In a further screen for resistance to the clinical poly(ADP-ribose) polymerase (PARP) inhibitor olaparib we recovered multiple Parp1 mutants. olaparib 96-104 poly(ADP-ribose) polymerase 1 Homo sapiens 127-132 23634208-8 2013 Our results show that olaparib toxicity to normal cells is mediated predominantly via Parp1, and suggest that the clinical side effects of olaparib may be on target. olaparib 22-30 poly(ADP-ribose) polymerase 1 Homo sapiens 86-91 23275151-5 2013 Drug combination experiments revealed that two distinct PARP inhibitors, olaparib and veliparib, not only potentiated the cell killing by cisplatin but also conferred cytotoxicity as a single agent specifically in ERCC1-low HCC827 and PC9 but not in ERCC1-high A549 and H157 lung cancer cells. olaparib 73-81 poly(ADP-ribose) polymerase 1 Homo sapiens 56-60 23399959-4 2013 METHODS: We assessed clonogenic survival of 16 NSCLC cell lines in response to cisplatin, mitomycin C (MMC), and the PARP inhibitor olaparib. olaparib 132-140 poly(ADP-ribose) polymerase 1 Homo sapiens 117-121 23730208-6 2013 The effect of the drugs 4-methylthio-2-oxobutyric acid (MTOB) and poly(ADP-ribose) polymerase (PARP) inhibitor Olaparib on CtBP2 wild-type and knockdown cell lines was examined using methylthiazol tetrazolium assays and an xCELLigence System. olaparib 111-119 poly(ADP-ribose) polymerase 1 Homo sapiens 95-99 23917378-2 2013 PARP1 inhibitors [AZD2281 ; ABT888 ; NU1025 ; AG014699] interacted with CHK1 inhibitors [UCN-01 ; AZD7762 ; LY2603618] to kill mammary carcinoma cells. olaparib 18-25 poly(ADP-ribose) polymerase 1 Homo sapiens 0-5 24063698-1 2013 INTRODUCTION: This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADPribose) polymerase (PARP) inhibitor, in combination with paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). olaparib 84-92 poly(ADP-ribose) polymerase 1 Homo sapiens 108-134 24063698-1 2013 INTRODUCTION: This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADPribose) polymerase (PARP) inhibitor, in combination with paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). olaparib 84-92 poly(ADP-ribose) polymerase 1 Homo sapiens 136-140 22761336-5 2012 Overexpression of miR-96 decreased the efficiency of homologous recombination and enhanced sensitivity to the PARP inhibitor AZD2281 in vitro and to cisplatin both in vitro and in vivo. olaparib 125-132 poly(ADP-ribose) polymerase 1 Homo sapiens 110-114 23459506-6 2013 Novel targeted antiangiogenic agents (eg, bevacizumab), angiopoeitin inhibitors (eg, AMG 386), and poly ADP ribose polymerase inhibitors (eg, olaparib) are reviewed. olaparib 142-150 poly(ADP-ribose) polymerase 1 Homo sapiens 99-125 22875744-0 2012 Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. olaparib 91-99 poly(ADP-ribose) polymerase 1 Homo sapiens 76-80 22915751-7 2012 The PARP inhibitor olaparib alone attenuated tumor growth modestly; however, the combination of NVP-BKM120 and olaparib delayed tumor doubling to more than 70 days in the mouse model and more than 50 days in xenotransplants from human BRCA1-related tumors, suggesting that combined PI3K and PARP inhibition might be an effective treatment of BRCA1-related tumors. olaparib 111-119 poly(ADP-ribose) polymerase 1 Homo sapiens 291-295 22788971-5 2012 AREAS COVERED: Preclinical and clinical studies of Olaparib , the most investigated PARP inhibitor in ovarian cancer, are analyzed and discussed. olaparib 51-59 poly(ADP-ribose) polymerase 1 Homo sapiens 84-88 22788971-9 2012 PARP inhibition mediated by Olaparib in BRCA1 (breast cancer 1) and BRCA2 (breast cancer 2)-mutated and in sporadic ovarian cancer represents a promising field of investigation. olaparib 28-36 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 22926640-10 2012 A PARP inhibitor, olaparib, applied as maintenance treatment also improved PFS in platinum-sensitive relapsed ovarian cancer. olaparib 18-26 poly(ADP-ribose) polymerase 1 Homo sapiens 2-6 22759740-4 2012 PARP inhibitors exploit synthetic lethality to target DNA repair defects in hereditary breast and ovarian cancer.In recent clinical trials, EOC patients with BRCA mutations exhibited favorable responses to the PARP inhibitor olaparib compared with patients without BRCA mutations. olaparib 225-233 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 22759740-4 2012 PARP inhibitors exploit synthetic lethality to target DNA repair defects in hereditary breast and ovarian cancer.In recent clinical trials, EOC patients with BRCA mutations exhibited favorable responses to the PARP inhibitor olaparib compared with patients without BRCA mutations. olaparib 225-233 poly(ADP-ribose) polymerase 1 Homo sapiens 210-214 22759740-5 2012 Additionally, olaparib has been reported to augment the effects of cisplatin and carboplatin on recurrence-free survival and OS in mice bearing BRCA1/2-deficient tumors.Given that hereditary EOC with deleterious BRCA1/2 mutations and BRCAness sporadic EOC are profoundly susceptible to synthetic lethality with PARP inhibition, it is imperative to identify a population of EOC patients that is likely to respond to PARP inhibitors. olaparib 14-22 poly(ADP-ribose) polymerase 1 Homo sapiens 415-419 22404155-4 2012 Cell survival was assessed by colony formation assay after combination treatment with the PARP inhibitor AZD2281 and single fraction gamma-irradiation and carbon-ion irradiation (13 and 70 keV/mum [LET 13 and LET 70]). olaparib 105-112 poly(ADP-ribose) polymerase 1 Homo sapiens 90-94 21590367-0 2012 Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. olaparib 77-85 poly(ADP-ribose) polymerase 1 Homo sapiens 31-58 21590367-0 2012 Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. olaparib 77-85 poly(ADP-ribose) polymerase 1 Homo sapiens 60-64 21590367-0 2012 Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. olaparib 87-94 poly(ADP-ribose) polymerase 1 Homo sapiens 31-58 21590367-0 2012 Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. olaparib 87-94 poly(ADP-ribose) polymerase 1 Homo sapiens 60-64 23012300-6 2012 In particular, the substantial proportion of TNBC tumours associated with BRCA1 mutations is driving clinical research into the use of DNA-damaging agents such as platinums, as well as of potentiators of DNA damage such as the investigational agent iniparib and inhibitors of poly-ADP ribose polymerase such as olaparib. olaparib 311-319 poly(ADP-ribose) polymerase 1 Homo sapiens 276-302 22233320-4 2012 We report here crystal structures of human tankyrase 2 catalytic fragment in complex with a byproduct, nicotinamide, and with selective inhibitors of tankyrases (IWR-1) and PARPs 1 and 2 (olaparib). olaparib 188-196 poly(ADP-ribose) polymerase 1 Homo sapiens 173-186 22416035-2 2012 Here, we show that mantle cell lymphoma (MCL) cells deficient in both ATM and p53 are more sensitive to the PARP inhibitor olaparib than cells lacking ATM function alone. olaparib 123-131 poly(ADP-ribose) polymerase 1 Homo sapiens 108-112 22371451-11 2012 Olaparib inhibited PARP in PBMCs and tumor tissue, although PAR levels were less effectively inhibited when olaparib was used for a short duration. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 19-23 22145984-1 2012 Olaparib (AZD2281) is an orally active Poly(ADP-ribose) polymerase (PARP) inhibitor with favorable antitumor activity in advanced ovarian and breast cancers with BRCA1/2 mutations in Western (USA and European) studies. olaparib 10-17 poly(ADP-ribose) polymerase 1 Homo sapiens 39-66 22145984-1 2012 Olaparib (AZD2281) is an orally active Poly(ADP-ribose) polymerase (PARP) inhibitor with favorable antitumor activity in advanced ovarian and breast cancers with BRCA1/2 mutations in Western (USA and European) studies. olaparib 10-17 poly(ADP-ribose) polymerase 1 Homo sapiens 68-72 22496617-3 2012 Here, we used a PARP agent for positron emission tomography-computed tomography (PET-CT) imaging ((18)F-BO), which we developed based on the Olaparib scaffold using rapid bioorthogonal conjugation chemistries. olaparib 141-149 poly(ADP-ribose) polymerase 1 Homo sapiens 16-20 22706117-8 2012 After promising results of phase I and II trials with most commonly investigated PARP inhibitors--iniparib and olaparib--which recruited patients with triple negative breast cancer and ovarian cancer, further studies started. olaparib 111-119 poly(ADP-ribose) polymerase 1 Homo sapiens 81-85 22524618-2 2012 PARP inhibitors such as olaparib (KU-0059436, AZD-2281) enhance tumor sensitivity to radiation and to topoisomerase I inhibitors like camptothecin (CPT). olaparib 24-32 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 22524618-2 2012 PARP inhibitors such as olaparib (KU-0059436, AZD-2281) enhance tumor sensitivity to radiation and to topoisomerase I inhibitors like camptothecin (CPT). olaparib 34-44 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 22524618-2 2012 PARP inhibitors such as olaparib (KU-0059436, AZD-2281) enhance tumor sensitivity to radiation and to topoisomerase I inhibitors like camptothecin (CPT). olaparib 46-54 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 22524618-3 2012 Olaparib is an orally bioavailable inhibitor of PARP-1 and PARP-2 that has been tested in multiple clinical trials. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 48-54 22524618-17 2012 The combination of olaparib and CPT had a stronger radiosensitizing effect, indicating that combining a PARP inihibitor with a topoiomerase I inhibitor could be promising for clinical radiosensitization. olaparib 19-27 poly(ADP-ribose) polymerase 1 Homo sapiens 104-108 22145984-1 2012 Olaparib (AZD2281) is an orally active Poly(ADP-ribose) polymerase (PARP) inhibitor with favorable antitumor activity in advanced ovarian and breast cancers with BRCA1/2 mutations in Western (USA and European) studies. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 39-66 22145984-1 2012 Olaparib (AZD2281) is an orally active Poly(ADP-ribose) polymerase (PARP) inhibitor with favorable antitumor activity in advanced ovarian and breast cancers with BRCA1/2 mutations in Western (USA and European) studies. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 68-72 22343925-3 2012 Many of the best-known inhibitors, including TIQ-A, 6(5H)-phenanthridinone, olaparib, ABT-888 and rucaparib, bound to several PARP family members, suggesting that these molecules lack specificity and have promiscuous inhibitory activity. olaparib 76-84 poly(ADP-ribose) polymerase 1 Homo sapiens 126-130 22134241-3 2011 Thus, we hypothesized that inhibition of HRR (mediated by Chk1 via AZD7762) and PARP1 [via olaparib (AZD2281)] would selectively sensitize p53 mutant pancreatic cancer cells to radiation. olaparib 101-108 poly(ADP-ribose) polymerase 1 Homo sapiens 80-85 24451760-4 2012 The antiangiogenic antibody bevacizumab and the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib have recently been shown to improve progression-free survival of patients with ovarian cancer with better hazard ratios in certain groups than have been seen previously. olaparib 94-102 poly(ADP-ribose) polymerase 1 Homo sapiens 48-76 24451760-4 2012 The antiangiogenic antibody bevacizumab and the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib have recently been shown to improve progression-free survival of patients with ovarian cancer with better hazard ratios in certain groups than have been seen previously. olaparib 94-102 poly(ADP-ribose) polymerase 1 Homo sapiens 78-82 21926160-5 2012 Cells lacking REV3 were hypersensitive to agents that cause DSBs including the PARP inhibitor, olaparib. olaparib 95-103 poly(ADP-ribose) polymerase 1 Homo sapiens 79-83 22134241-3 2011 Thus, we hypothesized that inhibition of HRR (mediated by Chk1 via AZD7762) and PARP1 [via olaparib (AZD2281)] would selectively sensitize p53 mutant pancreatic cancer cells to radiation. olaparib 91-99 poly(ADP-ribose) polymerase 1 Homo sapiens 80-85 21613406-6 2011 Consistent with a role for the BER pathway, the poly(ADP-ribose) polymerase (PARP) inhibitors ABT-888 (veliparib) and AZD2281 (olaparib) markedly synergized with FdUrd but not with 5-FU in ovarian cancer cell lines. olaparib 118-125 poly(ADP-ribose) polymerase 1 Homo sapiens 77-81 22180407-2 2011 From the initial proof of concept study with the PARP1 inhibitor olaparib (AZD2281) in BRCA mutation carriers, in which 28% of ovarian cancer patients achieved an objective response, the target population of ovarian patients potentially sensitive to treatment with PARP inhibitors has greatly increased. olaparib 65-73 poly(ADP-ribose) polymerase 1 Homo sapiens 49-54 22180407-2 2011 From the initial proof of concept study with the PARP1 inhibitor olaparib (AZD2281) in BRCA mutation carriers, in which 28% of ovarian cancer patients achieved an objective response, the target population of ovarian patients potentially sensitive to treatment with PARP inhibitors has greatly increased. olaparib 65-73 poly(ADP-ribose) polymerase 1 Homo sapiens 49-53 22180407-2 2011 From the initial proof of concept study with the PARP1 inhibitor olaparib (AZD2281) in BRCA mutation carriers, in which 28% of ovarian cancer patients achieved an objective response, the target population of ovarian patients potentially sensitive to treatment with PARP inhibitors has greatly increased. olaparib 75-82 poly(ADP-ribose) polymerase 1 Homo sapiens 49-54 22180407-2 2011 From the initial proof of concept study with the PARP1 inhibitor olaparib (AZD2281) in BRCA mutation carriers, in which 28% of ovarian cancer patients achieved an objective response, the target population of ovarian patients potentially sensitive to treatment with PARP inhibitors has greatly increased. olaparib 75-82 poly(ADP-ribose) polymerase 1 Homo sapiens 49-53 21777194-3 2011 Recent proof-of-concept clinical studies have demonstrated the safety and substantial antitumor activity of the PARP inhibitor, olaparib in BRCA1/2 mutation carriers, highlighting the wide therapeutic window that can be achieved with this synthetic lethal strategy. olaparib 128-136 poly(ADP-ribose) polymerase 1 Homo sapiens 112-116 21825006-0 2011 Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. olaparib 24-32 poly(ADP-ribose) polymerase 1 Homo sapiens 14-20 21825006-0 2011 Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. olaparib 34-41 poly(ADP-ribose) polymerase 1 Homo sapiens 14-20 21825006-5 2011 Here, we investigate whether olaparib, a potent PARP-1 inhibitor, enhances radiotherapy, not only by inhibiting DNA repair but also by changing tumor vascular hemodynamics in non-small cell lung carcinoma (NSCLC). olaparib 29-37 poly(ADP-ribose) polymerase 1 Homo sapiens 48-54 21862407-1 2011 BACKGROUND: Olaparib (AZD2281) is a small-molecule, potent oral poly(ADP-ribose) polymerase (PARP) inhibitor. olaparib 12-20 poly(ADP-ribose) polymerase 1 Homo sapiens 64-91 21862407-1 2011 BACKGROUND: Olaparib (AZD2281) is a small-molecule, potent oral poly(ADP-ribose) polymerase (PARP) inhibitor. olaparib 12-20 poly(ADP-ribose) polymerase 1 Homo sapiens 93-97 21862407-1 2011 BACKGROUND: Olaparib (AZD2281) is a small-molecule, potent oral poly(ADP-ribose) polymerase (PARP) inhibitor. olaparib 22-29 poly(ADP-ribose) polymerase 1 Homo sapiens 64-91 21862407-1 2011 BACKGROUND: Olaparib (AZD2281) is a small-molecule, potent oral poly(ADP-ribose) polymerase (PARP) inhibitor. olaparib 22-29 poly(ADP-ribose) polymerase 1 Homo sapiens 93-97 21884642-2 2011 Notably, phase II trials indicate that olaparib, an oral PARP inhibitor, has activity as a single agent in BRCA-related tumours, and that a combination of iniparib, an intravenous PARP inhibitor, and chemotherapy offers a survival advantage, compared with chemotherapy alone, in triple-negative breast cancer. olaparib 39-47 poly(ADP-ribose) polymerase 1 Homo sapiens 57-61 22184287-5 2011 Aim of this study is to determine the radiosensitizing properties of the PARP inhibitor Olaparib in childhood medulloblastoma, ependymoma and high grade glioma (HGG). olaparib 88-96 poly(ADP-ribose) polymerase 1 Homo sapiens 73-77 21956491-5 2011 Intracellular PARP activity was measured 2 h after incubation with AZD-2281 (500 nmol/l) and ABT-888 using a colorimetric PARP assay kit. olaparib 67-75 poly(ADP-ribose) polymerase 1 Homo sapiens 14-18 21956491-10 2011 Two hours after incubation of Raji cells with 500 nmol/l of AZD-2281 or ABT-888, the colorimetric PARP activity assay showed a reduction of 30.36% with ABT-888 and of 47.8% with AZD-2281. olaparib 60-68 poly(ADP-ribose) polymerase 1 Homo sapiens 98-102 21956491-12 2011 CONCLUSION: PARP inhibitors AZD-2281 and ABT-888 are highly radiosensitizing agents when used before external beam radiation and 131I-tositumomab. olaparib 28-36 poly(ADP-ribose) polymerase 1 Homo sapiens 12-16 22015278-8 2011 Early phase trials with efficacy endpoints have been presented for the PARP inhibitors AG014699, olaparib, veliparib, iniparib and MK4827. olaparib 97-105 poly(ADP-ribose) polymerase 1 Homo sapiens 71-75 21613406-6 2011 Consistent with a role for the BER pathway, the poly(ADP-ribose) polymerase (PARP) inhibitors ABT-888 (veliparib) and AZD2281 (olaparib) markedly synergized with FdUrd but not with 5-FU in ovarian cancer cell lines. olaparib 127-135 poly(ADP-ribose) polymerase 1 Homo sapiens 48-75 21613406-6 2011 Consistent with a role for the BER pathway, the poly(ADP-ribose) polymerase (PARP) inhibitors ABT-888 (veliparib) and AZD2281 (olaparib) markedly synergized with FdUrd but not with 5-FU in ovarian cancer cell lines. olaparib 127-135 poly(ADP-ribose) polymerase 1 Homo sapiens 77-81 21622034-0 2011 Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma. olaparib 79-87 poly(ADP-ribose) polymerase 1 Homo sapiens 62-68 21622034-1 2011 A bioanalytical assay for the new poly(ADP-ribose) polymerase-1 inhibitor olaparib in combination with melphalan was developed and validated. olaparib 74-82 poly(ADP-ribose) polymerase 1 Homo sapiens 34-63 21326243-3 2011 This study evaluated the optimally tolerated dose of olaparib (4-(3--4-fluorophenyl) methyl-1(2H)-one; AZD2281, KU0059436), a potent PARP inhibitor, with dacarbazine and assessed safety, toxicity, clinical pharmacokinetics and efficacy of combination treatment. olaparib 53-61 poly(ADP-ribose) polymerase 1 Homo sapiens 133-137 21504625-9 2011 Olaparib, another oral small-molecule PARP inhibitor, demonstrated encouraging single-agent activity in patients with advanced breast or ovarian cancer. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 38-42 21468130-5 2011 MANAGEMENT: On the basis of her sensitivity to repeated platinum treatment she was treated with the oral poly(ADP)-ribose polymerase (PARP) 1 inhibitor olaparib as part of a phase I trial. olaparib 152-160 poly(ADP-ribose) polymerase 1 Homo sapiens 105-141 21326243-3 2011 This study evaluated the optimally tolerated dose of olaparib (4-(3--4-fluorophenyl) methyl-1(2H)-one; AZD2281, KU0059436), a potent PARP inhibitor, with dacarbazine and assessed safety, toxicity, clinical pharmacokinetics and efficacy of combination treatment. olaparib 103-110 poly(ADP-ribose) polymerase 1 Homo sapiens 133-137 20676117-3 2010 With AZD2281 and BSI-201 entering phase III clinical trials, the final application of PARP inhibitors in clinic would come true soon. olaparib 5-12 poly(ADP-ribose) polymerase 1 Homo sapiens 86-90 21097693-7 2011 Furthermore, olaparib-treated tumors showed highly reduced PARP-1 activity that correlated with olaparib levels. olaparib 13-21 poly(ADP-ribose) polymerase 1 Homo sapiens 59-65 21097693-7 2011 Furthermore, olaparib-treated tumors showed highly reduced PARP-1 activity that correlated with olaparib levels. olaparib 96-104 poly(ADP-ribose) polymerase 1 Homo sapiens 59-65 21368455-7 2011 Consistent with these results, the PARP inhibitor olaparib(previously known as AZD2281)has shown promising single-agent activity against it in early clinical testing. olaparib 50-58 poly(ADP-ribose) polymerase 1 Homo sapiens 35-39 21368455-7 2011 Consistent with these results, the PARP inhibitor olaparib(previously known as AZD2281)has shown promising single-agent activity against it in early clinical testing. olaparib 79-86 poly(ADP-ribose) polymerase 1 Homo sapiens 35-39 21870276-4 2011 Recently, the powerful antitumor PARP inhibitor Olaparib was shown to be effective in blocking the progression of BRCA1/2-associated tumors, prompting Bruce Alberts to call for an expansion of cancer research beyond utilization of cancer cell lines to include model organisms, such as bacteria, yeast, worms, flies, and mice. olaparib 48-56 poly(ADP-ribose) polymerase 1 Homo sapiens 33-37 22073281-6 2011 We also assessed whether inhibition of poly(ADP)ribosyltransferase (PARP) by olaparib would enhance the killing effect. olaparib 77-85 poly(ADP-ribose) polymerase 1 Homo sapiens 68-72 22073281-11 2011 A triple strategy including siRNA and the PARP inhibitor olaparib further improved the killing effect of temozolomide. olaparib 57-65 poly(ADP-ribose) polymerase 1 Homo sapiens 42-46 20609468-1 2010 BACKGROUND: Olaparib is a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in homozygous BRCA-deficient cells. olaparib 12-20 poly(ADP-ribose) polymerase 1 Homo sapiens 47-74 20485165-3 2010 RECENT FINDINGS: Preclinical recognition that BRCA1 and BRCA2-associated tumours are very sensitive to inhibition of poly-ADP ribose polymerase (PARP), a key molecule in DNA repair, led to ovarian cancer patients with germline BRCA1 and BRCA2 mutations being treated with the PARP inhibitor olaparib (AZD2281, KU-0059436; KuDOS/Astra-Zeneca). olaparib 291-299 poly(ADP-ribose) polymerase 1 Homo sapiens 117-143 20485165-3 2010 RECENT FINDINGS: Preclinical recognition that BRCA1 and BRCA2-associated tumours are very sensitive to inhibition of poly-ADP ribose polymerase (PARP), a key molecule in DNA repair, led to ovarian cancer patients with germline BRCA1 and BRCA2 mutations being treated with the PARP inhibitor olaparib (AZD2281, KU-0059436; KuDOS/Astra-Zeneca). olaparib 291-299 poly(ADP-ribose) polymerase 1 Homo sapiens 145-149 20485165-3 2010 RECENT FINDINGS: Preclinical recognition that BRCA1 and BRCA2-associated tumours are very sensitive to inhibition of poly-ADP ribose polymerase (PARP), a key molecule in DNA repair, led to ovarian cancer patients with germline BRCA1 and BRCA2 mutations being treated with the PARP inhibitor olaparib (AZD2281, KU-0059436; KuDOS/Astra-Zeneca). olaparib 291-299 poly(ADP-ribose) polymerase 1 Homo sapiens 276-280 20485165-3 2010 RECENT FINDINGS: Preclinical recognition that BRCA1 and BRCA2-associated tumours are very sensitive to inhibition of poly-ADP ribose polymerase (PARP), a key molecule in DNA repair, led to ovarian cancer patients with germline BRCA1 and BRCA2 mutations being treated with the PARP inhibitor olaparib (AZD2281, KU-0059436; KuDOS/Astra-Zeneca). olaparib 301-308 poly(ADP-ribose) polymerase 1 Homo sapiens 117-143 20485165-3 2010 RECENT FINDINGS: Preclinical recognition that BRCA1 and BRCA2-associated tumours are very sensitive to inhibition of poly-ADP ribose polymerase (PARP), a key molecule in DNA repair, led to ovarian cancer patients with germline BRCA1 and BRCA2 mutations being treated with the PARP inhibitor olaparib (AZD2281, KU-0059436; KuDOS/Astra-Zeneca). olaparib 301-308 poly(ADP-ribose) polymerase 1 Homo sapiens 145-149 20485165-3 2010 RECENT FINDINGS: Preclinical recognition that BRCA1 and BRCA2-associated tumours are very sensitive to inhibition of poly-ADP ribose polymerase (PARP), a key molecule in DNA repair, led to ovarian cancer patients with germline BRCA1 and BRCA2 mutations being treated with the PARP inhibitor olaparib (AZD2281, KU-0059436; KuDOS/Astra-Zeneca). olaparib 301-308 poly(ADP-ribose) polymerase 1 Homo sapiens 276-280 20609467-0 2010 Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. olaparib 43-51 poly(ADP-ribose) polymerase 1 Homo sapiens 5-32 20609467-1 2010 BACKGROUND: Olaparib, a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor, induced synthetic lethality in BRCA-deficient cells. olaparib 12-20 poly(ADP-ribose) polymerase 1 Homo sapiens 45-72 20609467-1 2010 BACKGROUND: Olaparib, a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor, induced synthetic lethality in BRCA-deficient cells. olaparib 12-20 poly(ADP-ribose) polymerase 1 Homo sapiens 74-78 20609468-0 2010 Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. olaparib 43-51 poly(ADP-ribose) polymerase 1 Homo sapiens 5-32 20609468-1 2010 BACKGROUND: Olaparib is a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in homozygous BRCA-deficient cells. olaparib 12-20 poly(ADP-ribose) polymerase 1 Homo sapiens 76-80 18954712-3 2008 KU-0059436 (AZD2281) is a potent and nontoxic inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) undergoing a Phase II clinical trial as a single agent. olaparib 0-10 poly(ADP-ribose) polymerase 1 Homo sapiens 59-88 20406929-3 2010 Olaparib is a potent, oral PARP inhibitor that is well tolerated, with antitumor activity in BRCA1/2 mutation carriers. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 27-31 20233726-4 2010 In this study, we use an RNAi screen to identify genes that when silenced cause synthetic lethality with the PARP inhibitor AZD2281. olaparib 124-131 poly(ADP-ribose) polymerase 1 Homo sapiens 109-113 20049732-2 2009 Following on a recent paper that demonstrates the clinical application of this strategy (Fong et al, 2009), Chris Lord and Alan Ashworth further explore the approach and show that poly(ADP-ribose) polymerase (PARP) inhibitors such as Olaparib can selectively target cancer cells defective in phosphatase and tensin homologue (PTEN, Mendes-Pereira et al, 2009) and that methotrexate is selectively lethal to MutS-homologue-2 (MSH2)-deficient tumour cells (Martin et al, 2009). olaparib 234-242 poly(ADP-ribose) polymerase 1 Homo sapiens 180-207 20049732-2 2009 Following on a recent paper that demonstrates the clinical application of this strategy (Fong et al, 2009), Chris Lord and Alan Ashworth further explore the approach and show that poly(ADP-ribose) polymerase (PARP) inhibitors such as Olaparib can selectively target cancer cells defective in phosphatase and tensin homologue (PTEN, Mendes-Pereira et al, 2009) and that methotrexate is selectively lethal to MutS-homologue-2 (MSH2)-deficient tumour cells (Martin et al, 2009). olaparib 234-242 poly(ADP-ribose) polymerase 1 Homo sapiens 209-213 19632796-5 2009 Recent trials have shown the poly(ADP-ribosyl)ation polymerase (PARP) inhibitors BSI-201 and olaparib to be highly effective in TNBC and BRCA1/2-positive disease, respectively. olaparib 93-101 poly(ADP-ribose) polymerase 1 Homo sapiens 29-62 19632796-5 2009 Recent trials have shown the poly(ADP-ribosyl)ation polymerase (PARP) inhibitors BSI-201 and olaparib to be highly effective in TNBC and BRCA1/2-positive disease, respectively. olaparib 93-101 poly(ADP-ribose) polymerase 1 Homo sapiens 64-68 19671736-5 2009 The radiosensitizing effects of 17-AAG and the PARP inhibitor olaparib were assessed, and the underlying mechanisms explored. olaparib 62-70 poly(ADP-ribose) polymerase 1 Homo sapiens 47-51 19553641-2 2009 We conducted a clinical evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor. olaparib 48-56 poly(ADP-ribose) polymerase 1 Homo sapiens 99-103 19553641-2 2009 We conducted a clinical evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor. olaparib 58-65 poly(ADP-ribose) polymerase 1 Homo sapiens 99-103 19553641-13 2009 CONCLUSIONS: Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCA2 mutation. olaparib 13-21 poly(ADP-ribose) polymerase 1 Homo sapiens 92-96 18954712-3 2008 KU-0059436 (AZD2281) is a potent and nontoxic inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) undergoing a Phase II clinical trial as a single agent. olaparib 0-10 poly(ADP-ribose) polymerase 1 Homo sapiens 90-96 18954712-3 2008 KU-0059436 (AZD2281) is a potent and nontoxic inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) undergoing a Phase II clinical trial as a single agent. olaparib 12-19 poly(ADP-ribose) polymerase 1 Homo sapiens 59-88 18954712-3 2008 KU-0059436 (AZD2281) is a potent and nontoxic inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) undergoing a Phase II clinical trial as a single agent. olaparib 12-19 poly(ADP-ribose) polymerase 1 Homo sapiens 90-96 30152517-3 2019 In our study, it was found that PARP inhibitors talazoparib (BMN-673) and olaparib (AZD-2281) both had synergistic activity with the common first-line chemotherapeutic gemcitabine in a panel of lung cancer cell lines. olaparib 74-82 poly(ADP-ribose) polymerase 1 Homo sapiens 32-36 33803939-1 2021 The benefit of PARP inhibitor olaparib in relapsed and advanced high-grade serous ovarian carcinoma (HGSOC) is well established especially in BRCA1/2 mutation carriers. olaparib 30-38 poly(ADP-ribose) polymerase 1 Homo sapiens 15-19 33803939-6 2021 We identify genes previously associated with olaparib response (SLFN11, ABCB1), and discover novel candidate olaparib sensitivity genes with known functions including interaction with PARP1 (PUM3, EEF1A1) and involvement in homologous recombination DNA repair (ELP4). olaparib 109-117 poly(ADP-ribose) polymerase 1 Homo sapiens 184-189 33236159-0 2021 PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports. olaparib 70-78 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 18800822-4 2008 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2 H-phthalazin-1-one (KU-0059436, AZD2281) 47 is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines. olaparib 89-99 poly(ADP-ribose) polymerase 1 Homo sapiens 159-165 33970687-1 2021 PURPOSE: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved as maintenance therapy for patients with advanced pancreatic cancer (PC) and a germline BRCA1 or BRCA2 pathogenic variant (PV). olaparib 9-17 poly(ADP-ribose) polymerase 1 Homo sapiens 21-49 33970687-1 2021 PURPOSE: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved as maintenance therapy for patients with advanced pancreatic cancer (PC) and a germline BRCA1 or BRCA2 pathogenic variant (PV). olaparib 9-17 poly(ADP-ribose) polymerase 1 Homo sapiens 51-55 33769071-5 2021 Olaparib, an inhibitor of poly-ADP-ribose polymerase, has recently gained approval for the treatment of mCRPC harboring alterations in homologous recombination repair genes. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 26-52 30152517-3 2019 In our study, it was found that PARP inhibitors talazoparib (BMN-673) and olaparib (AZD-2281) both had synergistic activity with the common first-line chemotherapeutic gemcitabine in a panel of lung cancer cell lines. olaparib 84-92 poly(ADP-ribose) polymerase 1 Homo sapiens 32-36 23934192-4 2013 The high-throughput screens identified multiple clinical poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors, such as olaparib (AZD-2281), niraparib (MK-4827) and BMN 673, as being selective for ERCC1 deficiency. olaparib 124-132 poly(ADP-ribose) polymerase 1 Homo sapiens 57-93 24882434-1 2014 BACKGROUND: Maintenance monotherapy with the PARP inhibitor olaparib significantly prolonged progression-free survival (PFS) versus placebo in patients with platinum-sensitive recurrent serous ovarian cancer. olaparib 60-68 poly(ADP-ribose) polymerase 1 Homo sapiens 45-49 26485111-6 2015 Olaparib is the only PARP inhibitor approved by FDA in the treatment of patients with germline BRCA mutated advanced ovarian cancer pretreated with >=3 prior lines of chemotherapy. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 21-25 23934192-4 2013 The high-throughput screens identified multiple clinical poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors, such as olaparib (AZD-2281), niraparib (MK-4827) and BMN 673, as being selective for ERCC1 deficiency. olaparib 134-142 poly(ADP-ribose) polymerase 1 Homo sapiens 57-93 34812476-1 2022 Poly (ADP-ribose) polymerase (PARP) inhibitors, including olaparib, niraparib, rucaparib, talazoparib and veliparib, have emerged as one of the most exciting new treatments for solid tumors, particularly in patients with breast-related cancer antigen 1/2 mutations. olaparib 58-66 poly(ADP-ribose) polymerase 1 Homo sapiens 0-28 34473525-4 2022 Poly-ADP ribose polymerase inhibitors (olaparib and rucaparib) have demonstrated significant clinical benefit for patients harboring deleterious mutations in genes belonging to the homologous recombination repair pathway and have received Food and Drug Administration approval. olaparib 39-47 poly(ADP-ribose) polymerase 1 Homo sapiens 0-26 34732853-1 2022 BACKGROUND: The search for biomarkers to evaluate ovarian cancer (OC) homologous recombination (HR) function and predict the response to therapy is an urgent clinical need to improve the selection of patients who could benefit from platinum- and olaparib (poly-ADP ribose polymerase inhibitors, PARPi)-based therapies. olaparib 246-254 poly(ADP-ribose) polymerase 1 Homo sapiens 256-282 34954029-5 2022 Olaparib induced the feedback overexpression of PARP1, FOXM1, CDC25A, CCND1, CDK1, CCNA2, CCNB1, CDC25B, BRCA1/2 and Rad51 to promote the acceleration of cell mitosis and recovery of DNA repair, which caused the generation of adaptive resistance. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 48-53 34812476-1 2022 Poly (ADP-ribose) polymerase (PARP) inhibitors, including olaparib, niraparib, rucaparib, talazoparib and veliparib, have emerged as one of the most exciting new treatments for solid tumors, particularly in patients with breast-related cancer antigen 1/2 mutations. olaparib 58-66 poly(ADP-ribose) polymerase 1 Homo sapiens 30-34 34919531-5 2021 Our results showed that using a PARP inhibitor (olaparib or AG14361) alone significantly inhibited the proliferation of A2780 cells but negligibly inhibited the proliferation of SKOV3 cells. olaparib 48-56 poly(ADP-ribose) polymerase 1 Homo sapiens 32-36 34663950-6 2021 Whilst caveated by small sample size, this trend was maintained for PFS, but not overall survival, when adjusting for BRCA status across the olaparib and placebo treatment groups, a key driver of PARP inhibitor sensitivity. olaparib 141-149 poly(ADP-ribose) polymerase 1 Homo sapiens 196-200 34944835-5 2021 PARP inhibition with Olaparib also results in replication stress and ATR activation, and sensitises NB cells to ATR inhibition independently of MYCN status, with synergistic levels of cell death seen in MYCN expressing ATR- and PARP-inhibited cells. olaparib 21-29 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 34813314-7 2021 The advantages of III-16 over Olaparib suggest that dual PARP/BRD4 inhibitors are novel and promising agents for the treatment of advanced pancreatic cancer. olaparib 30-38 poly(ADP-ribose) polymerase 1 Homo sapiens 57-61 34880209-2 2021 Herein, we find that repression of the oncogenic transcription factor FOXM1 using FOXM1 shRNA or FOXM1 inhibitor FDI-6 can sensitize BRCA-proficient TNBC to PARP inhibitor Olaparib in vitro and in vivo. olaparib 172-180 poly(ADP-ribose) polymerase 1 Homo sapiens 157-161 34880123-5 2022 We show that the PARP1-inhibitors olaparib or PJ34 inhibit cAMP-mediated autophagy and thereby potentiate the DNA damaging treatment. olaparib 34-42 poly(ADP-ribose) polymerase 1 Homo sapiens 17-22 34846107-0 2021 BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair. olaparib 91-99 poly(ADP-ribose) polymerase 1 Homo sapiens 40-44 34846107-1 2021 OBJECTIVE: We aimed to investigate the radiosensitizing efficacy of the poly-ADP-ribose polymerase (PARP) inhibitor, olaparib, and the Bloom syndrome protein (BLM) helicase inhibitor, ML216, in non-small cell lung cancer (NSCLC) cells. olaparib 117-125 poly(ADP-ribose) polymerase 1 Homo sapiens 72-98 34846107-1 2021 OBJECTIVE: We aimed to investigate the radiosensitizing efficacy of the poly-ADP-ribose polymerase (PARP) inhibitor, olaparib, and the Bloom syndrome protein (BLM) helicase inhibitor, ML216, in non-small cell lung cancer (NSCLC) cells. olaparib 117-125 poly(ADP-ribose) polymerase 1 Homo sapiens 100-104 34461785-3 2021 The most potent compound (PARP1/2 IC50 = 22/4.0 nM) displayed the highest selectivity towards PARP2 in the series (selectivity index = 5.5), more advantageous ADME prameters compared to the clinically used PARP inhibitor Olaparib. olaparib 221-229 poly(ADP-ribose) polymerase 1 Homo sapiens 26-31 34761497-5 2021 Combining the PARP inhibitor olaparib with the MET inhibitor crizotinib synergistically inhibited CRPC cell growth both in vivo and in vitro. olaparib 29-37 poly(ADP-ribose) polymerase 1 Homo sapiens 14-18 34461785-3 2021 The most potent compound (PARP1/2 IC50 = 22/4.0 nM) displayed the highest selectivity towards PARP2 in the series (selectivity index = 5.5), more advantageous ADME prameters compared to the clinically used PARP inhibitor Olaparib. olaparib 221-229 poly(ADP-ribose) polymerase 1 Homo sapiens 206-210 34482781-5 2021 The lead compound as well as its des-fluoro analog were compared to the approved PARP1 inhibitor, anticancer drug Olaparib, in terms of their molecular characteristics defining druglikeness as well as experimentally determined ADME parameters. olaparib 114-122 poly(ADP-ribose) polymerase 1 Homo sapiens 81-86 34854226-3 2022 So far, PARP inhibitors (olaparib) have been used to treat pancreatic cancer patients with BRCA mutation. olaparib 25-33 poly(ADP-ribose) polymerase 1 Homo sapiens 8-12 34715071-2 2021 In the primary analysis of SOLO1/GOG 3004, the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib significantly improved progression-free survival versus placebo in patients with a BRCA mutation; median progression-free survival was not reached. olaparib 92-100 poly(ADP-ribose) polymerase 1 Homo sapiens 47-74 34715071-2 2021 In the primary analysis of SOLO1/GOG 3004, the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib significantly improved progression-free survival versus placebo in patients with a BRCA mutation; median progression-free survival was not reached. olaparib 92-100 poly(ADP-ribose) polymerase 1 Homo sapiens 76-80 34729995-3 2021 Olaparib and rucaparib, two PARP inhibitors, were successfully tested in clinical trials for HRR-deficient metastatic castration-resistant prostate cancer. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 28-32 34866915-5 2021 Accordingly, the patient received the poly(adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitor olaparib treatment and demonstrated a favorable response to this treatment. olaparib 107-115 poly(ADP-ribose) polymerase 1 Homo sapiens 91-95 34115723-5 2021 The PARP inhibitor olaparib, originally developed for cancer therapy, paved the way for the expansion of its clinical use for non-oncological indications. olaparib 19-27 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 34115723-7 2021 The benefit of olaparib and other clinically approved PARP inhibitors has already been demonstrated in several experimental models of human diseases, such as neurodegeneration and neuroinflammation, acute hepatitis, skeletal muscle disorders, aging and acute ischemic stroke, protecting, for example, from the deterioration of the blood-brain barrier, restoring the cellular levels of NAD+, improving mitochondrial function and biogenesis and, among other effects, reducing oxidative stress and pro-inflammatory mediators, such as TNF-alpha, IL1-beta, IL-6 and VCAM1. olaparib 15-23 poly(ADP-ribose) polymerase 1 Homo sapiens 54-58 34726203-4 2021 We determined in vitro olaparib-PARP1 equilibrium constant (6.06 x 108 mol L-1). olaparib 23-31 poly(ADP-ribose) polymerase 1 Homo sapiens 32-37 34726203-5 2021 In the cell nucleus, we distinguished three states of olaparib: freely diffusing drug (24%), olaparib-PARP1 complex (50%), and olaparib-PARP1-RNA complex (26%). olaparib 54-62 poly(ADP-ribose) polymerase 1 Homo sapiens 102-107 34726203-5 2021 In the cell nucleus, we distinguished three states of olaparib: freely diffusing drug (24%), olaparib-PARP1 complex (50%), and olaparib-PARP1-RNA complex (26%). olaparib 54-62 poly(ADP-ribose) polymerase 1 Homo sapiens 136-141 34418731-7 2021 The combination of olaparib treatment and PDT enhanced PARP cleavage and deoxyribonucleic acid (DNA) damage, further decreasing the total cancer cell number down to 10+-2%. olaparib 19-27 poly(ADP-ribose) polymerase 1 Homo sapiens 55-59 34830911-4 2021 Data from SOLO1, PAOLA-1, PRIMA, and VELIA confirm the benefit of PARP inhibitors (olaparib, niraparib, veliparib) for women with newly diagnosed EOC. olaparib 83-91 poly(ADP-ribose) polymerase 1 Homo sapiens 66-70 34830911-8 2021 Recent PARP inhibitor approvals (olaparib, niraparib) in the newly diagnosed EOC setting have provided new maintenance treatment options for a broader patient population. olaparib 33-41 poly(ADP-ribose) polymerase 1 Homo sapiens 7-11 34819864-2 2021 Methods: The log normal hazard function model was established by using progression-free survival (PFS) data of 1,169 patients from published randomized trials on FDA-approved PARP inhibitors (olaparib, niraparib, and rucaparib). olaparib 192-200 poly(ADP-ribose) polymerase 1 Homo sapiens 175-179 34769368-6 2021 Unexpectedly, we found that PARP inhibitor olaparib, but not talazoparib, is also a mitochondrial Complex I inhibitor. olaparib 43-51 poly(ADP-ribose) polymerase 1 Homo sapiens 28-32 34904808-1 2021 ABSTRACT: In May 2020, the poly(ADP-ribose) polymerase (PARP) inhibitors rucaparib and olaparib were Food and Drug Administration approved for the management of metastatic castration-resistant prostate cancers. olaparib 87-95 poly(ADP-ribose) polymerase 1 Homo sapiens 27-54 34904808-1 2021 ABSTRACT: In May 2020, the poly(ADP-ribose) polymerase (PARP) inhibitors rucaparib and olaparib were Food and Drug Administration approved for the management of metastatic castration-resistant prostate cancers. olaparib 87-95 poly(ADP-ribose) polymerase 1 Homo sapiens 56-60 34518240-3 2021 PRIMARY OBJECTIVE: To determine whether the ATR inhibitor, ceralasertib, has clinical activity as a single agent and in combination with the PARP inhibitor, olaparib, in patients with ARID1A "loss" and "no loss" clear cell carcinomas and other relapsed gynecological cancers. olaparib 157-165 poly(ADP-ribose) polymerase 1 Homo sapiens 141-145 34508175-6 2021 Suboptimal doses of the CHK1 inhibitor MK-8776 plus the PARP inhibitor olaparib led to a MYCN-dependent accumulation of DNA damage and cell death in vitro and significantly reduced the growth of four in vivo models of MYCN-driven tumors, without major toxicities. olaparib 71-79 poly(ADP-ribose) polymerase 1 Homo sapiens 56-60 34667064-5 2021 Here, we present a case study of a patient with immunotherapy relapsed melanoma who was found to have detected HRD and was treated with nivolumab (ICB) and olaparib (PARP inhibitors). olaparib 156-164 poly(ADP-ribose) polymerase 1 Homo sapiens 166-170 34683150-5 2021 Herein, we identified that breast cancer cells with an elevated expression of protein arginine methyl transferase 1 (PRMT1) was associated with therapeutic sensitivity to the PARP inhibitor olaparib. olaparib 190-198 poly(ADP-ribose) polymerase 1 Homo sapiens 175-179 34629045-9 2022 RESULTS: For CF41.Mg and MDA-MB-468 cell lines, there was decrease in PARP-1 protein and gene expression after treatment with carboplatin, olaparib and both in combination compared to the group without treatment (control) (p<0.05). olaparib 139-147 poly(ADP-ribose) polymerase 1 Homo sapiens 70-76 34252319-2 2021 In addition to androgen receptor pathway inhibitors (like abiraterone and enzalutamide) or chemotherapy (like docetaxel), exists olaparib, a relatively new drug that interferes with the base excision repair (BER) pathway mainly due to selective inhibition of Poly ADP-ribose polymerase (PARP) 1 and 2. olaparib 129-137 poly(ADP-ribose) polymerase 1 Homo sapiens 259-300 34670865-7 2022 Finally, treatment with the PARP inhibitor olaparib plus AVB-500 led to decreased ovarian cancer cell survival in vitro and less tumor burden in vivo. olaparib 43-51 poly(ADP-ribose) polymerase 1 Homo sapiens 28-32 34786207-6 2021 Moreover, HRD cell lines identified by 24-GPS tended to be sensitive to PARP inhibitors (p = 6.6E-2 for olaparib; p = 2.6E-3 for niraparib). olaparib 104-112 poly(ADP-ribose) polymerase 1 Homo sapiens 72-76 34669358-3 2021 There are 2 FDA approved PARP inhibitors (PARPi), olaparib (Lynparza) and rucaparib (Rubraca), for the treatment of advanced prostate cancer with DNA repair deficiency. olaparib 50-58 poly(ADP-ribose) polymerase 1 Homo sapiens 25-29 34665339-6 2021 Recently, the PARP inhibitor olaparib has been demonstrated to improve progression-free survival when used as a maintenance treatment in the subgroup of patients with mPDAC and a BRCA1/-2 germ line mutation having received at least 16 weeks of platinum-based chemotherapy. olaparib 29-37 poly(ADP-ribose) polymerase 1 Homo sapiens 14-18 34639028-0 2021 Poly ADP Ribose Polymerase Inhibitor Olaparib Targeting Microhomology End Joining in Retinoblastoma Protein Defective Cancer: Analysis of the Retinoblastoma Cell-Killing Effects by Olaparib after Inducing Double-Strand Breaks. olaparib 37-45 poly(ADP-ribose) polymerase 1 Homo sapiens 0-26 34639028-11 2021 Our results demonstrated the killing effects in retinoblastoma cells by PARP inhibitor olaparib after inducing DNA double-strand breaks. olaparib 87-95 poly(ADP-ribose) polymerase 1 Homo sapiens 72-76 34280886-1 2021 Poly (ADP-ribose) polymerase (PARP) inhibitor olaparib selectively kills cancer cells with BRCA-deficiency and is approved for BRCA-mutated breast, ovarian and pancreatic cancers by FDA. olaparib 46-54 poly(ADP-ribose) polymerase 1 Homo sapiens 0-28 34280886-1 2021 Poly (ADP-ribose) polymerase (PARP) inhibitor olaparib selectively kills cancer cells with BRCA-deficiency and is approved for BRCA-mutated breast, ovarian and pancreatic cancers by FDA. olaparib 46-54 poly(ADP-ribose) polymerase 1 Homo sapiens 30-34 34572843-5 2021 Let-7i over-expression results in increased sensitivity to the PARP inhibitor olaparib in samples without BRCA mutations, consistent with induction of BRCAness phenotype. olaparib 78-86 poly(ADP-ribose) polymerase 1 Homo sapiens 63-67 34638899-1 2021 This study examined the effect of combination treatment with the poly (ADP-ribose) polymerase inhibitor olaparib and metformin on homologous recombination (HR)-proficient epithelial ovarian cancer (EOC). olaparib 104-112 poly(ADP-ribose) polymerase 1 Homo sapiens 65-93 34535173-2 2021 Olaparib, an inhibitor of poly (ADP-ribose) polymerase (PARP), is becoming widely used in ovarian cancer treatment. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 26-54 34535173-2 2021 Olaparib, an inhibitor of poly (ADP-ribose) polymerase (PARP), is becoming widely used in ovarian cancer treatment. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 56-60 34552338-4 2021 In May 2020, the first PARP inhibitor, olaparib, was approved by the US Food and Drug Administration for men with mCRPC with HHR gene mutations based on the findings of the Phase III PROfound trial that showed improved overall survival in men with mCRPC who received olaparib and whose disease had progressed on a novel hormonal agent. olaparib 39-47 poly(ADP-ribose) polymerase 1 Homo sapiens 23-27 34567413-0 2021 Olaparib: A Clinically Applied PARP Inhibitor Protects from Experimental Crohn"s Disease and Maintains Barrier Integrity by Improving Bioenergetics through Rescuing Glycolysis in Colonic Epithelial Cells. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 31-35 34567413-11 2021 Olaparib, a PARP inhibitor used in human cancer therapy, improved experimental CD and protected intestinal barrier integrity by preventing its energetic collapse; therefore, it could be repurposed for the therapy of Crohn"s disease. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 12-16 34567413-3 2021 Focusing on the epithelial barrier integrity and bioenergetics of epithelial cells, we investigated whether the clinically applied PARP inhibitor olaparib might improve experimental CD. olaparib 146-154 poly(ADP-ribose) polymerase 1 Homo sapiens 131-135 34527850-4 2021 Here, we report the results of the arm in which olaparib was combined with the orally bioavailable ataxia telangiectasia and RAD3-related inhibitor ceralasertib in patients with relapsed or refractory cancers harboring DNA damage response and repair alterations, including patients with BRCA-mutated PARP inhibitor-resistant high-grade serous ovarian cancer (HGSOC). olaparib 48-56 poly(ADP-ribose) polymerase 1 Homo sapiens 300-304 34527850-13 2021 CONCLUSION: Olaparib with ceralasertib demonstrated preliminary activity in ATM-mutated tumors and in PARP inhibitor-resistant BRCA1/2-mutated HGSOC. olaparib 12-20 poly(ADP-ribose) polymerase 1 Homo sapiens 102-106 34403012-4 2021 There are several targeted therapies approved by the Food and Drug administration (FDA) in PDAC: EGFR inhibitor erlotinib (combined with gemcitabine) in unselected patients, TRK inhibitors larotrectinib and entrectinib for patients with NTRK fusion mutation, the PD-1 inhibitor pembrolizumab for mismatch repair-deficient patients, and the poly-ADP-ribose polymerase (PARP) inhibitor olaparib in patients with germline BRCA mutation as a maintenance therapy. olaparib 384-392 poly(ADP-ribose) polymerase 1 Homo sapiens 368-372 34318678-5 2021 By harnessing the scaffold of the PARP inhibitor Olaparib, we were able to deliver therapeutic levels of Auger radiation to the site of human colorectal cancer xenograft tumors after systemic administration. olaparib 49-57 poly(ADP-ribose) polymerase 1 Homo sapiens 34-38 34131002-0 2021 Phase 1 Combination Study of the CHK1 inhibitor prexasertib, and the PARP inhibitor olaparib, in high-grade serous ovarian cancer and other solid tumors. olaparib 84-92 poly(ADP-ribose) polymerase 1 Homo sapiens 69-73 34131002-2 2021 In BRCA-deficient cancers with de novo or acquired PARP inhibitor resistance, the addition of the CHK1 inhibitor prexasertib to the PARP inhibitor olaparib compromises replication fork stability, as well as HR proficiency, allowing for sensitization to PARP inhibition. olaparib 147-155 poly(ADP-ribose) polymerase 1 Homo sapiens 132-136 34131002-2 2021 In BRCA-deficient cancers with de novo or acquired PARP inhibitor resistance, the addition of the CHK1 inhibitor prexasertib to the PARP inhibitor olaparib compromises replication fork stability, as well as HR proficiency, allowing for sensitization to PARP inhibition. olaparib 147-155 poly(ADP-ribose) polymerase 1 Homo sapiens 253-257 34168048-4 2021 EXPERIMENTAL DESIGN: We treated prostate cancer cell lines with potent, specific inhibitors of ATR kinase, as well as with PARP inhibitor, olaparib. olaparib 139-147 poly(ADP-ribose) polymerase 1 Homo sapiens 123-127 34144488-0 2021 Olaparib enhances curcumin-mediated apoptosis in oral cancer cells by inducing PARP trapping through modulation of BER and chromatin assembly. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 79-83 34144488-5 2021 Cur + Ola treatment inhibited PARylation, altered interaction of PARP-1 with representative BER proteins and arrested cells in S-phase. olaparib 6-9 poly(ADP-ribose) polymerase 1 Homo sapiens 65-71 34144488-6 2021 We have for the first time provided direct evidence and measured the cellular PARP-1 trapping potentiality of Ola in Cur pretreated H-357 cells. olaparib 110-113 poly(ADP-ribose) polymerase 1 Homo sapiens 78-84 34144488-11 2021 Thus, the present study reveals that Cur + Ola treatment increased oral cancer cell death not only through catalytic inhibition of PARP-1 but also predominantly through PARP-1 trapping and indirect inhibition of chromatin remodeling. olaparib 43-46 poly(ADP-ribose) polymerase 1 Homo sapiens 131-137 34144488-11 2021 Thus, the present study reveals that Cur + Ola treatment increased oral cancer cell death not only through catalytic inhibition of PARP-1 but also predominantly through PARP-1 trapping and indirect inhibition of chromatin remodeling. olaparib 43-46 poly(ADP-ribose) polymerase 1 Homo sapiens 169-175 34231369-1 2021 Aim: Two poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and talazoparib are approved for patients with germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer. olaparib 55-63 poly(ADP-ribose) polymerase 1 Homo sapiens 9-36 34231369-1 2021 Aim: Two poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and talazoparib are approved for patients with germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer. olaparib 55-63 poly(ADP-ribose) polymerase 1 Homo sapiens 38-42 34240844-3 2021 The inhibition of poly(ADP-ribose) polymerase 1 in such cells is a synthetically lethal, cytotoxic effect that has been exploited to produce anticancer drugs such as Olaparib. olaparib 166-174 poly(ADP-ribose) polymerase 1 Homo sapiens 18-47 34158347-1 2021 We analyzed the efficacy and mechanistic interactions of PARP inhibition (PARPi) (olaparib) and CDK4/6 inhibition (CDK4/6i) (palbociclib or abemaciclib) combination therapy in castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC) models. olaparib 82-90 poly(ADP-ribose) polymerase 1 Homo sapiens 57-61 34504648-3 2021 Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of patients with breast cancer harboring BRCA mutations. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 44-48 34497808-9 2021 As a result, combination of OXA and Olaparib (PARP-1/2/3 inhibitor), inhibited in vivo and in vitro OXA resistant organoid growth and viability. olaparib 36-44 poly(ADP-ribose) polymerase 1 Homo sapiens 46-56 34377000-4 2021 Methods: Two prostate cancer cell lines were exposed to the c-MET inhibitor PHA665752 and/or the PARP inhibitor olaparib. olaparib 112-120 poly(ADP-ribose) polymerase 1 Homo sapiens 97-101 34430738-0 2021 Anticancer activity of RAPTA-EA1 in triple-negative BRCA1 proficient breast cancer cells: single and combined treatment with the PARP inhibitor olaparib. olaparib 144-152 poly(ADP-ribose) polymerase 1 Homo sapiens 129-133 34430738-9 2021 Growth inhibition of the triple-negative BRCA1 wild-type MDA-MB-231 and the sporadic BRCA1 wild-type MCF-7 cells by olaparib (a poly (ADP-ribose) polymerase (PARP) inhibitor) is dose-dependent, with MDA-MB-231 cells being two-fold less susceptible to the drug than MCF-7 cells. olaparib 116-124 poly(ADP-ribose) polymerase 1 Homo sapiens 158-162 34377000-11 2021 Conclusion: The combination of the c-MET inhibitor PHA665752 and the PARP inhibitor olaparib may be a promising therapeutic strategy in patients with prostate cancer. olaparib 84-92 poly(ADP-ribose) polymerase 1 Homo sapiens 69-73 34532366-14 2021 Olaparib had the best safety profile among all PARP inhibitors because of its mild toxicity and narrow spectrum. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 47-51 34080025-11 2021 Treatment of HCC1937 cells with the combination of siMAPK4 and a PARP1 inhibitor olaparib decreased their proliferation and migration and increased their apoptosis. olaparib 81-89 poly(ADP-ribose) polymerase 1 Homo sapiens 65-70 34262130-5 2021 Here we found that CRIP1 downregulation causes HR repair deficiency with concomitant increase in cell sensitivity to cisplatin, epirubicin, and the poly ADP-ribose polymerase (PARP) inhibitor olaparib in gastric cancer cells. olaparib 192-200 poly(ADP-ribose) polymerase 1 Homo sapiens 148-174 34262130-5 2021 Here we found that CRIP1 downregulation causes HR repair deficiency with concomitant increase in cell sensitivity to cisplatin, epirubicin, and the poly ADP-ribose polymerase (PARP) inhibitor olaparib in gastric cancer cells. olaparib 192-200 poly(ADP-ribose) polymerase 1 Homo sapiens 176-180 34377227-2 2021 Currently, two PARP inhibitors, olaparib and rucaparib, have received approval as monotherapy by the Food and Drug Administration for the treatment of men with castration resistant prostate cancer with selected mutations involving the homologous recombination (HR) pathway. olaparib 32-40 poly(ADP-ribose) polymerase 1 Homo sapiens 15-19 34367977-3 2021 Here, we show that TNBCs with constitutively hyperactivated PARP-1 display greater tolerances for the PARPi olaparib and cisplatin, and respond synergistically to olaparib/cisplatin combinations with increased cytotoxicity. olaparib 108-116 poly(ADP-ribose) polymerase 1 Homo sapiens 60-66 34367977-3 2021 Here, we show that TNBCs with constitutively hyperactivated PARP-1 display greater tolerances for the PARPi olaparib and cisplatin, and respond synergistically to olaparib/cisplatin combinations with increased cytotoxicity. olaparib 163-171 poly(ADP-ribose) polymerase 1 Homo sapiens 60-66 34778690-1 2021 Two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and rucaparib) are US Food and Drug Administration-approved for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 mutations, but the relative efficacy of PARP inhibition in BRCA1- versus BRCA2-altered mCRPC is understudied. olaparib 52-60 poly(ADP-ribose) polymerase 1 Homo sapiens 4-32 34778690-1 2021 Two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and rucaparib) are US Food and Drug Administration-approved for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 mutations, but the relative efficacy of PARP inhibition in BRCA1- versus BRCA2-altered mCRPC is understudied. olaparib 52-60 poly(ADP-ribose) polymerase 1 Homo sapiens 34-38 34256353-4 2021 The recent regulatory approvals of PARP inhibitors olaparib and rucaparib represent the first molecular biomarker-guided drugs for men with prostate cancer. olaparib 51-59 poly(ADP-ribose) polymerase 1 Homo sapiens 35-39 34285720-5 2021 Although not confirmed in large, prospective trials, gemcitabine alone as a maintenance therapy following induction treatment with gemcitabine plus nab-paclitaxel could be an option, while a small subset of patients with a germline mutation of breast cancer gene (BRCA) can benefit from the polyadenosine diphosphate-ribose polymerase (PARP) inhibitor olaparib. olaparib 352-360 poly(ADP-ribose) polymerase 1 Homo sapiens 291-334 34285720-5 2021 Although not confirmed in large, prospective trials, gemcitabine alone as a maintenance therapy following induction treatment with gemcitabine plus nab-paclitaxel could be an option, while a small subset of patients with a germline mutation of breast cancer gene (BRCA) can benefit from the polyadenosine diphosphate-ribose polymerase (PARP) inhibitor olaparib. olaparib 352-360 poly(ADP-ribose) polymerase 1 Homo sapiens 336-340 34356606-3 2021 The drug conjugates M1-M3 combine Olaparib, the first PARP inhibitor approved for clinical use, with Cpd 1, an inhibitor of RAD51 that blocks its HR functions and yet permits RAD51 nucleoprotein filament formation on single-stranded DNA. olaparib 34-42 poly(ADP-ribose) polymerase 1 Homo sapiens 54-58 34151456-5 2022 Among this derivatives, compound 14p displayed the strongest inhibitory effects on PARP-1 enzyme (IC50 = 0.023 muM), which was close to that of Olaparib. olaparib 145-153 poly(ADP-ribose) polymerase 1 Homo sapiens 83-89 34289788-10 2021 The oral PARP inhibitor olaparib in the maintenance setting represents the first targeted therapy in metastatic PC based on a phase 3 study. olaparib 24-32 poly(ADP-ribose) polymerase 1 Homo sapiens 9-13 34182476-2 2021 The aim of this study was to evaluate the combination of the PARP inhibitor olaparib with temozolomide in the treatment of glioblastoma. olaparib 76-84 poly(ADP-ribose) polymerase 1 Homo sapiens 61-65 34182476-3 2021 MATERIALS AND METHODS: The in vitro and in vivo antitumor effects of the PARP inhibitor olaparib together with temozolomide were evaluated. olaparib 88-96 poly(ADP-ribose) polymerase 1 Homo sapiens 73-77 34430059-4 2021 In December 2019, the U.S. Food & Drug Administration approved the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib for maintenance treatment of germline BRCA-mutated metastatic pancreatic adenocarcinoma in individuals who have completed at least 16 weeks of progression-free treatment with first-line platinum-based chemotherapy. olaparib 112-120 poly(ADP-ribose) polymerase 1 Homo sapiens 67-94 34430059-4 2021 In December 2019, the U.S. Food & Drug Administration approved the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib for maintenance treatment of germline BRCA-mutated metastatic pancreatic adenocarcinoma in individuals who have completed at least 16 weeks of progression-free treatment with first-line platinum-based chemotherapy. olaparib 112-120 poly(ADP-ribose) polymerase 1 Homo sapiens 96-100 34195200-5 2021 Materials and Methods: Depletion of VRK1, an enzyme that regulates chromatin dynamic reorganization and facilitates resistance to DNA damage, was performed in glioblastoma cells treated with temozolomide, an alkylating agent used for GBM treatment; and olaparib, an inhibitor of PARP-1, used as sensitizer. olaparib 253-261 poly(ADP-ribose) polymerase 1 Homo sapiens 279-285 34208492-6 2021 We also show that B02-iso sensitizes triple-negative breast cancer MDA-MB-231 cells to the PARP inhibitor (PARPi) olaparib. olaparib 114-122 poly(ADP-ribose) polymerase 1 Homo sapiens 91-95 34589994-2 2021 Olaparib, a PARP inhibitor, reduces BRCA1 expression. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 12-16 34193711-2 2021 Olaparib has been approved as a PARP inhibitor. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 32-36 35000525-4 2022 Then, pancreatic Capan-1 cells were repeatedly treated with the PARP1 inhibitor olaparib, the Chk1 inhibitor rabusertib or their combination for 211-214 days, during which the changes in drug sensitivity were monitored at a 35-day interval. olaparib 80-88 poly(ADP-ribose) polymerase 1 Homo sapiens 64-69 35000525-11 2022 Our findings indicate that repeated treatments with the rabusertib/olaparib combination result in increased drug resistance and a more aggressive cell phenotype than those with either single agent, providing new clues for future clinical anticancer tests of PARP1 and Chk1 inhibitor combinations. olaparib 67-75 poly(ADP-ribose) polymerase 1 Homo sapiens 258-263 34079088-5 2021 Besides, PARP inhibition with Olaparib selectively radiosensitized Oct4 A knockout, but not wild-type HNSCC cells. olaparib 30-38 poly(ADP-ribose) polymerase 1 Homo sapiens 9-13 35628590-3 2022 Transcriptomic classification of cancer cell lines based on MET expression showed that response to the PARP inhibitor (PARPi) olaparib is poorer in MET overexpressing cell lines. olaparib 126-134 poly(ADP-ribose) polymerase 1 Homo sapiens 103-107 35636395-8 2022 As for PARP monotherapy, progression free survival has been observed using the FDA and EMA approved drugs olaparib and talazoparib. olaparib 106-114 poly(ADP-ribose) polymerase 1 Homo sapiens 7-11 35624090-5 2022 Interestingly, replication fork instability by 5hmdC or 5hmdU was associated to the presence of Poly(ADP-ribose) polymerase 1 (PARP1) on chromatin, being both phenotypes exacerbated by olaparib treatment. olaparib 185-193 poly(ADP-ribose) polymerase 1 Homo sapiens 96-125 35624090-5 2022 Interestingly, replication fork instability by 5hmdC or 5hmdU was associated to the presence of Poly(ADP-ribose) polymerase 1 (PARP1) on chromatin, being both phenotypes exacerbated by olaparib treatment. olaparib 185-193 poly(ADP-ribose) polymerase 1 Homo sapiens 127-132 35593736-3 2022 METHODS: This open-label, multicenter phase 1 clinical trial evaluated the safety, tolerability, and efficacy of olaparib, a PARP inhibitor, in pediatric patients with refractory solid tumors to recommend a dose for Phase 2 trials. olaparib 113-121 poly(ADP-ribose) polymerase 1 Homo sapiens 125-129 35419627-10 2022 Additive anti-proliferation effect of LAE003 and Olaparib was also observed in three ovarian cancer cell lines with high PARP1 protein level. olaparib 49-57 poly(ADP-ribose) polymerase 1 Homo sapiens 121-126 35545049-6 2022 PARP inhibitors, such as olaparib, mimick lactate in the reduction of stromal p62 levels, as well as the subsequent stromal activation both in vitro and in vivo, which suggests that therapies using olaparib would benefit from strategies aimed at inhibiting CAF activity. olaparib 25-33 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 35545049-6 2022 PARP inhibitors, such as olaparib, mimick lactate in the reduction of stromal p62 levels, as well as the subsequent stromal activation both in vitro and in vivo, which suggests that therapies using olaparib would benefit from strategies aimed at inhibiting CAF activity. olaparib 198-206 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 35619904-6 2022 Besides, TH5487 enhances the sensitivity to the PARP inhibitor olaparib, especially in the context of BRCA1 deficiency, reflecting an additive interaction. olaparib 63-71 poly(ADP-ribose) polymerase 1 Homo sapiens 48-52 35419627-11 2022 Interestingly, mechanism study revealed that AKT inhibition decreased PARP enzyme activity as measured by PAR level and/or reduced PARP1 protein level in the tumor cell lines and PDX tumor tissues, which may explain the observed combined anti-tumor effect of LAE003 and Olaparib. olaparib 270-278 poly(ADP-ribose) polymerase 1 Homo sapiens 131-136 35194903-0 2022 XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA. olaparib 61-69 poly(ADP-ribose) polymerase 1 Homo sapiens 18-44 35194903-0 2022 XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA. olaparib 61-69 poly(ADP-ribose) polymerase 1 Homo sapiens 170-175 35194903-8 2022 We reveal the synthetic lethality of the XRCC1-/- mutation, but not POLbeta-/- , with olaparib and talazoparib, indicating that XRCC1 is a unique BER factor in suppressing toxic PARP1/SSB complex and can suppress even when PARP1 catalysis is inhibited. olaparib 86-94 poly(ADP-ribose) polymerase 1 Homo sapiens 178-183 35194903-0 2022 XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA. olaparib 61-69 poly(ADP-ribose) polymerase 1 Homo sapiens 46-50 35486574-0 2022 Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin"s lymphoma in vitro. olaparib 82-90 poly(ADP-ribose) polymerase 1 Homo sapiens 67-71 35486574-3 2022 Here we investigate the combined effect of anti-CD37 beta-emitting 177Lu-NNV003 radioimmunotherapy and the PARP inhibitor olaparib, and gene expression profiles in CD37 positive non-Hodgkin"s lymphoma cell lines. olaparib 122-130 poly(ADP-ribose) polymerase 1 Homo sapiens 107-111 35486574-11 2022 CONCLUSION: The cytotoxic effect of the combination of the PARP inhibitor olaparib and the beta-emitting radioimmunoconjugate 177Lu-NNV003 was synergistic in the majority of tested lymphoma cell lines. olaparib 74-82 poly(ADP-ribose) polymerase 1 Homo sapiens 59-63 35444023-2 2022 Based on the results from clinical trials, olaparib, a PARP inhibitor, is indicated for use in the first-line treatment for patients with BRCA gene mutations, and as a maintenance treatment in platinum-sensitive relapsed ovarian cancer after a complete or partial response to platinum-based chemotherapy. olaparib 43-51 poly(ADP-ribose) polymerase 1 Homo sapiens 55-59 35517402-7 2022 Combining DCZ0415 with PARP1 inhibitor, Olaparib induced synergistic anti-HCC activity. olaparib 40-48 poly(ADP-ribose) polymerase 1 Homo sapiens 23-28 35611209-1 2022 BACKGROUND: The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib has displayed superior clinical effect in metastatic castration-resistant prostate cancer (mCRPC) patients with the homologous recombination repair (HRR) genes mutations. olaparib 62-70 poly(ADP-ribose) polymerase 1 Homo sapiens 16-44 35611209-1 2022 BACKGROUND: The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib has displayed superior clinical effect in metastatic castration-resistant prostate cancer (mCRPC) patients with the homologous recombination repair (HRR) genes mutations. olaparib 62-70 poly(ADP-ribose) polymerase 1 Homo sapiens 46-50 35611209-9 2022 Two identified reverse missense mutations in partner and localizer of BRCA2 (PALB2) may have recovered the reading frame, restoring function of the primary germline PALB2 mutation and causing resistance to the PARP inhibitor olaparib. olaparib 225-233 poly(ADP-ribose) polymerase 1 Homo sapiens 210-214 35494030-4 2022 In this case study, we report that treatments with olaparib, a Poly (ADP-ribose) polymerase (PARP) inhibitor, combined with dacomitinib, a second-generation EGFR TKI, benefited a lung cancer patient with osimertinib-resistant brain and leptomeningeal metastases. olaparib 51-59 poly(ADP-ribose) polymerase 1 Homo sapiens 63-91 35494030-4 2022 In this case study, we report that treatments with olaparib, a Poly (ADP-ribose) polymerase (PARP) inhibitor, combined with dacomitinib, a second-generation EGFR TKI, benefited a lung cancer patient with osimertinib-resistant brain and leptomeningeal metastases. olaparib 51-59 poly(ADP-ribose) polymerase 1 Homo sapiens 93-97 35466317-13 2022 Conclusion: The present study reveals that inhibition of PARP potentiates immune checkpoint therapy through the miR-513/PD-L1 pathway in HCC and the combination of PARP inhibitor olaparib and anti-PD1 is beneficial to HCC therapy. olaparib 179-187 poly(ADP-ribose) polymerase 1 Homo sapiens 57-61 35466317-13 2022 Conclusion: The present study reveals that inhibition of PARP potentiates immune checkpoint therapy through the miR-513/PD-L1 pathway in HCC and the combination of PARP inhibitor olaparib and anti-PD1 is beneficial to HCC therapy. olaparib 179-187 poly(ADP-ribose) polymerase 1 Homo sapiens 164-168 35480123-5 2022 In addition, we subjected the patient to olaparib, a PARP inhibitor, for the treatment of tumor with HRD and obtained a partial response. olaparib 41-49 poly(ADP-ribose) polymerase 1 Homo sapiens 53-57 35517402-10 2022 In conclusion, our study demonstrated that DCZ0415 targeting TRIP13 impaired non-homologous end-joining repair to inhibit HCC progression and had a synergistic effect with PARP1 inhibitor Olaparib in HCC, suggesting a potential treatment of HCC. olaparib 188-196 poly(ADP-ribose) polymerase 1 Homo sapiens 172-177 35408930-7 2022 Cell death triggered by zafirlukast could be rescued with antioxidants and the PARP-1 inhibitor Olaparib, and additionally relies on HIF-2alpha. olaparib 96-104 poly(ADP-ribose) polymerase 1 Homo sapiens 79-85 35324529-3 2022 poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib are currently approved to treat BReast CAncer gene 1/2 (BRCA1/2)-mutated patients in a few tumor types. olaparib 56-64 poly(ADP-ribose) polymerase 1 Homo sapiens 0-28 35324529-3 2022 poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib are currently approved to treat BReast CAncer gene 1/2 (BRCA1/2)-mutated patients in a few tumor types. olaparib 56-64 poly(ADP-ribose) polymerase 1 Homo sapiens 30-34 35269669-2 2022 Olaparib is a PARP1 inhibitor that blocks polyADP-ribosylation, which is involved in the epithelial-mesenchymal transition (EMT) characteristic of tumor recurrence. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 14-19 35343196-6 2022 Four PARP inhibitors (olaparib, niraparib, rucaparib, and talazoparib) are currently approved by the Food and Drug Administration for OC, breast, and pancreatic cancer indications and are being evaluated for other BRCA-associated cancers. olaparib 22-30 poly(ADP-ribose) polymerase 1 Homo sapiens 5-9 35269669-8 2022 Moreover, SNAIL and PARP1 were downregulated, while E-cadherin was increased, indicating the effect of olaparib on proteins associated with EMT in this model. olaparib 103-111 poly(ADP-ribose) polymerase 1 Homo sapiens 20-25 35156571-2 2022 Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has been granted accelerated approval by FDA for patients with deleterious BRCA-mutated human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 12-40 35188042-3 2022 We demonstrated the synergism of (Bis + ABT199/venetoclax) in combination with panobinostat (Pano), decitabine (DAC), or olaparib (Ola), known inhibitors of BCL2, histone deacetylase, DNA methyltransferase, and poly(ADP-ribose) polymerase, respectively, in AML cells. olaparib 121-129 poly(ADP-ribose) polymerase 1 Homo sapiens 211-238 35188042-3 2022 We demonstrated the synergism of (Bis + ABT199/venetoclax) in combination with panobinostat (Pano), decitabine (DAC), or olaparib (Ola), known inhibitors of BCL2, histone deacetylase, DNA methyltransferase, and poly(ADP-ribose) polymerase, respectively, in AML cells. olaparib 131-134 poly(ADP-ribose) polymerase 1 Homo sapiens 211-238 35091172-6 2022 III-7 reversed Olaparib-induced adaptive resistance and induced cell cycle arrest and DNA damage by perturbing PARP1 and BRD4-involved signaling pathways. olaparib 15-23 poly(ADP-ribose) polymerase 1 Homo sapiens 111-116 35267438-7 2022 We give a comprehensive overview over the preclinical development of PARP imaging agents, which are mostly based on the PARPi olaparib, rucaparib, and recently also talazoparib. olaparib 126-134 poly(ADP-ribose) polymerase 1 Homo sapiens 69-73 35191009-1 2022 BACKGROUND: In 2018, BRACAnalysis was covered by medical insurance in Japan as a companion diagnostic test for the poly ADP-ribose polymerase inhibitor olaparib. olaparib 153-161 poly(ADP-ribose) polymerase 1 Homo sapiens 116-142 35156571-2 2022 Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has been granted accelerated approval by FDA for patients with deleterious BRCA-mutated human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 42-46 35205643-6 2022 Selective poly (ADP-ribose) polymerase (PARP) inhibitors such as Niraparib, Olaparib, Talazoparib, Rucaparib, and Veliparib are now approved for several cancers with loss of high-fidelity double-strand break homologous recombination (HR), namely those with deleterious mutations to BRCA1/2, PALB2, and other functionally related genes. olaparib 76-84 poly(ADP-ribose) polymerase 1 Homo sapiens 10-38 35205643-6 2022 Selective poly (ADP-ribose) polymerase (PARP) inhibitors such as Niraparib, Olaparib, Talazoparib, Rucaparib, and Veliparib are now approved for several cancers with loss of high-fidelity double-strand break homologous recombination (HR), namely those with deleterious mutations to BRCA1/2, PALB2, and other functionally related genes. olaparib 76-84 poly(ADP-ribose) polymerase 1 Homo sapiens 40-44 35130631-4 2022 The aim of the present study was to determine the underlying molecular mechanisms by which the PARP-1 inhibitor Olaparib enhances the chemosensitivity of the leukemia cell line K562 and THP1 to IDA. olaparib 112-120 poly(ADP-ribose) polymerase 1 Homo sapiens 95-101 35159068-5 2022 The regulatory approval of two PARP inhibitors in 2020-rucaparib and olaparib-has provided the first targeted therapy option for patients harboring defects in selected DNA damage response and repair (DDR) pathway genes. olaparib 69-77 poly(ADP-ribose) polymerase 1 Homo sapiens 31-35 35130631-5 2022 Our data demonstrated that PARP-1 is upregulated in AML patients as well as in K562 and THP1 cells, and that the suppression of PARP-1 activity by Olaparib enhances the inhibitory effect of IDA. olaparib 147-155 poly(ADP-ribose) polymerase 1 Homo sapiens 27-33 35130631-5 2022 Our data demonstrated that PARP-1 is upregulated in AML patients as well as in K562 and THP1 cells, and that the suppression of PARP-1 activity by Olaparib enhances the inhibitory effect of IDA. olaparib 147-155 poly(ADP-ribose) polymerase 1 Homo sapiens 128-134 35163134-8 2022 Combination of THZ531 with either DNA-PK inhibitor (KU-0060648) or PARP inhibitor (Olaparib) led to synergistic cell death. olaparib 83-91 poly(ADP-ribose) polymerase 1 Homo sapiens 67-71 35400012-0 2022 Complete Response of a Mutated BRCA2 Metastatic Clear Cell Endometrial Adenocarcinoma to the Poly (ADP ribose) Polymerase (PARP) Inhibitor Olaparib. olaparib 139-147 poly(ADP-ribose) polymerase 1 Homo sapiens 93-121 35163037-2 2022 In this work, we show that the two structurally-related sesquiterpene lactones, a 2-bromobenzyloxy derivative of dehydrosantonin (BdS) and alantolactone (ATL) sensitise p53 wildtype, homologous recombination-proficient cancer cells to low-dose treatment with the PARP inhibitor, olaparib. olaparib 279-287 poly(ADP-ribose) polymerase 1 Homo sapiens 263-267 35163037-4 2022 Mechanistically, we uncover that mitotic errors likely depend on oxidative stress elicited by the electrophilic lactone warheads and olaparib-mediated PARP-trapping, culminating in replication stress. olaparib 133-141 poly(ADP-ribose) polymerase 1 Homo sapiens 151-155 35097256-7 2022 Moreover, a combination treatment with olaparib (a PARP1 inhibitor) and NU7441 (a DNA-PKcs inhibitor) sensitized NPC cells to VP-16 in vitro and in vivo, suggesting that the combined treatment of olaparib, NU7441, and a DNA-damaging agent may be a successful treatment regimen in patients with NPC. olaparib 39-47 poly(ADP-ribose) polymerase 1 Homo sapiens 51-56 35400012-0 2022 Complete Response of a Mutated BRCA2 Metastatic Clear Cell Endometrial Adenocarcinoma to the Poly (ADP ribose) Polymerase (PARP) Inhibitor Olaparib. olaparib 139-147 poly(ADP-ribose) polymerase 1 Homo sapiens 123-127 34969765-2 2022 Although olaparib, a poly ADP ribose polymerase (PARP) inhibitor, is considered a potential effective agent for gastric cancer, the effect and underlying mechanism of olaparib on gastric cancer depending on EBV infection is not fully understood. olaparib 9-17 poly(ADP-ribose) polymerase 1 Homo sapiens 21-47 34969765-2 2022 Although olaparib, a poly ADP ribose polymerase (PARP) inhibitor, is considered a potential effective agent for gastric cancer, the effect and underlying mechanism of olaparib on gastric cancer depending on EBV infection is not fully understood. olaparib 9-17 poly(ADP-ribose) polymerase 1 Homo sapiens 49-53 34969765-2 2022 Although olaparib, a poly ADP ribose polymerase (PARP) inhibitor, is considered a potential effective agent for gastric cancer, the effect and underlying mechanism of olaparib on gastric cancer depending on EBV infection is not fully understood. olaparib 167-175 poly(ADP-ribose) polymerase 1 Homo sapiens 21-47 34969765-2 2022 Although olaparib, a poly ADP ribose polymerase (PARP) inhibitor, is considered a potential effective agent for gastric cancer, the effect and underlying mechanism of olaparib on gastric cancer depending on EBV infection is not fully understood. olaparib 167-175 poly(ADP-ribose) polymerase 1 Homo sapiens 49-53 35400012-7 2022 Case Report: We here present the case report of an 81-year-old woman with a mutated BRCA2 metastatic clear cell endometrial adenocarcinoma that showed an excellent clinical and radiological response to the PARP inhibitor olaparib. olaparib 221-229 poly(ADP-ribose) polymerase 1 Homo sapiens 206-210 33652085-11 2021 In conclusion, by exploring the functionality of the Fra-1 and PARP1 interaction, we propose that targeting Fra-1 could serve as a combinatory therapeutic approach to improve olaparib treatment outcome for TNBC patients. olaparib 175-183 poly(ADP-ribose) polymerase 1 Homo sapiens 63-68 32814472-4 2021 MATERIALS AND METHODS: The sensitivity of PARP inhibitor, Olaparib, to different NSCLC cell lines was determined by half maximal inhibitory concentration (IC50). olaparib 58-66 poly(ADP-ribose) polymerase 1 Homo sapiens 42-46 33652085-3 2021 PARP1 inhibitor (olaparib) is currently in clinical use for treatment of BRCA-mutated TNBC breast cancer. olaparib 17-25 poly(ADP-ribose) polymerase 1 Homo sapiens 0-5 34050611-8 2022 Notably, the clonogenicity of LDHC-silenced cells was further reduced by treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib, and with the DNA-damaging drug cisplatin. olaparib 138-146 poly(ADP-ribose) polymerase 1 Homo sapiens 92-120 34050611-8 2022 Notably, the clonogenicity of LDHC-silenced cells was further reduced by treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib, and with the DNA-damaging drug cisplatin. olaparib 138-146 poly(ADP-ribose) polymerase 1 Homo sapiens 122-126 35165509-3 2022 Olaparib, a PARP inhibitor, has benefited many ovarian cancer patients, but olaparib is much less effective as a single agent in 50% of patients with high grade severe tumors. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 12-16 35165509-3 2022 Olaparib, a PARP inhibitor, has benefited many ovarian cancer patients, but olaparib is much less effective as a single agent in 50% of patients with high grade severe tumors. olaparib 76-84 poly(ADP-ribose) polymerase 1 Homo sapiens 12-16 33652085-4 2021 Here, we demonstrate that the Fra-1-PARP1 interaction impacts the efficacy of olaparib treatment. olaparib 78-86 poly(ADP-ribose) polymerase 1 Homo sapiens 36-41 34025781-9 2021 The phase III POLO trial showed a near doubling of progression-free survival (PFS) compared with placebo in advanced PDAC when a PARP inhibitor, olaparib, was used as maintenance therapy. olaparib 145-153 poly(ADP-ribose) polymerase 1 Homo sapiens 129-133 34037269-8 2021 We found that the inhibition of PARP1 in patient derived xenografts from aggressive HBL by FDA approved inhibitor Olaparib, significantly inhibits tumor growth. olaparib 114-122 poly(ADP-ribose) polymerase 1 Homo sapiens 32-37 34037269-12 2021 By utilizing the PARP1 inhibitor Olaparib, we suppressed tumor growth in HBL-PDX models, which demonstrated its utility in future clinical models. olaparib 33-41 poly(ADP-ribose) polymerase 1 Homo sapiens 17-22 34025781-11 2021 The success of olaparib in treating advanced PDAC opened the new field for utilizing PARP inhibitors in patients with DNA damage repair (DDR) gene defects. olaparib 15-23 poly(ADP-ribose) polymerase 1 Homo sapiens 85-89 33382149-2 2021 Olaparib was the first PARP inhibitor to gain approval as maintenance therapy for patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer establishing a new standard of care. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 23-27 33986609-8 2021 This action was described, among others, for olaparib, a PARP-1 inhibitor approved for use in oncology. olaparib 45-53 poly(ADP-ribose) polymerase 1 Homo sapiens 57-63 33866131-3 2021 Targeting DNA damage response (DDR) pathways in prostate cancer became a promising treatment strategy and olaparib and rucaparib, Poly(ADP-ribose) polymerase (PARP) inhibitors, have been approved for patients carrying mutations in homologous recombination (HR) repair pathways. olaparib 106-114 poly(ADP-ribose) polymerase 1 Homo sapiens 130-157 33743851-1 2021 BACKGROUND: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously been shown to extend progression-free survival versus placebo when given to patients with relapsed high-grade serous or endometrioid ovarian cancer who were platinum sensitive and who had a BRCA1 or BRCA2 (BRCA1/2) mutation, as part of the SOLO2/ENGOT-Ov21 trial. olaparib 12-20 poly(ADP-ribose) polymerase 1 Homo sapiens 24-52 33743851-1 2021 BACKGROUND: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously been shown to extend progression-free survival versus placebo when given to patients with relapsed high-grade serous or endometrioid ovarian cancer who were platinum sensitive and who had a BRCA1 or BRCA2 (BRCA1/2) mutation, as part of the SOLO2/ENGOT-Ov21 trial. olaparib 12-20 poly(ADP-ribose) polymerase 1 Homo sapiens 54-58 33743851-16 2021 Median overall survival was 51 7 months (95% CI 41 5-59 1) with olaparib and 38 8 months (31 4-48 6) with placebo (hazard ratio 0 74 [95% CI 0 54-1 00]; p=0 054), unadjusted for the 38% of patients in the placebo group who received subsequent PARP inhibitor therapy. olaparib 64-72 poly(ADP-ribose) polymerase 1 Homo sapiens 243-247 33747222-3 2021 The present study aimed to explore the synergistic effects of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib combined with ERCC1 on the sensitivity of NSCLC cells to cisplatin. olaparib 111-119 poly(ADP-ribose) polymerase 1 Homo sapiens 66-93 33747222-3 2021 The present study aimed to explore the synergistic effects of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib combined with ERCC1 on the sensitivity of NSCLC cells to cisplatin. olaparib 111-119 poly(ADP-ribose) polymerase 1 Homo sapiens 95-99 33753103-8 2021 Our findings identified a PMN-induced HR-deficient CRC phenotype, featuring low RAD51 and low Ku70 levels, rendering it susceptible to synthetic lethality induced by clinically approved PARP1 inhibitor Olaparib. olaparib 202-210 poly(ADP-ribose) polymerase 1 Homo sapiens 186-191 33888065-3 2021 A growing body of evidence supports the role of Poly-(ADP-ribose) polymerase (PARP) inhibitors, such as Olaparib, in the treatment of different subsets of cancer beyond the tumors with homologous recombination deficiencies. olaparib 104-112 poly(ADP-ribose) polymerase 1 Homo sapiens 48-76 33888065-3 2021 A growing body of evidence supports the role of Poly-(ADP-ribose) polymerase (PARP) inhibitors, such as Olaparib, in the treatment of different subsets of cancer beyond the tumors with homologous recombination deficiencies. olaparib 104-112 poly(ADP-ribose) polymerase 1 Homo sapiens 78-82 33617901-4 2021 The FDA and EMA has recently approved olaparib, a Poly (ADP-ribose) polymerase (PARP) inhibitor, as a maintenance strategy for platinum-sensitive advanced PDAC patients with BRCA mutations. olaparib 38-46 poly(ADP-ribose) polymerase 1 Homo sapiens 50-78 33617901-4 2021 The FDA and EMA has recently approved olaparib, a Poly (ADP-ribose) polymerase (PARP) inhibitor, as a maintenance strategy for platinum-sensitive advanced PDAC patients with BRCA mutations. olaparib 38-46 poly(ADP-ribose) polymerase 1 Homo sapiens 80-84 33788167-6 2021 10e is a structural analogue of FDA-approved PARPi olaparib, with high PARP-1 affinity and selectivity. olaparib 51-59 poly(ADP-ribose) polymerase 1 Homo sapiens 71-77 33710534-4 2021 Olaparib and talazoparib are PARP inhibitors approved as monotherapies for deleterious/suspected deleterious germline BRCA-mutated, HER2-negative BC. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 29-33 33710534-10 2021 Differences in efficacy and safety across PARP inhibitors (olaparib, talazoparib, veliparib, niraparib, rucaparib) may relate to differences in potency of PARP trapping on DNA and cytotoxic specificity. olaparib 59-67 poly(ADP-ribose) polymerase 1 Homo sapiens 42-46 33710534-10 2021 Differences in efficacy and safety across PARP inhibitors (olaparib, talazoparib, veliparib, niraparib, rucaparib) may relate to differences in potency of PARP trapping on DNA and cytotoxic specificity. olaparib 59-67 poly(ADP-ribose) polymerase 1 Homo sapiens 155-159 33959007-1 2021 Background: The PARP inhibitor olaparib has been shown to have clinical efficacy in patients with a germline BRCA mutation and ovarian or breast cancer. olaparib 31-39 poly(ADP-ribose) polymerase 1 Homo sapiens 16-20 33827356-4 2021 AREAS COVERED: Here, the authors" review the clinical trials leading to the recent approvals of two PARP inhibitors (PARPi), olaparib and rucaparib, specifically TOPARP-A, TOPARP-B, PROfound and TRITON-2. olaparib 125-133 poly(ADP-ribose) polymerase 1 Homo sapiens 100-104 33358233-1 2021 Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. olaparib 221-229 poly(ADP-ribose) polymerase 1 Homo sapiens 12-16 33262140-1 2021 PURPOSE: To identify a maximum tolerated dose (MTD) of the PARP inhibitor olaparib in combination with loco-regional radiotherapy with/without cisplatin for the treatment of non-small cell lung cancer (NSCLC). olaparib 74-82 poly(ADP-ribose) polymerase 1 Homo sapiens 59-63 33646064-3 2021 The authors then summarize the area and provide their expert perspectives on the area.Expert opinionTwo PARP inhibitors are approved in metastatic breast cancer, including olaparib and talozaparib. olaparib 172-180 poly(ADP-ribose) polymerase 1 Homo sapiens 104-108 33358234-1 2021 Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. olaparib 221-229 poly(ADP-ribose) polymerase 1 Homo sapiens 12-16 33630412-2 2021 The recent approvals of the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and rucaparib in the metastatic castration-resistant prostate cancer (mCRPC) setting signal the need to embed molecular diagnostics in the clinical pathway of patients with mCRPC to identify those who can benefit from targeted therapies. olaparib 74-82 poly(ADP-ribose) polymerase 1 Homo sapiens 28-55 33981756-10 2021 After initial treatment by FOLFOX, maintenance therapy with the poly-ADP-ribose-polymerase (PARP) inhibitor olaparib was initiated. olaparib 108-116 poly(ADP-ribose) polymerase 1 Homo sapiens 64-90 33981756-10 2021 After initial treatment by FOLFOX, maintenance therapy with the poly-ADP-ribose-polymerase (PARP) inhibitor olaparib was initiated. olaparib 108-116 poly(ADP-ribose) polymerase 1 Homo sapiens 92-96 33637776-7 2021 We found that dual PI3K and PARP inhibition with BKM120 and olaparib significantly reduced the proliferation of BRCA-proficient TNBC cell lines MDA-MB-231 and MDA231-LM2. olaparib 60-68 poly(ADP-ribose) polymerase 1 Homo sapiens 28-32 33637776-9 2021 Olaparib resulted in concomitant gain of PARP1, forkhead box M1 (FOXM1) and Exonuclease 1 (Exo1) while inhibited the activity of PARP. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 41-46 33637776-9 2021 Olaparib resulted in concomitant gain of PARP1, forkhead box M1 (FOXM1) and Exonuclease 1 (Exo1) while inhibited the activity of PARP. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 41-45 33637776-10 2021 BKM120 downregulated the expression of PARP1 and PARP2 to assist olaparib in blocking PARP mediated repair of DNA SSBs. olaparib 65-73 poly(ADP-ribose) polymerase 1 Homo sapiens 39-44 33637776-10 2021 BKM120 downregulated the expression of PARP1 and PARP2 to assist olaparib in blocking PARP mediated repair of DNA SSBs. olaparib 65-73 poly(ADP-ribose) polymerase 1 Homo sapiens 39-43 33511412-4 2021 Here we present a study of isolated CAT domain from human PARP-1, using NMR-based dynamics experiments to analyse WT apo-protein as well as a set of inhibitor complexes (with veliparib, olaparib, talazoparib and EB-47) and point mutants (L713F, L765A and L765F), together with new crystal structures of the free CAT domain and inhibitor complexes. olaparib 186-194 poly(ADP-ribose) polymerase 1 Homo sapiens 58-64 33630412-2 2021 The recent approvals of the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and rucaparib in the metastatic castration-resistant prostate cancer (mCRPC) setting signal the need to embed molecular diagnostics in the clinical pathway of patients with mCRPC to identify those who can benefit from targeted therapies. olaparib 74-82 poly(ADP-ribose) polymerase 1 Homo sapiens 57-61 33069804-0 2021 Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib. olaparib 121-129 poly(ADP-ribose) polymerase 1 Homo sapiens 105-110 33627685-1 2021 The poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib has shown antitumor activity in patients with ovarian or breast cancer with or without BRCA1/2 mutations. olaparib 50-58 poly(ADP-ribose) polymerase 1 Homo sapiens 4-32 33627685-1 2021 The poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib has shown antitumor activity in patients with ovarian or breast cancer with or without BRCA1/2 mutations. olaparib 50-58 poly(ADP-ribose) polymerase 1 Homo sapiens 34-38 33671709-7 2021 Furthermore, cell pretreatment with proteasome inhibitor MG132 completely abrogates the effect of Olaparib, suggesting that PARP1 acts with NF-kappaB in the same regulatory pathway, which controls pro-inflammatory cytokine transcription. olaparib 98-106 poly(ADP-ribose) polymerase 1 Homo sapiens 124-129 33608381-5 2021 He achieved a complete response to platinum-containing chemotherapy, but a limited remission duration with the use of olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, as maintenance therapy. olaparib 118-126 poly(ADP-ribose) polymerase 1 Homo sapiens 130-157 33608381-5 2021 He achieved a complete response to platinum-containing chemotherapy, but a limited remission duration with the use of olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, as maintenance therapy. olaparib 118-126 poly(ADP-ribose) polymerase 1 Homo sapiens 159-163 33069804-2 2021 In this study, we investigated the cytotoxicity induced by PARP inhibitor olaparib in FLCN deficient RCC cells, and the interaction between FLCN and BRCA1 A complex-regulated DNA repair pathway. olaparib 74-82 poly(ADP-ribose) polymerase 1 Homo sapiens 59-63 33069804-11 2021 Decreased BRCA1 A complex expression and disruption of DNA repair ability were detected in FLCN-deficient cells, suggesting that FLCN deficiency impaired BRCA1 A complex expression and sensitized cells to PARP inhibitor olaparib. olaparib 220-228 poly(ADP-ribose) polymerase 1 Homo sapiens 205-209 33069804-13 2021 The results suggest that PARP inhibitor, such as olaparib, may be a potentially effective therapeutic approach for kidney tumors with deficiency of FLCN protein. olaparib 49-57 poly(ADP-ribose) polymerase 1 Homo sapiens 25-29 33388624-3 2021 Olaparib is an oral inhibitor of Poly (ADP-Ribose) polymerase (PARP) and has demonstrated optimal efficacy and clinical activity in trials. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 33-61 33388624-3 2021 Olaparib is an oral inhibitor of Poly (ADP-Ribose) polymerase (PARP) and has demonstrated optimal efficacy and clinical activity in trials. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 63-67 33388624-8 2021 The combination of talaporfin PDT and olaparib enhanced PARP1 accumulation (the entrapment of PARP1-DNA complexes) in bound chromatin. olaparib 38-46 poly(ADP-ribose) polymerase 1 Homo sapiens 56-61 33388624-8 2021 The combination of talaporfin PDT and olaparib enhanced PARP1 accumulation (the entrapment of PARP1-DNA complexes) in bound chromatin. olaparib 38-46 poly(ADP-ribose) polymerase 1 Homo sapiens 94-99 33388624-12 2021 Our results demonstrated that olaparib enhances the efficacy of talaporfin PDT by inducing the formation of PARP-DNA complexes. olaparib 30-38 poly(ADP-ribose) polymerase 1 Homo sapiens 108-112 33592660-8 2021 In patients with a proven germline mutation in the BRCA gene, a therapy with the PARP inhibitor olaparib is in the approval process.This article provides an overview of differential diagnoses, meaningful diagnostics, therapeutic concepts to improve surgical treatment, possibilities of palliative chemotherapy and targeted therapy in the presence of a BRCA mutation. olaparib 96-104 poly(ADP-ribose) polymerase 1 Homo sapiens 81-85 33531508-5 2021 Here we demonstrate that HPF1 significantly increases the affinity for a PARP1 - DNA complex of some PARPi (i.e., olaparib), but not others (i.e., veliparib). olaparib 114-122 poly(ADP-ribose) polymerase 1 Homo sapiens 73-78 33531508-6 2021 This effect of HPF1 on the binding affinity of Olaparib also holds true for the more physiologically relevant PARP1 - nucleosome complex but does not extend to PARP2. olaparib 47-55 poly(ADP-ribose) polymerase 1 Homo sapiens 110-115 33169439-7 2021 Further, p.Ser64Leu and p.Pro104Leu both largely compromise DNA double-strand break-initiated homologous recombination, and confer increased cellular sensitivity to ionizing radiation (IR) and the poly (ADP-ribose) polymerase (PARP) inhibitor Olaparib. olaparib 243-251 poly(ADP-ribose) polymerase 1 Homo sapiens 197-225 33319340-1 2021 PURPOSE: Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for ovarian and metastatic breast cancer. olaparib 9-17 poly(ADP-ribose) polymerase 1 Homo sapiens 23-51 33319340-1 2021 PURPOSE: Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for ovarian and metastatic breast cancer. olaparib 9-17 poly(ADP-ribose) polymerase 1 Homo sapiens 53-57 33169439-7 2021 Further, p.Ser64Leu and p.Pro104Leu both largely compromise DNA double-strand break-initiated homologous recombination, and confer increased cellular sensitivity to ionizing radiation (IR) and the poly (ADP-ribose) polymerase (PARP) inhibitor Olaparib. olaparib 243-251 poly(ADP-ribose) polymerase 1 Homo sapiens 227-231 33268569-0 2021 Combinatorial efficacy of olaparib with radiation and ATR inhibitor requires PARP1 protein in homologous recombination proficient pancreatic cancer. olaparib 26-34 poly(ADP-ribose) polymerase 1 Homo sapiens 77-82 32409690-7 2021 Importantly, the growth related role of TET1 in T-ALL could be antagonized by the clinically approved PARP inhibitor Olaparib, which abrogated TET1 expression, induced loss of 5hmC marks, and antagonized leukemic growth of T-ALL cells, opening a therapeutic avenue for this disease. olaparib 117-125 poly(ADP-ribose) polymerase 1 Homo sapiens 102-106 33268569-10 2021 These findings suggest that PARP1-DNA complexes are required for the therapeutic activity of olaparib combined with radiation and ATR inhibitor in HR-proficient pancreatic cancer and support the clinical development of this combination for tumors intrinsically resistant to PARP inhibitors. olaparib 93-101 poly(ADP-ribose) polymerase 1 Homo sapiens 28-33 33268569-10 2021 These findings suggest that PARP1-DNA complexes are required for the therapeutic activity of olaparib combined with radiation and ATR inhibitor in HR-proficient pancreatic cancer and support the clinical development of this combination for tumors intrinsically resistant to PARP inhibitors. olaparib 93-101 poly(ADP-ribose) polymerase 1 Homo sapiens 28-32 33268569-1 2021 PARP inhibitor monotherapy (olaparib) was recently FDA-approved for the treatment of BRCA1/2 mutant, HR (homologous recombination repair)-deficient pancreatic cancer. olaparib 28-36 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 33268569-5 2021 While catalytic inhibition of PARP with low concentrations of olaparib radiosensitized HR-deficient models, maximal sensitization in HR-proficient models required concentrations of olaparib that induce formation of PARP1-DNA complexes. olaparib 62-70 poly(ADP-ribose) polymerase 1 Homo sapiens 30-34 33268569-5 2021 While catalytic inhibition of PARP with low concentrations of olaparib radiosensitized HR-deficient models, maximal sensitization in HR-proficient models required concentrations of olaparib that induce formation of PARP1-DNA complexes. olaparib 181-189 poly(ADP-ribose) polymerase 1 Homo sapiens 215-220 33268569-6 2021 Furthermore, CRISPR-Cas9-mediated PARP1 deletion failed to recapitulate the effects of olaparib on radiosensitivity and negated the combinatorial efficacy of olaparib and AZD6738 on radiosensitization, suggesting that PARP1-DNA complexes, rather than PARP catalytic inhibition, were responsible for radiosensitization. olaparib 158-166 poly(ADP-ribose) polymerase 1 Homo sapiens 34-39 33485358-0 2021 PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma. olaparib 15-23 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 33485358-7 2021 PARP inhibitor Olaparib extensively suppressed the DNA damage repair signaling, and significantly inhibited the global pluripotent transcriptional network. olaparib 15-23 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 33481867-8 2021 When the 6-Fluo-10-NAD+ based PARP activity assay was performed in the presence of the PARP specific inhibitor olaparib, the activity signal was completely abolished, attesting to the specificity of the assay. olaparib 111-119 poly(ADP-ribose) polymerase 1 Homo sapiens 30-34 33481867-8 2021 When the 6-Fluo-10-NAD+ based PARP activity assay was performed in the presence of the PARP specific inhibitor olaparib, the activity signal was completely abolished, attesting to the specificity of the assay. olaparib 111-119 poly(ADP-ribose) polymerase 1 Homo sapiens 87-91 33520371-11 2021 As described herein, we proposed to expand PARP inhibitor-targeted therapy to more pancreatic cancer patients regardless of BRCA mutation status by combining olaparib, a PARP inhibitor, with c-MET inhibitors as we demonstrated in our previous studies in breast cancer. olaparib 158-166 poly(ADP-ribose) polymerase 1 Homo sapiens 43-47 33407459-3 2021 Recent studies demonstrated a significant progression-free survival (PFS) benefit from maintenance olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor administered to patients with germline BRCA mutations and metastatic pancreatic cancer. olaparib 99-107 poly(ADP-ribose) polymerase 1 Homo sapiens 111-139 33407459-3 2021 Recent studies demonstrated a significant progression-free survival (PFS) benefit from maintenance olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor administered to patients with germline BRCA mutations and metastatic pancreatic cancer. olaparib 99-107 poly(ADP-ribose) polymerase 1 Homo sapiens 141-145 33361107-6 2021 Using surface plasmon resonance, we measured the dissociation constants of talazoparib, olaparib, niraparib and veliparib for their interaction with PARP1 and tankyrase1. olaparib 88-96 poly(ADP-ribose) polymerase 1 Homo sapiens 149-154 33402194-0 2021 Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer. olaparib 119-127 poly(ADP-ribose) polymerase 1 Homo sapiens 104-108 33520371-11 2021 As described herein, we proposed to expand PARP inhibitor-targeted therapy to more pancreatic cancer patients regardless of BRCA mutation status by combining olaparib, a PARP inhibitor, with c-MET inhibitors as we demonstrated in our previous studies in breast cancer. olaparib 158-166 poly(ADP-ribose) polymerase 1 Homo sapiens 170-174 32079692-4 2021 PARP1 knockdown or its pharmacological inhibition by Olaparib impaired MM cells viability in vitro and was effective against in vivo xenografts of human MM. olaparib 53-61 poly(ADP-ribose) polymerase 1 Homo sapiens 0-5 32164505-3 2021 Currently, four PARP inhibitors including olaparib, rucaparib, niraparib, and talazoparib have been approved by FDA for cancer treatment and have achieved great success in the treatment of ovarian cancer, breast cancer, and pancreatic cancer etc. olaparib 42-50 poly(ADP-ribose) polymerase 1 Homo sapiens 16-20 33468723-1 2021 In 2018, olaparib, a PARP inhibitor, was approved for the treatment of BRCA1/2 gene-mutation positive and HER2-negative inoperable and recurrent breast cancer; BRCA1/2 gene testing was also listed as a companion diagnostics. olaparib 9-17 poly(ADP-ribose) polymerase 1 Homo sapiens 21-25 33468723-4 2021 Moreover, the expression of miR-141 in MDA-MB-436 cells treated with the PARP-1 inhibitor together with gemcitabine increased more than 10 times; additionally, the expression of miR-205 increased more in the context of combination therapy versus single exposure to olaparib. olaparib 265-273 poly(ADP-ribose) polymerase 1 Homo sapiens 73-79 33250205-1 2021 PURPOSE: Maintenance therapy with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib provided a substantial progression-free survival (PFS) benefit compared with placebo in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (BRCAm) who were in clinical complete or partial response following platinum-based chemotherapy in the Phase III SOLO1 global study. olaparib 83-91 poly(ADP-ribose) polymerase 1 Homo sapiens 38-65 33250205-1 2021 PURPOSE: Maintenance therapy with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib provided a substantial progression-free survival (PFS) benefit compared with placebo in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (BRCAm) who were in clinical complete or partial response following platinum-based chemotherapy in the Phase III SOLO1 global study. olaparib 83-91 poly(ADP-ribose) polymerase 1 Homo sapiens 67-71 32790034-1 2021 The U.S. Food and Drug Administration (FDA) recently approved two poly-ADP ribose polymerase (PARP) inhibitors, olaparib and rucaparib, for treatment of biomarker-positive metastatic castrate resistant prostate cancer. olaparib 112-120 poly(ADP-ribose) polymerase 1 Homo sapiens 66-92 33495297-1 2021 BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors (eg, olaparib) are effective against BRCA-mutated cancers at/near maximum tolerated doses by trapping PARP-1 on damaged chromatin, benefitting only small patient proportions. olaparib 63-71 poly(ADP-ribose) polymerase 1 Homo sapiens 12-39 33495297-1 2021 BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors (eg, olaparib) are effective against BRCA-mutated cancers at/near maximum tolerated doses by trapping PARP-1 on damaged chromatin, benefitting only small patient proportions. olaparib 63-71 poly(ADP-ribose) polymerase 1 Homo sapiens 41-45 33495297-1 2021 BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors (eg, olaparib) are effective against BRCA-mutated cancers at/near maximum tolerated doses by trapping PARP-1 on damaged chromatin, benefitting only small patient proportions. olaparib 63-71 poly(ADP-ribose) polymerase 1 Homo sapiens 160-166 33576344-6 2021 In addition, we examined the effect of classic cytotoxic drugs (Doxorubicin, Gemcitabine, Irinotecan and 5-Fluorouracil) and a PARP-1 inhibitor (Olaparib) in cultured cells and 3D tumorspheres. olaparib 145-153 poly(ADP-ribose) polymerase 1 Homo sapiens 127-133 32790034-1 2021 The U.S. Food and Drug Administration (FDA) recently approved two poly-ADP ribose polymerase (PARP) inhibitors, olaparib and rucaparib, for treatment of biomarker-positive metastatic castrate resistant prostate cancer. olaparib 112-120 poly(ADP-ribose) polymerase 1 Homo sapiens 94-98 33352723-6 2020 PARP expression was associated with sensitivity to olaparib or inhibitors of RSR. olaparib 51-59 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 33119476-1 2020 PURPOSE: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) in germline (g)BRCA1/2 mutation carriers. olaparib 9-17 poly(ADP-ribose) polymerase 1 Homo sapiens 21-49 33119476-1 2020 PURPOSE: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) in germline (g)BRCA1/2 mutation carriers. olaparib 9-17 poly(ADP-ribose) polymerase 1 Homo sapiens 51-55 33519476-6 2020 Blocking DNA repair with the PARP inhibitor olaparib markedly synergized with alkannin to yield synergistic cytotoxicity in colorectal cancer cells at nontoxic doses of both drugs. olaparib 44-52 poly(ADP-ribose) polymerase 1 Homo sapiens 29-33 33519476-7 2020 Synergy between alkannin and olaparib resulted from interrupted repair of alkannin-induced oxidative DNA damage and PARP-trapping, as it was significantly attenuated by NAC or by OGG1 inhibition and the non-trapping PARP inhibitor veliparib did not yield synergism. olaparib 29-37 poly(ADP-ribose) polymerase 1 Homo sapiens 116-120 33519476-7 2020 Synergy between alkannin and olaparib resulted from interrupted repair of alkannin-induced oxidative DNA damage and PARP-trapping, as it was significantly attenuated by NAC or by OGG1 inhibition and the non-trapping PARP inhibitor veliparib did not yield synergism. olaparib 29-37 poly(ADP-ribose) polymerase 1 Homo sapiens 216-220 32347934-1 2020 BACKGROUND: The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib potentiated radiation and temozolomide chemotherapy in pre-clinical glioblastoma models but brain penetration was poor. olaparib 61-69 poly(ADP-ribose) polymerase 1 Homo sapiens 16-43 32347934-1 2020 BACKGROUND: The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib potentiated radiation and temozolomide chemotherapy in pre-clinical glioblastoma models but brain penetration was poor. olaparib 61-69 poly(ADP-ribose) polymerase 1 Homo sapiens 45-49 33355125-2 2020 In a genome-wide CRISPR knockout screen with olaparib, we identify ALC1 (Amplified in Liver Cancer 1)-a cancer-relevant poly(ADP-ribose)-regulated chromatin remodeling enzyme-as a key modulator of sensitivity to PARP inhibitor. olaparib 45-53 poly(ADP-ribose) polymerase 1 Homo sapiens 212-216 33277249-4 2020 Small molecules, such as olaparib, that trap PARP1 to chromatin are able to evict the minimal pool of chromatin-bound MYBBP1A protein in MYBBP1A hemizygous cells and impair cell growth, greater than its impact on wild-type cells. olaparib 25-33 poly(ADP-ribose) polymerase 1 Homo sapiens 45-50 33327923-7 2021 RESULTS: In in-silico molecular docking studies compounds B3 and B9 show binding affinity like known PARP1 inhibitor olaparib. olaparib 117-125 poly(ADP-ribose) polymerase 1 Homo sapiens 101-106 33333852-0 2020 The PARP Inhibitor Olaparib Modulates the Transcriptional Regulatory Networks of Long Non-Coding RNAs during Vasculogenic Mimicry. olaparib 19-27 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 33200929-0 2020 Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer. olaparib 141-149 poly(ADP-ribose) polymerase 1 Homo sapiens 126-130 33200929-5 2020 SBP-7455 inhibited starvation-induced autophagic flux in TNBC cells that were dependent on autophagy for survival and displayed synergistic cytotoxicity with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib against TNBC cells. olaparib 208-216 poly(ADP-ribose) polymerase 1 Homo sapiens 162-190 33200929-5 2020 SBP-7455 inhibited starvation-induced autophagic flux in TNBC cells that were dependent on autophagy for survival and displayed synergistic cytotoxicity with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib against TNBC cells. olaparib 208-216 poly(ADP-ribose) polymerase 1 Homo sapiens 192-196 32980128-0 2020 The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib. olaparib 131-139 poly(ADP-ribose) polymerase 1 Homo sapiens 116-120 32881420-2 2020 After the FDA approvals of the poly ADP ribose polymerase (PARP) inhibitors, olaparib and talazoparib, for treatment of metastatic breast cancer, carrying germline mutations in BRCA1 and BRCA2 genes, the genetic testing result has become critical in their care. olaparib 77-85 poly(ADP-ribose) polymerase 1 Homo sapiens 59-63 33406057-1 2020 The management of prostate cancer entered a new era of biomarker-driven therapy in May of 2020, when the US Food and Drug Administration (FDA) approved the poly (ADP-ribose) polymerase (PARP) inhibitors rucaparib and olaparib as the first targeted therapies in biomarker-preselected patients with metastatic castration-resistant prostate cancer. olaparib 217-225 poly(ADP-ribose) polymerase 1 Homo sapiens 156-184 33406057-1 2020 The management of prostate cancer entered a new era of biomarker-driven therapy in May of 2020, when the US Food and Drug Administration (FDA) approved the poly (ADP-ribose) polymerase (PARP) inhibitors rucaparib and olaparib as the first targeted therapies in biomarker-preselected patients with metastatic castration-resistant prostate cancer. olaparib 217-225 poly(ADP-ribose) polymerase 1 Homo sapiens 186-190 33059228-5 2020 The PARP inhibitors olaparib, veliparib, talazoparib, niraparib, and rucaparib have predominantly been studied in patients with breast or ovarian cancers associated with deleterious germline mutations in BRCA1 and BRCA2. olaparib 20-28 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 33293727-9 2020 Clinical studies have also shown the efficacy of angiogenesis inhibitors such as bevacizumab and the PARP inhibitors olaparib, niraparib and rucaparib. olaparib 117-125 poly(ADP-ribose) polymerase 1 Homo sapiens 101-105 33293727-12 2020 The PARP inhibitors niraparib, olaparib and rucaparib have already been approved for use by the FDA and the EMA. olaparib 31-39 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 32988624-1 2020 OBJECTIVE: Olaparib is a potent inhibitor of poly(ADP-ribose) polymerase (PARP)-1, 2, and 3 with potential activity in endometrial cancer (EC). olaparib 11-19 poly(ADP-ribose) polymerase 1 Homo sapiens 45-91 32988624-12 2020 CONCLUSIONS: Olaparib reduced expression of cyclin D1, which positively correlated with PARP-1 levels. olaparib 13-21 poly(ADP-ribose) polymerase 1 Homo sapiens 88-94 33262410-3 2020 PARP1-mediated autophagy was evaluated in vitro by CCK-8 assay, clonogenic assay, immunofluorescence, and western blot in the HCC-827, H1975, and H1299 cells treated with icotinib (Ico), rapamycin, and AZD2281 (olaparib) alone or in combination. olaparib 202-209 poly(ADP-ribose) polymerase 1 Homo sapiens 0-5 33183763-8 2020 Preclinical data, presented here, demonstrates marked activity for the PARP inhibitor olaparib in combination with the alkylating agent temozolomide in leiomyosarcoma models. olaparib 86-94 poly(ADP-ribose) polymerase 1 Homo sapiens 71-75 33070053-3 2020 Since the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib, may attenuate and/or prevent BRCA1 expression, the addition of olaparib to gefitinib could improve outcome in EGFR-mutant advanced NSCLC. olaparib 57-65 poly(ADP-ribose) polymerase 1 Homo sapiens 10-38 33070053-3 2020 Since the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib, may attenuate and/or prevent BRCA1 expression, the addition of olaparib to gefitinib could improve outcome in EGFR-mutant advanced NSCLC. olaparib 57-65 poly(ADP-ribose) polymerase 1 Homo sapiens 40-44 33262410-3 2020 PARP1-mediated autophagy was evaluated in vitro by CCK-8 assay, clonogenic assay, immunofluorescence, and western blot in the HCC-827, H1975, and H1299 cells treated with icotinib (Ico), rapamycin, and AZD2281 (olaparib) alone or in combination. olaparib 211-219 poly(ADP-ribose) polymerase 1 Homo sapiens 0-5 33262410-6 2020 AZD2281 and a lysosomal inhibitor reversed resistance to Ico by decreasing PARP1 and LC3 in cells, but an mTOR inhibitor did not decrease Ico resistance. olaparib 0-7 poly(ADP-ribose) polymerase 1 Homo sapiens 75-80 33262410-7 2020 The combination of AZD2281 and Ico exerted a markedly enhanced antitumor effect by reducing PARP1 expression and autophagy in vivo. olaparib 19-26 poly(ADP-ribose) polymerase 1 Homo sapiens 92-97 33330039-10 2020 In this case, after failing conventional therapies, patient was treated with PARP inhibitor olaparib. olaparib 92-100 poly(ADP-ribose) polymerase 1 Homo sapiens 77-81 32936912-9 2020 We tested the effect of adding cetuximab and/or olaparib (inhibitors of EGFR and PARP1, respectively) to radiation and compared it to that of cisplatin and radiation combination, which is the standard of care. olaparib 48-56 poly(ADP-ribose) polymerase 1 Homo sapiens 81-86 33336070-4 2020 Based on the results, several impressive drugs have been approved to benefit patients with TNBC, including the PARP inhibitors olaparib and talazoparib for germline BRCA mutation-associated breast cancer (gBRCAm-BC) and immunotherapy using the checkpoint inhibitor atezolizumab in combination with nab-paclitaxel for programmed cell death-ligand 1-positive (PD-L1+) advanced TNBC. olaparib 127-135 poly(ADP-ribose) polymerase 1 Homo sapiens 111-115 32878963-9 2020 If the prior PARP inhibitor used was olaparib then patients must have received treatment without significant toxicity or the need for a permanent dose reduction. olaparib 37-45 poly(ADP-ribose) polymerase 1 Homo sapiens 13-17 33167505-7 2020 Combination treatment with 7c and olaparib (a poly (ADP-ribose) polymerase [PARP] inhibitor) synergistically inhibited cell proliferation in Molm-13 and MV4-11 cells. olaparib 34-42 poly(ADP-ribose) polymerase 1 Homo sapiens 46-74 33167505-7 2020 Combination treatment with 7c and olaparib (a poly (ADP-ribose) polymerase [PARP] inhibitor) synergistically inhibited cell proliferation in Molm-13 and MV4-11 cells. olaparib 34-42 poly(ADP-ribose) polymerase 1 Homo sapiens 76-80 33099187-4 2020 Recently, targeted therapy with the angiogenesis inhibitor bevacizumab and the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib, niraparib, and rucaparib have demonstrated significant clinical benefits as maintenance treatment for recurrent disease. olaparib 125-133 poly(ADP-ribose) polymerase 1 Homo sapiens 79-106 33099187-4 2020 Recently, targeted therapy with the angiogenesis inhibitor bevacizumab and the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib, niraparib, and rucaparib have demonstrated significant clinical benefits as maintenance treatment for recurrent disease. olaparib 125-133 poly(ADP-ribose) polymerase 1 Homo sapiens 108-112 33310779-3 2020 Subsequently, the results of three phase III trials (PRIMA, PAOLA-1, VELIA) evaluating the use of first-line PARP inhibitors beyond patients with BRCA1/2 mutations and as combination strategies were presented in 2019, leading to the recent approval of maintenance niraparib irrespective of biomarker status and olaparib in combination with bevacizumab in homologous recombination deficiency-positive-associated advanced ovarian cancer. olaparib 311-319 poly(ADP-ribose) polymerase 1 Homo sapiens 109-113 32799562-5 2020 Olaparib, an oral PARP inhibitor, initially demonstrated activity in Phase II clinical trials including germline BRCA-mutated patients. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 18-22 33069237-0 2020 The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer. olaparib 104-112 poly(ADP-ribose) polymerase 1 Homo sapiens 89-93 33093458-2 2020 The PARP inhibitor olaparib is a molecularly targeted drug that continues to be investigated in BRCA-mutated tumors. olaparib 19-27 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 32726747-3 2020 Olaparib, a PARP inhibitor, has been approved for the treatment of breast or ovarian cancer patients with breast cancer gene 1/2 (BRCA1/2) mutations. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 12-16 32726747-6 2020 Hydrophobic-tagged olaparib induces the proteasome-dependent degradation of PARP1 and shows enhanced antitumor effects compared to olaparib in TNBC cells. olaparib 19-27 poly(ADP-ribose) polymerase 1 Homo sapiens 76-81 33069237-8 2020 Furthermore, we showed that CUDC-907 treatment enhanced the therapeutic efficacy of PARP inhibitor olaparib in SCLC cellular models and a PDX model. olaparib 99-107 poly(ADP-ribose) polymerase 1 Homo sapiens 84-88 33069237-10 2020 CONCLUSIONS: Our study uncovers that dual PI3K and HDAC inhibition by CUDC-907 exerts significant single-agent activity and strong synergistic effects with PARP inhibitor olaparib in SCLC, which thus provides a rational combination treatment strategy for SCLC clinical investigation. olaparib 171-179 poly(ADP-ribose) polymerase 1 Homo sapiens 156-160 32532747-0 2020 Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers. olaparib 66-74 poly(ADP-ribose) polymerase 1 Homo sapiens 21-48 32532747-0 2020 Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers. olaparib 66-74 poly(ADP-ribose) polymerase 1 Homo sapiens 50-54 32636098-1 2020 Recent data have revealed antitumor activity for four PARP inhibitors, two of which (olaparib and rucaparib) are approved by the US Food and Drug Administration for metastatic castrate-resistant prostate cancer with selected DNA repair defects. olaparib 85-93 poly(ADP-ribose) polymerase 1 Homo sapiens 54-58 32814685-2 2020 The recent Food and Drug Administration (FDA) approval of the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and rucaparib for the treatment of advanced prostate cancer heralds the onset of precision medicine for this disease. olaparib 108-116 poly(ADP-ribose) polymerase 1 Homo sapiens 62-89 32814685-2 2020 The recent Food and Drug Administration (FDA) approval of the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and rucaparib for the treatment of advanced prostate cancer heralds the onset of precision medicine for this disease. olaparib 108-116 poly(ADP-ribose) polymerase 1 Homo sapiens 91-95 32814685-9 2020 The PARP inhibitors olaparib and rucaparib are now FDA approved for mCRPC patients with HRR mutations and BRCA1/2 mutations, respectively. olaparib 20-28 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 32814685-12 2020 PATIENT SUMMARY: The poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and rucaparib are now approved by the Food and Drug Administration for the treatment of advanced prostate cancer. olaparib 67-75 poly(ADP-ribose) polymerase 1 Homo sapiens 21-48 32814685-12 2020 PATIENT SUMMARY: The poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and rucaparib are now approved by the Food and Drug Administration for the treatment of advanced prostate cancer. olaparib 67-75 poly(ADP-ribose) polymerase 1 Homo sapiens 50-54 32717529-4 2020 To date, four PARP1 inhibitors namely olaparib, rucaparib, niraparib and talazoparib, have been approved by Food and Drug Administration (FDA) for treating ovarian cancer and breast cancer with BRCA1/2 mutation. olaparib 38-46 poly(ADP-ribose) polymerase 1 Homo sapiens 14-19 33130698-1 2020 The characteristic adverse events of olaparib, a PARP inhibitor, are nausea, vomiting, and anemia, and interstitial pneumonia is rarely reported. olaparib 37-45 poly(ADP-ribose) polymerase 1 Homo sapiens 49-53 32817083-1 2020 INTRODUCTION: We aimed to evaluate poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) regimens in BRCA-mutated ovarian cancer for patients responsive to front-line platinum (bevacizumab and olaparib, veliparib and chemotherapy, olaparib) or platinum-sensitive relapsed (olaparib, rucaprib, niraparib) patients in phase III randomized controlled trials. olaparib 193-201 poly(ADP-ribose) polymerase 1 Homo sapiens 35-63 32817083-1 2020 INTRODUCTION: We aimed to evaluate poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) regimens in BRCA-mutated ovarian cancer for patients responsive to front-line platinum (bevacizumab and olaparib, veliparib and chemotherapy, olaparib) or platinum-sensitive relapsed (olaparib, rucaprib, niraparib) patients in phase III randomized controlled trials. olaparib 193-201 poly(ADP-ribose) polymerase 1 Homo sapiens 65-69 32817083-1 2020 INTRODUCTION: We aimed to evaluate poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) regimens in BRCA-mutated ovarian cancer for patients responsive to front-line platinum (bevacizumab and olaparib, veliparib and chemotherapy, olaparib) or platinum-sensitive relapsed (olaparib, rucaprib, niraparib) patients in phase III randomized controlled trials. olaparib 231-239 poly(ADP-ribose) polymerase 1 Homo sapiens 35-63 32817083-1 2020 INTRODUCTION: We aimed to evaluate poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) regimens in BRCA-mutated ovarian cancer for patients responsive to front-line platinum (bevacizumab and olaparib, veliparib and chemotherapy, olaparib) or platinum-sensitive relapsed (olaparib, rucaprib, niraparib) patients in phase III randomized controlled trials. olaparib 231-239 poly(ADP-ribose) polymerase 1 Homo sapiens 65-69 32817083-1 2020 INTRODUCTION: We aimed to evaluate poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) regimens in BRCA-mutated ovarian cancer for patients responsive to front-line platinum (bevacizumab and olaparib, veliparib and chemotherapy, olaparib) or platinum-sensitive relapsed (olaparib, rucaprib, niraparib) patients in phase III randomized controlled trials. olaparib 231-239 poly(ADP-ribose) polymerase 1 Homo sapiens 35-63 32817083-1 2020 INTRODUCTION: We aimed to evaluate poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) regimens in BRCA-mutated ovarian cancer for patients responsive to front-line platinum (bevacizumab and olaparib, veliparib and chemotherapy, olaparib) or platinum-sensitive relapsed (olaparib, rucaprib, niraparib) patients in phase III randomized controlled trials. olaparib 231-239 poly(ADP-ribose) polymerase 1 Homo sapiens 65-69 32831909-4 2020 Three PARP inhibitors, olaparib, rucaparib and niraparib, have been recently approved by the Food and Drug Administration for clinical use in EOC patients, though with different clinical indications and profiles of toxicity, while two other molecules, veliparib and talazoparib, are still under clinical investigation. olaparib 23-31 poly(ADP-ribose) polymerase 1 Homo sapiens 6-10 33133138-4 2020 Here, we show that the combination of the DNA-PK inhibitor NU7441 and the PARP inhibitor olaparib significantly decrease proliferation (61-78%) compared to no reduction with either agent alone (p < 0.001) in both SCC1 and SCC6 cell lines. olaparib 89-97 poly(ADP-ribose) polymerase 1 Homo sapiens 74-78 32963528-5 2020 In addition, BRCA mutations predict good response to poly-ADP ribose polymerase (PARP) inhibitors, such as olaparib, rucaparib, and niraparib. olaparib 107-115 poly(ADP-ribose) polymerase 1 Homo sapiens 53-79 32963528-5 2020 In addition, BRCA mutations predict good response to poly-ADP ribose polymerase (PARP) inhibitors, such as olaparib, rucaparib, and niraparib. olaparib 107-115 poly(ADP-ribose) polymerase 1 Homo sapiens 81-85 32282108-0 2020 Olaparib based photo-affinity probes for PARP-1 detection in living cells. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 41-47 32282108-2 2020 Inhibition of PARP activity by olaparib can cause cell death which is of clinical relevance in some tumor types. olaparib 31-39 poly(ADP-ribose) polymerase 1 Homo sapiens 14-18 32848424-5 2020 The oral PARP inhibitor olaparib was used and achieved a partial tumor response over a period of 2.5 months. olaparib 24-32 poly(ADP-ribose) polymerase 1 Homo sapiens 9-13 32903519-5 2020 As expected, miR-155-5p ectopic overexpression followed by Olaparib administration resulted in a greater reduction of cell viability as compared to Olaparib administration alone, suggesting that miR-155-5p might induce a synthetic lethal effect in cancer cells when coupled with PARP-1-inhibition. olaparib 59-67 poly(ADP-ribose) polymerase 1 Homo sapiens 279-285 32758032-4 2020 Several PARP inhibitors (PARPi) are under development, such as olaparib, talazoparib, niraparib, rucaparib, and veliparib. olaparib 63-71 poly(ADP-ribose) polymerase 1 Homo sapiens 8-12 32732457-3 2020 We found that autophagy was downregulated following H2O2-induced PARP1 activation in ARPE-19 cells and olaparib, PARP1 inhibitor, preserved the autophagy process upon H2O2 exposure in ARPE-19 cells. olaparib 103-111 poly(ADP-ribose) polymerase 1 Homo sapiens 113-118 32604417-27 2020 WIDER IMPLICATIONS OF THE FINDINGS: Olaparib dramatically depleted primordial follicles and this could be attributed to loss of intrinsic PARP-mediated DNA repair mechanisms. olaparib 36-44 poly(ADP-ribose) polymerase 1 Homo sapiens 138-142 32388810-5 2020 Upon TRAF4 knockdown, the colony numbers of EC cells were markedly down-regulated, and the markers of DNA double-strand breakage were significantly up-regulated after the treatment of olaparib, a PARP1 inhibitor. olaparib 184-192 poly(ADP-ribose) polymerase 1 Homo sapiens 196-201 32711558-5 2020 Drug-sensitivity of cervical cancer cells to PARP1 inhibitors, olaparib or veliparib, was analyzed by CCK-8 cell viability assays, and the 50% inhibitory concentration (IC50) was quantified using GraphPad Prism. olaparib 63-71 poly(ADP-ribose) polymerase 1 Homo sapiens 45-50 32371137-5 2020 The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) recently approved several PARP inhibitors, such as olaparib, niraparib, talazoparib, and rucaparib, for the treatment of ovarian and germline BRCA-mutant breast cancers. olaparib 129-137 poly(ADP-ribose) polymerase 1 Homo sapiens 104-108 32679669-9 2020 Olaparib is a PARP inhibitor with proven efficacy in BRCA-mutated ovarian cancer, but its effectiveness remains to be demonstrated in tumors with a BRCAness (breast cancer) profile (i.e., also including sporadic tumors in patients with deficient DNA repair genes). olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 14-18 32502343-5 2020 Consistent with its effect on DNA damage repair gene expression, MFH290 augments the anti-proliferative effect of the PARP inhibitor, Olaparib. olaparib 134-142 poly(ADP-ribose) polymerase 1 Homo sapiens 118-122 32630796-2 2020 Within the treatment options for advanced triple negative breast cancer, the PARP inhibitor olaparib is only given to patients with BRCA1/2 mutations. olaparib 92-100 poly(ADP-ribose) polymerase 1 Homo sapiens 77-81 32668858-8 2020 Thus, treatment with olaparib, a poly(ADP-ribose)polymerase(PARP)inhibitor, was started. olaparib 21-29 poly(ADP-ribose) polymerase 1 Homo sapiens 33-59 32668858-8 2020 Thus, treatment with olaparib, a poly(ADP-ribose)polymerase(PARP)inhibitor, was started. olaparib 21-29 poly(ADP-ribose) polymerase 1 Homo sapiens 60-64 32279088-12 2020 CONCLUSION: We show high PARP1 and SLFN11 expression in DSRCT tumor material and antitumor effects following olaparib and TMZ combination treatment in a preclinical DSRCT model. olaparib 109-117 poly(ADP-ribose) polymerase 1 Homo sapiens 25-30 32229503-0 2020 Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib. olaparib 95-103 poly(ADP-ribose) polymerase 1 Homo sapiens 80-84 32555282-7 2020 Moreover, synergistic effects were observed when Ur-A and Ur-C were combined with clinically approved PARP inhibitor olaparib. olaparib 117-125 poly(ADP-ribose) polymerase 1 Homo sapiens 102-106 32243226-13 2020 Poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and talazoparib) are preferable to nonplatinum single-agent chemotherapy for treatment of advanced BC in BRCA1/2 carriers. olaparib 48-56 poly(ADP-ribose) polymerase 1 Homo sapiens 0-28 32243226-13 2020 Poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and talazoparib) are preferable to nonplatinum single-agent chemotherapy for treatment of advanced BC in BRCA1/2 carriers. olaparib 48-56 poly(ADP-ribose) polymerase 1 Homo sapiens 30-34 32526907-4 2020 Our aim is to compare mechanisms of resistance to the PARP inhibitor olaparib in these two main molecular categories of HGSOC and investigate a way to overcome resistance that we considered particularly suited to a cancer like HGSOC, where there is a very high incidence of TP53 gene mutation, making HGSOC cells heavily reliant on the G2 checkpoint for repair of DNA damage and survival. olaparib 69-77 poly(ADP-ribose) polymerase 1 Homo sapiens 54-58 32139402-2 2020 Here, we study if SMAD4 loss sensitizes HNSCCs to olaparib (PARP inhibitor) in combination with radiotherapy (RT). olaparib 50-58 poly(ADP-ribose) polymerase 1 Homo sapiens 60-64 32215876-4 2020 US Food and Drug Administration (FDA)-approved PARP inhibitors include olaparib, rucaparib, and niraparib, while veliparib is in the late stage of clinical development. olaparib 71-79 poly(ADP-ribose) polymerase 1 Homo sapiens 47-51 32468256-2 2020 We reported recently a BRCA2 mutant high grade serous ovarian cancer (HGSOC) patient with acquired resistance to the PARP-1 olaparib due to a STV detected by next generation tumor sequencing (NGTS). olaparib 124-132 poly(ADP-ribose) polymerase 1 Homo sapiens 117-123 33071527-1 2020 The successful use of PARP1 inhibitors like olaparib (Loparza ) in the treatment of BRCA1/2- deficient breast cancer has provided clinical proof of concept for applying personalized medicine based on synthetic lethality to the treatment of cancer. olaparib 44-52 poly(ADP-ribose) polymerase 1 Homo sapiens 22-27 32222339-4 2020 Herein we report a series of compounds by molecular hybridization PARP-1 inhibitor Olaparib (Ola) with HSP90 inhibitor C0817 (one curcumin derivative). olaparib 83-86 poly(ADP-ribose) polymerase 1 Homo sapiens 66-72 32329510-4 2020 We also found that IRCs treated with the PARP1 inhibitor, Olaparib (AZD2281) had a higher 53BP1 expression. olaparib 58-66 poly(ADP-ribose) polymerase 1 Homo sapiens 41-46 32329510-4 2020 We also found that IRCs treated with the PARP1 inhibitor, Olaparib (AZD2281) had a higher 53BP1 expression. olaparib 68-75 poly(ADP-ribose) polymerase 1 Homo sapiens 41-46 32329510-6 2020 We further revealed that treatment of IRCs with CM together with Olaparib led to significantly lower mRNA expression levels and fluorescent intensities of NF-kappaB, while treatment of IRCs with CM together the NF-kappaB inhibitor BAY-11-7082 led to significantly lower mRNA expression levels as well as fluorescent intensities of PARP1. olaparib 65-73 poly(ADP-ribose) polymerase 1 Homo sapiens 331-336 32392755-8 2020 The PARP inhibitor, olaparib, sensitized wild type but not NMNAT1-/- cells to cisplatin-induced anti-clonogenic effects, suggesting that impaired PARP1 activity is important for chemosensitization. olaparib 20-28 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 32392755-8 2020 The PARP inhibitor, olaparib, sensitized wild type but not NMNAT1-/- cells to cisplatin-induced anti-clonogenic effects, suggesting that impaired PARP1 activity is important for chemosensitization. olaparib 20-28 poly(ADP-ribose) polymerase 1 Homo sapiens 146-151 32222339-4 2020 Herein we report a series of compounds by molecular hybridization PARP-1 inhibitor Olaparib (Ola) with HSP90 inhibitor C0817 (one curcumin derivative). olaparib 83-91 poly(ADP-ribose) polymerase 1 Homo sapiens 66-72 33361032-11 2020 This study also indicates that a combination TKIs and Poly (ADP-ribose) polymerase (PARP) inhibitors like Olaparib (FDA approved anti-cancer drug for FA-pathway gene mutations) could improve the clinical outcome CML patients in accelerated and blast-crisis phases of the disease. olaparib 106-114 poly(ADP-ribose) polymerase 1 Homo sapiens 54-82 33361032-11 2020 This study also indicates that a combination TKIs and Poly (ADP-ribose) polymerase (PARP) inhibitors like Olaparib (FDA approved anti-cancer drug for FA-pathway gene mutations) could improve the clinical outcome CML patients in accelerated and blast-crisis phases of the disease. olaparib 106-114 poly(ADP-ribose) polymerase 1 Homo sapiens 84-88 32354033-5 2020 Methods: Single agent sensitivity to VE-821 (ATR inhibitor) and olaparib (PARP inhibitor), and the combination, was determined using cell proliferation and clonogenic assays, in HR-NB cell lines. olaparib 64-72 poly(ADP-ribose) polymerase 1 Homo sapiens 74-78 31274831-0 2020 Effects of The Poly(ADP-ribose) Polymerase Inhibitor Olaparib in Cerulein-Induced Pancreatitis. olaparib 53-61 poly(ADP-ribose) polymerase 1 Homo sapiens 15-42 31274831-2 2020 The objective of our study was to evaluate the efficacy and safety of the clinically approved PARP inhibitor olaparib in an experimental model of pancreatitis in vivo and in a pancreatic cell line subjected to oxidative stress in vitro. olaparib 109-117 poly(ADP-ribose) polymerase 1 Homo sapiens 94-98 31274831-12 2020 In HPDE cells subjected to oxidative stress olaparib (1 muM) inhibited PARP activity, protected against the loss of cell viability and prevented the loss of cellular NAD levels. olaparib 44-52 poly(ADP-ribose) polymerase 1 Homo sapiens 71-75 32411727-6 2020 Recently developed PARP inhibitors, such as ABT-888 and olaparib, provide beneficial effects in limiting experimental AF, and are also found to limit atherosclerotic coronary artery disease and heart failure. olaparib 56-64 poly(ADP-ribose) polymerase 1 Homo sapiens 19-23 32276472-5 2020 Compared with the limited effect of single-agent olaparib (PARP inhibitor) or PD173074 on PANC-1 and SUIT-2 cells, low-dose combination (olaparib + PD173074) treatment significantly, dose-dependently, and synergistically reduced cell viability, upregulated cleaved PARP, pro-caspase (CASP)-9, cleaved-CASP9, and cleaved-CASP3 protein expression, and downregulated Bcl-xL protein expression. olaparib 137-145 poly(ADP-ribose) polymerase 1 Homo sapiens 265-269 32276472-8 2020 In conclusion, FGFR1 inhibitor-resistant PDAC cells exhibited sensitivity to PD173074 after olaparib-mediated loss of PARP signaling. olaparib 92-100 poly(ADP-ribose) polymerase 1 Homo sapiens 118-122 32183851-1 2020 BACKGROUND: Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, has proven to be effective and safe as maintenance therapy and multiline therapy in ovarian cancer, especially in patients with BRCA mutations. olaparib 12-20 poly(ADP-ribose) polymerase 1 Homo sapiens 24-50 32111986-4 2020 Here, we describe the workflow that led to the automated radiosynthesis of the poly(ADP-ribose) polymerase (PARP) inhibitor [18F]olaparib. olaparib 129-137 poly(ADP-ribose) polymerase 1 Homo sapiens 79-106 32111986-4 2020 Here, we describe the workflow that led to the automated radiosynthesis of the poly(ADP-ribose) polymerase (PARP) inhibitor [18F]olaparib. olaparib 129-137 poly(ADP-ribose) polymerase 1 Homo sapiens 108-112 32368391-0 2020 CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer. olaparib 64-72 poly(ADP-ribose) polymerase 1 Homo sapiens 49-53 32368391-4 2020 By using a CDK9 inhibitor CDKI-73, we found that its combination with the PARP inhibitor olaparib significantly suppressed cell viability and colony formation and induced apoptosis in BRCA1-proficient ovarian cancer cells. olaparib 89-97 poly(ADP-ribose) polymerase 1 Homo sapiens 74-78 32111986-0 2020 Manual and automated Cu-mediated radiosynthesis of the PARP inhibitor [18F]olaparib. olaparib 75-83 poly(ADP-ribose) polymerase 1 Homo sapiens 55-59 32297440-7 2020 Based on supporting evidence for poly (ADP-ribose) polymerase (PARP) inhibition in other BRCA-mutated tumors, the patient was started on the PARP inhibitor olaparib. olaparib 156-164 poly(ADP-ribose) polymerase 1 Homo sapiens 33-61 32297440-7 2020 Based on supporting evidence for poly (ADP-ribose) polymerase (PARP) inhibition in other BRCA-mutated tumors, the patient was started on the PARP inhibitor olaparib. olaparib 156-164 poly(ADP-ribose) polymerase 1 Homo sapiens 63-67 32297440-7 2020 Based on supporting evidence for poly (ADP-ribose) polymerase (PARP) inhibition in other BRCA-mutated tumors, the patient was started on the PARP inhibitor olaparib. olaparib 156-164 poly(ADP-ribose) polymerase 1 Homo sapiens 141-145 32221289-1 2020 PARP1 and PARP2 dual inhibitors, such as olaparib, have been recently FDA approved for the treatment of advanced breast and ovarian cancers. olaparib 41-49 poly(ADP-ribose) polymerase 1 Homo sapiens 0-5 31976528-0 2020 PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation. olaparib 15-23 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 32609449-4 2020 We present a novel case of chemotherapy-associated DSAP inflammation in a 66-year-old woman after triple therapy with durvalumab (PD-L1 inhibitor), olaparib (PARP inhibitor) and paclitaxel, showing similarities to primary lichen planus-like eruption from immune checkpoint inhibitors. olaparib 148-156 poly(ADP-ribose) polymerase 1 Homo sapiens 158-162 32183851-1 2020 BACKGROUND: Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, has proven to be effective and safe as maintenance therapy and multiline therapy in ovarian cancer, especially in patients with BRCA mutations. olaparib 12-20 poly(ADP-ribose) polymerase 1 Homo sapiens 52-56 32151005-4 2020 This has resulted in the development of PARP inhibitors such as olaparib, which are increasingly employed in cancer chemotherapeutic approaches. olaparib 64-72 poly(ADP-ribose) polymerase 1 Homo sapiens 40-44 31537627-1 2020 BACKGROUND: With the approval of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib for newly diagnosed, breast cancer gene (BRCA)1/2 mutated, ovarian cancer women, the assessment of BRCA1/2 tumour status will be shortly required at the time of diagnosis. olaparib 83-91 poly(ADP-ribose) polymerase 1 Homo sapiens 37-65 31931287-7 2020 To date, three PARP inhibitor drugs have been approved for treating ovarian cancer by FDA in United States, namely Olaparib, Rucaparib, and Niraparib. olaparib 115-123 poly(ADP-ribose) polymerase 1 Homo sapiens 15-19 31537627-1 2020 BACKGROUND: With the approval of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib for newly diagnosed, breast cancer gene (BRCA)1/2 mutated, ovarian cancer women, the assessment of BRCA1/2 tumour status will be shortly required at the time of diagnosis. olaparib 83-91 poly(ADP-ribose) polymerase 1 Homo sapiens 67-71 31939072-10 2020 Finally, an additional targeted approach being pursued involves PARP inhibitors (rucaparib and olaparib are both in Phase II) based on earlier study results. olaparib 95-103 poly(ADP-ribose) polymerase 1 Homo sapiens 64-68 32093123-8 2020 Notably, both Syk and EGFR inhibitors could induce PARP activation, and synergistic cytotoxic actions were observed in SCC cells upon the combined treatment of the PARP1 inhibitor olaparib with Syk or the EGFR inhibitor. olaparib 180-188 poly(ADP-ribose) polymerase 1 Homo sapiens 51-55 32093123-8 2020 Notably, both Syk and EGFR inhibitors could induce PARP activation, and synergistic cytotoxic actions were observed in SCC cells upon the combined treatment of the PARP1 inhibitor olaparib with Syk or the EGFR inhibitor. olaparib 180-188 poly(ADP-ribose) polymerase 1 Homo sapiens 164-169 31499579-1 2020 RATIONALES: Olaparib is a Poly (ADP-ribose) Polimerase (PARP) inhibitor, which has been developed as an anti-cancer agent. olaparib 12-20 poly(ADP-ribose) polymerase 1 Homo sapiens 56-60 32043779-3 2020 In this report, we present the case of a 3-year-old girl with glioblastoma who continues to experience an exceptional and durable response (>2 years) to the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib. olaparib 203-211 poly(ADP-ribose) polymerase 1 Homo sapiens 157-185 32043779-3 2020 In this report, we present the case of a 3-year-old girl with glioblastoma who continues to experience an exceptional and durable response (>2 years) to the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib. olaparib 203-211 poly(ADP-ribose) polymerase 1 Homo sapiens 187-191 32043779-8 2020 Nine months later the PARP inhibitor olaparib was administered in combination with temozolomide for 16 cycles. olaparib 37-45 poly(ADP-ribose) polymerase 1 Homo sapiens 22-26 32043779-11 2020 To our knowledge, this represents the first case of a pediatric glioblastoma that maintains a durable response to a therapeutic strategy that included the PARP inhibitor olaparib and more generally highlights the potential clinical utility of incorporating these agents into the treatment of pediatric high-grade gliomas. olaparib 170-178 poly(ADP-ribose) polymerase 1 Homo sapiens 155-159 31391296-2 2020 One subtype identified for the presence of DNA damage repair deficiency can be targeted therapeutically with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib. olaparib 159-167 poly(ADP-ribose) polymerase 1 Homo sapiens 113-141 31669203-1 2020 PARP1 inhibitor (Niraparib, Olaparib, Rucaparib) maintenance therapy improves progression-free survival in platinum sensitive sporadic epithelial ovarian cancers. olaparib 28-36 poly(ADP-ribose) polymerase 1 Homo sapiens 0-5 31534014-3 2020 Here, we demonstrated that PARP inhibitor (olaparib)-resistant epithelial ovarian cancer (EOC) cells exhibited an elevated aldehyde dehydrogenase (ALDH) activity, mainly contributed by increased expression of ALDH1A1 due to olaparib-induced expression of BRD4, a member of bromodomain and extraterminal (BET) family protein. olaparib 43-51 poly(ADP-ribose) polymerase 1 Homo sapiens 27-31 31534014-3 2020 Here, we demonstrated that PARP inhibitor (olaparib)-resistant epithelial ovarian cancer (EOC) cells exhibited an elevated aldehyde dehydrogenase (ALDH) activity, mainly contributed by increased expression of ALDH1A1 due to olaparib-induced expression of BRD4, a member of bromodomain and extraterminal (BET) family protein. olaparib 224-232 poly(ADP-ribose) polymerase 1 Homo sapiens 27-31 31391296-2 2020 One subtype identified for the presence of DNA damage repair deficiency can be targeted therapeutically with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib. olaparib 159-167 poly(ADP-ribose) polymerase 1 Homo sapiens 143-147 31699977-3 2019 Using ATM-deficient cells, we demonstrate that AZD7648, in combination with the PARP inhibitor olaparib, increases genomic instability, resulting in cell growth inhibition and apoptosis. olaparib 95-103 poly(ADP-ribose) polymerase 1 Homo sapiens 80-84 31490091-8 2019 Radiosensitization by IC87361 and olaparib was significantly enhanced under acute anoxia and chronic hypoxia.Conclusions: The DNA-PK inhibitors KU57788 and IC87361 are more effective radiosensitizers than the PARP-1 inhibitors olaparib and veliparib at non-cytotoxic concentrations in HNSCC cell cultures and their activity is enhanced by SLFN11 and hypoxia. olaparib 34-42 poly(ADP-ribose) polymerase 1 Homo sapiens 209-215 30427217-0 2019 Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors. olaparib 82-90 poly(ADP-ribose) polymerase 1 Homo sapiens 120-126 30427217-1 2019 A series of new Olaparib derivatives was designed and synthesized, and their inhibitory activities against poly (ADP-ribose) polymerases-1 (PARP-1) enzyme and cancer cell line MDA-MB-436 in vitro were evaluated. olaparib 16-24 poly(ADP-ribose) polymerase 1 Homo sapiens 140-146 30427217-2 2019 The results showed that compound 5l exhibited the most potent inhibitory effects on PARP-1 enzyme (16.10 +- 1.25 nM) and MDA-MB-436 cancer cell (11.62 +- 2.15 muM), which was close to that of Olaparib. olaparib 192-200 poly(ADP-ribose) polymerase 1 Homo sapiens 84-90 31625002-3 2019 Since 2014, four PARP inhibitors have been approved in various indications: olaparib, niraparib, and rucaparib in high-grade serous ovarian cancer, and olaparib and talazoparib in metastatic breast cancer. olaparib 76-84 poly(ADP-ribose) polymerase 1 Homo sapiens 17-21 31625002-3 2019 Since 2014, four PARP inhibitors have been approved in various indications: olaparib, niraparib, and rucaparib in high-grade serous ovarian cancer, and olaparib and talazoparib in metastatic breast cancer. olaparib 152-160 poly(ADP-ribose) polymerase 1 Homo sapiens 17-21 31754897-5 2019 Recently, we have seen 3 newly approved targeted therapies for TNBC, including the PARP inhibitors olaparib and talazoparib for germline BRCA mutation associated breast cancer (gBRCAm-BC) and most recently the checkpoint inhibitor, atezolizumab in combination with nab-paclitaxel for programmed death-ligand 1 (PD-L1+) advanced TNBC. olaparib 99-107 poly(ADP-ribose) polymerase 1 Homo sapiens 83-87 31512408-9 2019 In support of these findings, USP9X knockdown significantly enhanced sensitivity to PARP inhibitor Olaparib and methyl methanesulfonate (MMS). olaparib 99-107 poly(ADP-ribose) polymerase 1 Homo sapiens 84-88 31529615-4 2019 In this study, we found that forced mitotic entry upon ATR inhibition potentiates cytotoxic effects of PARP inhibition using olaparib in BRCA2-depleted and Brca2 knock-out cancer cell line models. olaparib 125-133 poly(ADP-ribose) polymerase 1 Homo sapiens 103-107 31508509-3 2019 Here we perform a CRISPR/Cas9-based genome-scale loss-of-function screen, using the sensitivity of PARP inhibitor olaparib as a surrogate. olaparib 114-122 poly(ADP-ribose) polymerase 1 Homo sapiens 99-103 31434613-0 2019 PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. olaparib 71-79 poly(ADP-ribose) polymerase 1 Homo sapiens 0-6 31434613-9 2019 Olaparib activity in CC involved both PARP enzyme inhibition and trapping. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 38-42 31527467-2 2019 Olaparib is a potent, orally bioavailable poly(ADP-ribose) polymerase 1 (PARP1) inhibitor with acceptable toxicity profile, designed as targeted therapy for DNA repair defective tumors. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 42-71 31527467-2 2019 Olaparib is a potent, orally bioavailable poly(ADP-ribose) polymerase 1 (PARP1) inhibitor with acceptable toxicity profile, designed as targeted therapy for DNA repair defective tumors. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 73-78 31500595-0 2019 Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib. olaparib 104-112 poly(ADP-ribose) polymerase 1 Homo sapiens 89-93 31500595-3 2019 Olaparib is a PARP inhibitor with a favourable safety profile in comparison to clinically used radiosensitisers including cisplatin when used as single agent. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 14-18 31500595-15 2019 DISCUSSION: We designed three parallel phase 1 trials to assess the safety and tolerability of the PARP inhibitor olaparib in combination with radical (chemo-)radiotherapy treatment regimens. olaparib 114-122 poly(ADP-ribose) polymerase 1 Homo sapiens 99-103 30797618-1 2019 BACKGROUND: Poly ADP-ribose polymerase (PARP) inhibitors, such as olaparib, are being explored as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) in men harboring mutations in homologous recombination DNA-repair genes. olaparib 66-74 poly(ADP-ribose) polymerase 1 Homo sapiens 12-38 30797618-1 2019 BACKGROUND: Poly ADP-ribose polymerase (PARP) inhibitors, such as olaparib, are being explored as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) in men harboring mutations in homologous recombination DNA-repair genes. olaparib 66-74 poly(ADP-ribose) polymerase 1 Homo sapiens 40-44 31554189-7 2019 Our results show that compared to either drug alone, the combination of AIU2001 with a poly (ADP-ribose) polymerase (PARP) inhibitor olaparib or irradiation showed synergistic efficacy in H1299 and A549 cells. olaparib 133-141 poly(ADP-ribose) polymerase 1 Homo sapiens 87-115 31554189-7 2019 Our results show that compared to either drug alone, the combination of AIU2001 with a poly (ADP-ribose) polymerase (PARP) inhibitor olaparib or irradiation showed synergistic efficacy in H1299 and A549 cells. olaparib 133-141 poly(ADP-ribose) polymerase 1 Homo sapiens 117-121 30880062-2 2019 Because histone-dependent activation is unique to PARP-1, non-NAD-like PARP-1 inhibitors have the potential to bypass the off-target effects of classical NAD-dependent PARP-1 inhibitors, such as olaparib, veliparib, and rucaparib. olaparib 195-203 poly(ADP-ribose) polymerase 1 Homo sapiens 71-77 31218365-3 2019 In 2009, a first-in-man clinical trial of the PARP inhibitor olaparib clinically validated the synthetic lethal interaction between inhibition of PARP1, a key sensor of DNA damage, and BRCA1/2 deficiency. olaparib 61-69 poly(ADP-ribose) polymerase 1 Homo sapiens 46-50 31218365-3 2019 In 2009, a first-in-man clinical trial of the PARP inhibitor olaparib clinically validated the synthetic lethal interaction between inhibition of PARP1, a key sensor of DNA damage, and BRCA1/2 deficiency. olaparib 61-69 poly(ADP-ribose) polymerase 1 Homo sapiens 146-151 31218365-4 2019 In this review, we summarize a decade of PARP inhibitor clinical development, a work which has resulted in the registration of several PARP inhibitors in breast (olaparib and talazoparib) and ovarian cancer (olaparib, niraparib and rucaparib, either alone or following platinum chemotherapy as maintenance therapy). olaparib 162-170 poly(ADP-ribose) polymerase 1 Homo sapiens 41-45 31218365-4 2019 In this review, we summarize a decade of PARP inhibitor clinical development, a work which has resulted in the registration of several PARP inhibitors in breast (olaparib and talazoparib) and ovarian cancer (olaparib, niraparib and rucaparib, either alone or following platinum chemotherapy as maintenance therapy). olaparib 162-170 poly(ADP-ribose) polymerase 1 Homo sapiens 135-139 31218365-4 2019 In this review, we summarize a decade of PARP inhibitor clinical development, a work which has resulted in the registration of several PARP inhibitors in breast (olaparib and talazoparib) and ovarian cancer (olaparib, niraparib and rucaparib, either alone or following platinum chemotherapy as maintenance therapy). olaparib 208-216 poly(ADP-ribose) polymerase 1 Homo sapiens 41-45 31218365-4 2019 In this review, we summarize a decade of PARP inhibitor clinical development, a work which has resulted in the registration of several PARP inhibitors in breast (olaparib and talazoparib) and ovarian cancer (olaparib, niraparib and rucaparib, either alone or following platinum chemotherapy as maintenance therapy). olaparib 208-216 poly(ADP-ribose) polymerase 1 Homo sapiens 135-139 30936015-7 2019 When HepG2 cells, a human hepatoma cell line, were cultured in the presence of another PARP inhibitor, olaparib, ADH activity of the cell was significantly increased. olaparib 103-111 poly(ADP-ribose) polymerase 1 Homo sapiens 87-91 31251940-6 2019 A subset of hADMSCs were differentiated to white adipocytes in the presence of Olaparib, a potent PARP inhibitor currently in clinical use, to induce browning. olaparib 79-87 poly(ADP-ribose) polymerase 1 Homo sapiens 98-102 30880062-2 2019 Because histone-dependent activation is unique to PARP-1, non-NAD-like PARP-1 inhibitors have the potential to bypass the off-target effects of classical NAD-dependent PARP-1 inhibitors, such as olaparib, veliparib, and rucaparib. olaparib 195-203 poly(ADP-ribose) polymerase 1 Homo sapiens 71-77 30989461-0 2019 Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression. olaparib 58-66 poly(ADP-ribose) polymerase 1 Homo sapiens 81-87 31388783-1 2019 Olaparib (OLA) is a poly ADP ribose polymerase (PARP) inhibitor approved for germline BRCA-mutated (gBRCAm) advanced ovarian cancer and breast cancer. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 20-46 31388783-1 2019 Olaparib (OLA) is a poly ADP ribose polymerase (PARP) inhibitor approved for germline BRCA-mutated (gBRCAm) advanced ovarian cancer and breast cancer. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 48-52 31388783-1 2019 Olaparib (OLA) is a poly ADP ribose polymerase (PARP) inhibitor approved for germline BRCA-mutated (gBRCAm) advanced ovarian cancer and breast cancer. olaparib 10-13 poly(ADP-ribose) polymerase 1 Homo sapiens 20-46 31388783-1 2019 Olaparib (OLA) is a poly ADP ribose polymerase (PARP) inhibitor approved for germline BRCA-mutated (gBRCAm) advanced ovarian cancer and breast cancer. olaparib 10-13 poly(ADP-ribose) polymerase 1 Homo sapiens 48-52 31238782-4 2019 In this work, we used PARP (Olaparib) and RAD51 (B02) inhibitors to radiosensitize cancer cells to proton and X-ray radiation. olaparib 28-36 poly(ADP-ribose) polymerase 1 Homo sapiens 22-26 31201471-7 2019 Combining the FDA-approved PARP inhibitor, olaparib, with chemotherapeutics not only potentiated DNA damage accumulation, cell cycle arrest, and apoptosis in vitro but also suppressed chordoma xenograft expansion in vivo. olaparib 43-51 poly(ADP-ribose) polymerase 1 Homo sapiens 27-31 31304797-5 2019 The PARP inhibitor Olaparib, has recently been evaluated in the Phase III OlympiAD trial, and demonstrated a significant progression-free survival advantage in patients with HER2-negative metastatic breast cancer and a germline BRCA-mutation. olaparib 19-27 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 30851349-7 2019 Increased radiosensitivity of cells to high-LET protons as a consequence of defective CDD repair was furthermore mimicked using the PARP inhibitor olaparib, and through PARP-1 small interfering RNA. olaparib 147-155 poly(ADP-ribose) polymerase 1 Homo sapiens 132-136 31071432-17 2019 In in vitro experiments in U937 cells subjected to oxidative stress, olaparib (1-100 muM) inhibited PARP activity, protected against the loss of cell viability, preserved NAD+ levels and improved cellular bioenergetics. olaparib 69-77 poly(ADP-ribose) polymerase 1 Homo sapiens 100-104 30895466-4 2019 Three PARP inhibitors (olaparib, niraparib, and rucaparib) are now approved for use in women with recurrent EOC. olaparib 23-31 poly(ADP-ribose) polymerase 1 Homo sapiens 6-10 30952061-4 2019 The best PARP-1 inhibitory activity was observed for compound 8a with (IC50 = 36 nM) compared to Olaparib as a reference drug (IC50 = 34 nM). olaparib 97-105 poly(ADP-ribose) polymerase 1 Homo sapiens 9-15 31015319-3 2019 We demonstrate that the PARP inhibitor olaparib induces CD8+ T-cell infiltration and activation in vivo, and that CD8+ T-cell depletion severely compromises antitumor efficacy. olaparib 39-47 poly(ADP-ribose) polymerase 1 Homo sapiens 24-28 30585620-1 2019 Olaparib is a poly ADP-ribose polymerase inhibitor that induces synthetic lethality in tumors with deficient homologous recombination repair. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 14-40 30955858-9 2019 We also performed colony-formation assay after combination treatment with LLY-507 and PARP inhibitor olaparib in HGSOC cells. olaparib 101-109 poly(ADP-ribose) polymerase 1 Homo sapiens 86-90 31092693-1 2019 Combining the anti-angiogenic agent cediranib with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib improves progression-free survival compared to olaparib alone in ovarian cancer patients through an unknown mechanism. olaparib 100-108 poly(ADP-ribose) polymerase 1 Homo sapiens 55-82 31191001-3 2019 Currently, PARP inhibitors such as olaparib, rucaparib and niraparib, which improve progression-free survival, particularly in patients harboring BRCA mutations, are approved by the Food and Drug Administration (FDA) and European Medicine Agency (EMA) for the treatment of ovarian cancers. olaparib 35-43 poly(ADP-ribose) polymerase 1 Homo sapiens 11-15 30887180-1 2019 PURPOSE: Chinese patients have been enrolled in multiple Phase III trials of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza); however, the pharmacokinetic (PK) profile of olaparib has not been investigated in this population. olaparib 126-134 poly(ADP-ribose) polymerase 1 Homo sapiens 110-114 30887180-1 2019 PURPOSE: Chinese patients have been enrolled in multiple Phase III trials of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza); however, the pharmacokinetic (PK) profile of olaparib has not been investigated in this population. olaparib 192-200 poly(ADP-ribose) polymerase 1 Homo sapiens 81-108 30912451-3 2019 PARP inhibitors olaparib, veliparib, talazoparib, niraparib and rucaparib have predominantly been studied in women with breast or ovarian cancers associated with deleterious germline mutations in BRCA1 and BRCA2 (gBRCA1/2+). olaparib 16-24 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 33343988-1 2019 Rucaparib and niraparib are two of the newest U.S. Food and Drug Administration-approved PARP inhibitors, joining olaparib with indications in ovarian cancer. olaparib 114-122 poly(ADP-ribose) polymerase 1 Homo sapiens 89-93 31117037-2 2019 Additionally, 3 new PARP inhibitors (olaparib, rucaparib, niraparib) have been approved for use in ovarian cancer, with different indications as maintenance therapy or treatment of recurrence. olaparib 37-45 poly(ADP-ribose) polymerase 1 Homo sapiens 20-24 30824588-5 2019 As a result, treatment with GO-203 synergistically sensitized both mutant and wild-type BRCA1 TNBC cells to the PARP inhibitor olaparib. olaparib 127-135 poly(ADP-ribose) polymerase 1 Homo sapiens 112-116 30967556-4 2019 The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib, which is preferentially toxic to HR-incompetent cells, led to prolonged clinical benefit in a patient with refractory chordoma, and whole-genome analysis at progression revealed a PARP1 p.T910A mutation predicted to disrupt the autoinhibitory PARP1 helical domain. olaparib 49-57 poly(ADP-ribose) polymerase 1 Homo sapiens 4-31 30967556-4 2019 The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib, which is preferentially toxic to HR-incompetent cells, led to prolonged clinical benefit in a patient with refractory chordoma, and whole-genome analysis at progression revealed a PARP1 p.T910A mutation predicted to disrupt the autoinhibitory PARP1 helical domain. olaparib 49-57 poly(ADP-ribose) polymerase 1 Homo sapiens 33-37 30967556-4 2019 The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib, which is preferentially toxic to HR-incompetent cells, led to prolonged clinical benefit in a patient with refractory chordoma, and whole-genome analysis at progression revealed a PARP1 p.T910A mutation predicted to disrupt the autoinhibitory PARP1 helical domain. olaparib 49-57 poly(ADP-ribose) polymerase 1 Homo sapiens 239-244 30672100-2 2019 To date, three PARP inhibitors, namely, olaparib, rucaparib and niraparib have been approved for the treatment of ovarian cancer in the United States. olaparib 40-48 poly(ADP-ribose) polymerase 1 Homo sapiens 15-19 30880072-2 2019 We aimed to assess the safety and identify the recommended phase 2 dose of the PARP inhibitor olaparib in combination with the PI3K inhibitor alpelisib in patients with epithelial ovarian cancer and in patients with breast cancer. olaparib 94-102 poly(ADP-ribose) polymerase 1 Homo sapiens 79-83 30737031-2 2019 PARP inhibitors including olaparib and rucaparib, have been specially developed against breast and ovarian cancers deficient in DNA repair systems. olaparib 26-34 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 30737031-3 2019 In this study, we found that PARP1-defective olaparib-resistant A2780 cells (ola-R cells) cells were still sensitive to two PARP inhibitors, rucaparib and veliparib. olaparib 45-53 poly(ADP-ribose) polymerase 1 Homo sapiens 29-34 30737031-3 2019 In this study, we found that PARP1-defective olaparib-resistant A2780 cells (ola-R cells) cells were still sensitive to two PARP inhibitors, rucaparib and veliparib. olaparib 45-53 poly(ADP-ribose) polymerase 1 Homo sapiens 29-33 30740957-2 2019 Olaparib, as PARP inhibitor, has an anti-tumor effect on high grade serous ovarian cancer, but its effects on cellular senescence have not been reported. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 13-17 30409489-8 2019 Lastly, it reviews key trials for the three poly-adenosine diphosphate [ADP]-ribose polymerases (PARP) inhibitors that have been FDA-approved for maintenance therapy in platinum-sensitive recurrent EOC: olaparib, rucaparib, and niraparib. olaparib 203-211 poly(ADP-ribose) polymerase 1 Homo sapiens 97-101 30289618-8 2019 Consequently, HMGA2 decreased caspase 3/7 induction and increased cell survival upon treatment with the alkylating methyl methanesulfonate alone or in combination with the PARP inhibitor AZD2281 (olaparib). olaparib 187-194 poly(ADP-ribose) polymerase 1 Homo sapiens 172-176 30289618-8 2019 Consequently, HMGA2 decreased caspase 3/7 induction and increased cell survival upon treatment with the alkylating methyl methanesulfonate alone or in combination with the PARP inhibitor AZD2281 (olaparib). olaparib 196-204 poly(ADP-ribose) polymerase 1 Homo sapiens 172-176 30691488-10 2019 Olaparib, the first PARP inhibitor to be granted approval, is currently indicated as maintenance monotherapy in ovarian cancer patients with relapsed disease and mutated BRCA who have achieved a complete or partial response to platinum-based chemotherapy. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 20-24 30622252-4 2019 We show that hypersensitivity of ATM-mutant cells to topotecan or the poly-(ADP-ribose) polymerase (PARP) inhibitor olaparib reflects delayed engagement of homologous recombination at DNA-replication-fork associated single-ended double-strand breaks (DSBs), allowing some to be subject to toxic NHEJ. olaparib 116-124 poly(ADP-ribose) polymerase 1 Homo sapiens 70-98 30622252-4 2019 We show that hypersensitivity of ATM-mutant cells to topotecan or the poly-(ADP-ribose) polymerase (PARP) inhibitor olaparib reflects delayed engagement of homologous recombination at DNA-replication-fork associated single-ended double-strand breaks (DSBs), allowing some to be subject to toxic NHEJ. olaparib 116-124 poly(ADP-ribose) polymerase 1 Homo sapiens 100-104 30470508-9 2019 These predictions were confirmed by clonogenic cell survival assays of p12KO cells treated with cisplatin and mitomycin C, and with the PARP inhibitors Olaparib, Talazoparib, Rucaparib, and Niraparib. olaparib 152-160 poly(ADP-ribose) polymerase 1 Homo sapiens 136-140 31787769-3 2019 BRCA-mutated tumors are more sensitive to PARP inhibitors such as olaparib. olaparib 66-74 poly(ADP-ribose) polymerase 1 Homo sapiens 42-46 31375040-0 2019 PARP Inhibitor Olaparib Use in a BRCA1-Positive Patient With Metastatic Triple-Negative Breast Cancer, Without the Initial Use of Platinum-Based Chemotherapy, Showing Significant Rapid Near Resolution of Large Liver Metastasis While Patient Experienced Gout-Like Symptoms. olaparib 15-23 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 30431088-2 2019 Olaparib is a poly (adenosine diphosphate-ribose) polymerase (PARP) 1 inhibitor, which has promising antitumor activity in patients with metastatic breast cancer and germline BRCA mutations. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 62-69 30647872-11 2018 We showed that combined inhibition of PARP by olaparib and XIAP by embelin significantly and synergistically inhibited cell growth and induced apoptosis in BC cell lines. olaparib 46-54 poly(ADP-ribose) polymerase 1 Homo sapiens 38-42 30647872-14 2018 Furthermore, our data support the potential clinical development of combined inhibition of PARP and XIAP, which eventually could extend the utility of olaparib beyond BRCA deficient cancer. olaparib 151-159 poly(ADP-ribose) polymerase 1 Homo sapiens 91-95 30543656-4 2018 The study aimed to determine whether defective DNA repair could be associated with sensitivity to inhibition of DNA repair using the PARP inhibitor Olaparib. olaparib 148-156 poly(ADP-ribose) polymerase 1 Homo sapiens 133-137 31374917-9 2019 Olaparib and veliparib have also been combined with chemotherapy with the rationale of disrupting base excision repair via PARP inhibition. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 123-127 31075528-3 2019 The TOPARP-A clinical trial demonstrated that the PARP inhibitor olaparib may be an effective strategy for treating prostate cancer. olaparib 65-73 poly(ADP-ribose) polymerase 1 Homo sapiens 6-10 31075528-8 2019 Docetaxel-resistant cells exhibited robust resistance to olaparib which could be attributed to blunted PARP trapping in response to olaparib treatment. olaparib 57-65 poly(ADP-ribose) polymerase 1 Homo sapiens 103-107 31075528-8 2019 Docetaxel-resistant cells exhibited robust resistance to olaparib which could be attributed to blunted PARP trapping in response to olaparib treatment. olaparib 132-140 poly(ADP-ribose) polymerase 1 Homo sapiens 103-107 31049637-8 2019 In the TOPARP-A trial, the PARP inhibitor olaparib led to high response rates (88%) in patients with mutated DNA repair genes. olaparib 42-50 poly(ADP-ribose) polymerase 1 Homo sapiens 9-13 31074636-2 2019 Three different poly ADP ribose polymerase inhibitors (olaparib, niraparib and rucaparib) have been already approved as maintenance after response to platinum-based chemotherapy; two of them (olaparib and rucaparib) also as single agents. olaparib 55-63 poly(ADP-ribose) polymerase 1 Homo sapiens 16-42 31146482-3 2019 Here, we use UM patient-derived xenografts (PDXs) to study the therapeutic activity of the PARP inhibitor olaparib, alone or in combination. olaparib 106-114 poly(ADP-ribose) polymerase 1 Homo sapiens 91-95 31092693-1 2019 Combining the anti-angiogenic agent cediranib with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib improves progression-free survival compared to olaparib alone in ovarian cancer patients through an unknown mechanism. olaparib 100-108 poly(ADP-ribose) polymerase 1 Homo sapiens 84-88 30940648-5 2019 Moreover, the PARP1 inhibitor Olaparib significantly enhances the sensitivity of BRD7-positive cancer cells to chemotherapeutic drugs, while it has little effect on cells with low BRD7 expression. olaparib 30-38 poly(ADP-ribose) polymerase 1 Homo sapiens 14-19 31189798-1 2019 In July 2018, olaparib, an oral poly adenosine diphosphate-ribose polymerase(PARP)inhibitor, was approved for the first time in Japan as a companion diagnostic drug for the treatment of recurrent breast cancer in BRCA-positive patients. olaparib 14-22 poly(ADP-ribose) polymerase 1 Homo sapiens 77-81 31040352-6 2019 By combining this dual metabolic labelling strategy with highly sensitive tandem mass tag (TMT) isobaric mass spectrometry and hierarchical Bayesian analysis, we have quantified the responses of thousands of endogenous proteins to clinical PARP inhibitors Olaparib and Rucaparib. olaparib 256-264 poly(ADP-ribose) polymerase 1 Homo sapiens 240-244 30952721-3 2019 Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, enhances the cytotoxicity of various anticancer drugs and has been used to treat advanced ovarian and breast cancers. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 12-40 30952721-3 2019 Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, enhances the cytotoxicity of various anticancer drugs and has been used to treat advanced ovarian and breast cancers. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 42-46 30389822-3 2019 Methods: Here, via the copper-mediated 18F-radiofluorination of aryl boronic esters, we accessed, for the first time (to our knowledge), the 18F-radiolabeled isotopolog of the Food and Drug Administration-approved PARP inhibitor olaparib. olaparib 229-237 poly(ADP-ribose) polymerase 1 Homo sapiens 214-218 30832617-12 2019 DISCUSSION: Combining PARP inhibitors, such as olaparib, with radiotherapy and chemotherapy in GBM may improve survival outcomes, while sparing healthy tissue and preserving neurocognitive function, given the replication-dependent efficacy of olaparib, and the increased PARP expression in GBM as compared to non-neoplastic brain tissue. olaparib 47-55 poly(ADP-ribose) polymerase 1 Homo sapiens 22-26 30832617-12 2019 DISCUSSION: Combining PARP inhibitors, such as olaparib, with radiotherapy and chemotherapy in GBM may improve survival outcomes, while sparing healthy tissue and preserving neurocognitive function, given the replication-dependent efficacy of olaparib, and the increased PARP expression in GBM as compared to non-neoplastic brain tissue. olaparib 47-55 poly(ADP-ribose) polymerase 1 Homo sapiens 271-275 30832617-12 2019 DISCUSSION: Combining PARP inhibitors, such as olaparib, with radiotherapy and chemotherapy in GBM may improve survival outcomes, while sparing healthy tissue and preserving neurocognitive function, given the replication-dependent efficacy of olaparib, and the increased PARP expression in GBM as compared to non-neoplastic brain tissue. olaparib 243-251 poly(ADP-ribose) polymerase 1 Homo sapiens 22-26 30390553-1 2019 Poly(ADP-ribose)polymerase-1 inhibitor (PARPi) AZD2461 was designed to be a weak P-glycoprotein (P-gp) analogue of FDA approved olaparib. olaparib 128-136 poly(ADP-ribose) polymerase 1 Homo sapiens 0-28 30580238-7 2019 AR antagonists MDV3100 enhances the PARP1 inhibitor Olaparib-mediated decrease of cell viability in AR-positive/BRCA1-inactivated cells in vitro and in vivo. olaparib 52-60 poly(ADP-ribose) polymerase 1 Homo sapiens 36-41 30663191-2 2019 Olaparib, the first-in-class PARP inhibitor, has shown remarkable clinical benefits in the treatment of BRCA-mutated ovarian or breast cancer. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 29-33 30684797-7 2019 There are currently three FDA approved PARP1 inhibitors namely Olaparib, Rucaparib and Niraparib in the market while Veliparib and Talazoparib are in the late stage of clinical development. olaparib 63-71 poly(ADP-ribose) polymerase 1 Homo sapiens 39-44 31538027-4 2019 The recent approval of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in HER2-negative, metastatic breast cancer provides an additional treatment option for patients with a gBRCAm. olaparib 23-31 poly(ADP-ribose) polymerase 1 Homo sapiens 35-63 31538027-4 2019 The recent approval of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in HER2-negative, metastatic breast cancer provides an additional treatment option for patients with a gBRCAm. olaparib 23-31 poly(ADP-ribose) polymerase 1 Homo sapiens 65-69 30333088-6 2019 Three different PARP inhibitors (olaparib, niraparib, and rucaparib) have been approved for the treatment of ovarian cancer and one (olaparib) for breast cancer harboring BRCA mutations. olaparib 33-41 poly(ADP-ribose) polymerase 1 Homo sapiens 16-20 30333088-6 2019 Three different PARP inhibitors (olaparib, niraparib, and rucaparib) have been approved for the treatment of ovarian cancer and one (olaparib) for breast cancer harboring BRCA mutations. olaparib 133-141 poly(ADP-ribose) polymerase 1 Homo sapiens 16-20 30565790-3 2019 Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, olaparib is useful for patients with recurrent EOC or PPC. olaparib 65-73 poly(ADP-ribose) polymerase 1 Homo sapiens 48-52 30559256-5 2019 Simultaneous treatment with the NF-kappaB inhibitor BMS-345541 and the PARP1 inhibitor olaparib resulted in robust killing of AML cells. olaparib 87-95 poly(ADP-ribose) polymerase 1 Homo sapiens 71-76 30520109-7 2019 For sensitivity to DNA repair intervention, tumors slices from BRCA2 wild-type and mutated PDXs were treated with the poly (ADP-ribose) polymerase-1 inhibitor olaparib. olaparib 159-167 poly(ADP-ribose) polymerase 1 Homo sapiens 118-148 30824778-4 2019 PARP1 is a DNA repair gene critical for chemotherapy response and for which FDA-approved inhibitors are clinically available (olaparib). olaparib 126-134 poly(ADP-ribose) polymerase 1 Homo sapiens 0-5 30824778-5 2019 We demonstrated that two PARP inhibitors (ABT-888 and olaparib) make SNP carrier cancer cells of various histologic subtypes more sensitive to alkylating agents, but they have no effect in wild-type cells. olaparib 54-62 poly(ADP-ribose) polymerase 1 Homo sapiens 25-29 30824778-6 2019 Furthermore, PARP1 inhibitors act synergistically with chemotherapy in SNP carrier cells (especially in ovarian cancer for which olaparib is FDA-approved), but they are additive at best in wild-type cancer cells. olaparib 129-137 poly(ADP-ribose) polymerase 1 Homo sapiens 13-18 30954761-1 2019 The poly-(ADP-ribose) polymerase (PARP) inhibitor (PARPi) olaparib was the first licenced cancer drug that targeted an inherited form of cancer, namely ovarian cancers caused by germline BRCA1 or BRCA2 gene mutations. olaparib 58-66 poly(ADP-ribose) polymerase 1 Homo sapiens 4-32 30954761-1 2019 The poly-(ADP-ribose) polymerase (PARP) inhibitor (PARPi) olaparib was the first licenced cancer drug that targeted an inherited form of cancer, namely ovarian cancers caused by germline BRCA1 or BRCA2 gene mutations. olaparib 58-66 poly(ADP-ribose) polymerase 1 Homo sapiens 34-38 30583807-1 2019 Olaparib is the first poly(ADP-ribose) polymerase (PARP) inhibitor approved by the Food and Drug Administration (FSA), with three approvals in two different cancer types. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 22-49 30583807-1 2019 Olaparib is the first poly(ADP-ribose) polymerase (PARP) inhibitor approved by the Food and Drug Administration (FSA), with three approvals in two different cancer types. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 51-55 30719229-12 2019 Combination treatment with PARP1 inhibitor olaparib, whose sensitivity was enhanced by BRCA 1/2 deficiency, showed synergistic effects in CRC cells. olaparib 43-51 poly(ADP-ribose) polymerase 1 Homo sapiens 27-32 30297533-7 2018 The PARP1 inhibitor olaparib was synthetically lethal in XRCC1-deficient DCIS and invasive breast cancer cells. olaparib 20-28 poly(ADP-ribose) polymerase 1 Homo sapiens 4-9 30518089-2 2018 Clinical studies have confirmed the validity of the synthetic lethality approach and four different PARP inhibitors (PARPi; olaparib, rucaparib, niraparib and talazoparib) have been approved as monotherapies for BRCA-mutated or platinum-sensitive recurrent ovarian cancer and/or for BRCA-mutated HER2-negative metastatic breast cancer. olaparib 124-132 poly(ADP-ribose) polymerase 1 Homo sapiens 100-104 30076413-7 2018 NSCLC RANBP9 KO cells were also more sensitive than control cells to the PARP inhibitor olaparib alone and in combination with cisplatin, due to defective ATM-dependent and hyper-activated PARP-dependent DDR. olaparib 88-96 poly(ADP-ribose) polymerase 1 Homo sapiens 73-77 30076413-7 2018 NSCLC RANBP9 KO cells were also more sensitive than control cells to the PARP inhibitor olaparib alone and in combination with cisplatin, due to defective ATM-dependent and hyper-activated PARP-dependent DDR. olaparib 88-96 poly(ADP-ribose) polymerase 1 Homo sapiens 189-193 30456461-1 2018 Olaparib (Lynparza ), a first-in-class poly (ADP-ribose) polymerase (PARP) inhibitor, has recently been approved in a new tablet formulation as maintenance treatment for recurrent high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial response to platinum-based chemotherapy. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 39-67 30456461-1 2018 Olaparib (Lynparza ), a first-in-class poly (ADP-ribose) polymerase (PARP) inhibitor, has recently been approved in a new tablet formulation as maintenance treatment for recurrent high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial response to platinum-based chemotherapy. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 69-73 30456461-1 2018 Olaparib (Lynparza ), a first-in-class poly (ADP-ribose) polymerase (PARP) inhibitor, has recently been approved in a new tablet formulation as maintenance treatment for recurrent high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial response to platinum-based chemotherapy. olaparib 10-18 poly(ADP-ribose) polymerase 1 Homo sapiens 39-67 30456461-1 2018 Olaparib (Lynparza ), a first-in-class poly (ADP-ribose) polymerase (PARP) inhibitor, has recently been approved in a new tablet formulation as maintenance treatment for recurrent high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial response to platinum-based chemotherapy. olaparib 10-18 poly(ADP-ribose) polymerase 1 Homo sapiens 69-73 30446872-1 2018 BACKGROUND: Although olaparib, the first poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor approved, has been used in routine clinical practice for over three years, little has been published on its uptake, utilization patterns, and clinical outcomes. olaparib 21-29 poly(ADP-ribose) polymerase 1 Homo sapiens 95-99 30989461-2 2019 Olaparib is proved to have anticancer effect by inhibiting DNA repairing protein poly (ADP-ribose) polymerase (PARP). olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 81-109 30989461-2 2019 Olaparib is proved to have anticancer effect by inhibiting DNA repairing protein poly (ADP-ribose) polymerase (PARP). olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 111-115 30989461-9 2019 Moreover, olaparib treatment not only inhibits PARP1, but also reduces the expression of APE1 in both mRNA and protein levels. olaparib 10-18 poly(ADP-ribose) polymerase 1 Homo sapiens 47-52 30466996-12 2018 Docking experiment showed that AMF can stably bind to PARP-1 with a comparable binding energy to olaparib. olaparib 97-105 poly(ADP-ribose) polymerase 1 Homo sapiens 54-60 30395643-5 2018 These LMP1-expressing cells were then treated with the PARP inhibitor olaparib and prepared for RNA sequencing. olaparib 70-78 poly(ADP-ribose) polymerase 1 Homo sapiens 55-59 29866945-6 2018 For example, the FDA-approved use of the PARP inhibitor olaparib is for ovarian or breast cancers in patients harboring a BRCA germline mutation [N Engl J Med 2012;366:1382-1392, N Eng J Med 2017;377:523-533]. olaparib 56-64 poly(ADP-ribose) polymerase 1 Homo sapiens 41-45 30324586-1 2018 INTRODUCTION: The PARP inhibitor olaparib is efficacious as monotherapy and has potential application in combination with endocrine therapy for the treatment of breast cancer. olaparib 33-41 poly(ADP-ribose) polymerase 1 Homo sapiens 18-22 30303856-11 2018 The poly ADP ribose polymerase inhibitor, olaparib, added to second-line paclitaxel in advanced gastric cancer failed to improve overall survival compared with paclitaxel alone. olaparib 42-50 poly(ADP-ribose) polymerase 1 Homo sapiens 4-30 30039287-10 2018 Olaparib which was originally described as a PARP1 and 2 inhibitor has recently been shown to be a potent PARP3 inhibitor while ME0328 is a more selective PARP3 inhibitor. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 45-56 30092674-4 2018 Olaparib is an orally active inhibitor of poly(ADP-ribose) polymerase (PARP) which has demonstrated anti-tumor activity in ovarian cancer. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 42-69 30067444-11 2018 In rhabdomyosarcoma, olaparib enhanced the formation of radiation-induced gamma-H2AX/Rad51 foci and PARP-1 cleavage, induced slightly increased expression of cleaved caspase-3 and reduced phospho-ERK expression. olaparib 21-29 poly(ADP-ribose) polymerase 1 Homo sapiens 100-106 30075398-1 2018 Olaparib (OLA) is a poly ADP ribose polymerase (PARP) enzyme inhibitor used to treat prostate, ovarian and breast cancer. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 20-46 30075398-1 2018 Olaparib (OLA) is a poly ADP ribose polymerase (PARP) enzyme inhibitor used to treat prostate, ovarian and breast cancer. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 48-52 30075398-1 2018 Olaparib (OLA) is a poly ADP ribose polymerase (PARP) enzyme inhibitor used to treat prostate, ovarian and breast cancer. olaparib 10-13 poly(ADP-ribose) polymerase 1 Homo sapiens 20-46 30075398-1 2018 Olaparib (OLA) is a poly ADP ribose polymerase (PARP) enzyme inhibitor used to treat prostate, ovarian and breast cancer. olaparib 10-13 poly(ADP-ribose) polymerase 1 Homo sapiens 48-52 29941481-0 2018 The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer. olaparib 38-46 poly(ADP-ribose) polymerase 1 Homo sapiens 23-27 29941481-3 2018 Following our development of circulating tumor cell patient-derived explants (CDX) as models that faithfully mirror patient disease, here we exploit CDX to examine new therapeutic options for SCLC.Experimental Design: We investigated the efficacy of the PARP inhibitor olaparib alone or in combination with the WEE1 kinase inhibitor AZD1775 in 10 phenotypically distinct SCLC CDX in vivo and/or ex vivo These CDX represent chemosensitive and chemorefractory disease including the first reported paired CDX generated longitudinally before treatment and upon disease progression.Results: There was a heterogeneous depth and duration of response to olaparib/AZD1775 that diminished when tested at disease progression. olaparib 269-277 poly(ADP-ribose) polymerase 1 Homo sapiens 254-258 30092674-4 2018 Olaparib is an orally active inhibitor of poly(ADP-ribose) polymerase (PARP) which has demonstrated anti-tumor activity in ovarian cancer. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 71-75 30217671-2 2018 Based on our preclinical data, we hypothesised that poly(ADP-ribose) polymerase 1 (PARP1) inhibitors might be an ideal partner of trabectedin and aimed to assess the safety, identify the recommended phase 2 dose, and explore preliminary signs of activity of trabectedin and olaparib combination treatment in patients with bone and soft-tissue sarcoma. olaparib 274-282 poly(ADP-ribose) polymerase 1 Homo sapiens 52-81 30217671-2 2018 Based on our preclinical data, we hypothesised that poly(ADP-ribose) polymerase 1 (PARP1) inhibitors might be an ideal partner of trabectedin and aimed to assess the safety, identify the recommended phase 2 dose, and explore preliminary signs of activity of trabectedin and olaparib combination treatment in patients with bone and soft-tissue sarcoma. olaparib 274-282 poly(ADP-ribose) polymerase 1 Homo sapiens 83-88 30127642-2 2018 As the first PARP inhibitor approved for the treatment of advanced BRCA-mutated ovarian cancer, olaparib has proven to be effective in the treatment of several solid tumors. olaparib 96-104 poly(ADP-ribose) polymerase 1 Homo sapiens 13-17 30157440-4 2018 Proteome-wide analysis identifies 3,090 serine ADPr sites, with 97% of acceptor sites modulating more than 2-fold upon oxidative stress, while treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib abrogates this induction. olaparib 208-216 poly(ADP-ribose) polymerase 1 Homo sapiens 162-190 30157440-4 2018 Proteome-wide analysis identifies 3,090 serine ADPr sites, with 97% of acceptor sites modulating more than 2-fold upon oxidative stress, while treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib abrogates this induction. olaparib 208-216 poly(ADP-ribose) polymerase 1 Homo sapiens 192-196 30271179-1 2018 Olaparib is an oral poly ADP-ribose polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2)-associated breast and ovarian cancers. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 20-46 30198004-2 2018 AZD2461, a congener of FDA approved olaparib, is a potent PARPi with high affinity for PARP-1 and nonsubstrate for P-glycoprotein (P-gp), an attractive characteristic for cancer therapeutics. olaparib 36-44 poly(ADP-ribose) polymerase 1 Homo sapiens 87-93 30116283-3 2018 The small-molecule NAD+ mimetics, olaparib, niraparib, rucaparib, veliparib, and talazoparib, inhibit the catalytic activity of PARP-1 and PARP-2 and are currently being studied in later-stage clinical trials. olaparib 34-42 poly(ADP-ribose) polymerase 1 Homo sapiens 128-134 28643365-0 2018 A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. olaparib 51-59 poly(ADP-ribose) polymerase 1 Homo sapiens 36-40 29570891-10 2018 Sensitivity to olaparib was seen in the Merkel cell carcinoma line with highest PARP1 expression. olaparib 15-23 poly(ADP-ribose) polymerase 1 Homo sapiens 80-85 29937315-1 2018 A 42-year-old woman with a germline BRCA2 mutation and recurrent low-grade endometrioid endometrial adenocarcinoma experienced clinical and radiographic response to the poly (ADP ribose) polymerase (PARP) inhibitor, olaparib. olaparib 216-224 poly(ADP-ribose) polymerase 1 Homo sapiens 199-203 29954730-1 2018 Recent findings from a phase II trial suggest that combining the antiandrogen abiraterone and the PARP inhibitor olaparib significantly improves progression-free survival among patients with metastatic castration-resistant prostate cancer, regardless of their homologous recombination repair-mutation status. olaparib 113-121 poly(ADP-ribose) polymerase 1 Homo sapiens 98-102 30012171-1 2018 BACKGROUND: The poly ADP ribose polymerase (PARP) inhibitor olaparib has been approved for treating prostate cancer (PCa) with BRCA mutations, and veliparib, another PARP inhibitor, is being tested in clinical trials. olaparib 60-68 poly(ADP-ribose) polymerase 1 Homo sapiens 16-42 30012171-1 2018 BACKGROUND: The poly ADP ribose polymerase (PARP) inhibitor olaparib has been approved for treating prostate cancer (PCa) with BRCA mutations, and veliparib, another PARP inhibitor, is being tested in clinical trials. olaparib 60-68 poly(ADP-ribose) polymerase 1 Homo sapiens 44-48 29992957-5 2018 The approach illuminates cellular mechanisms of drug synergism and, through a targeted multivariate screen, could identify a functional interaction between PARPi olaparib and NEDD8/SCF inhibition, which we show is dependent on PARP1 and linked to PARP1 trapping. olaparib 162-170 poly(ADP-ribose) polymerase 1 Homo sapiens 227-232 30080919-3 2018 Two PARP inhibitors, olaparib and rucaparib, have been approved by the US Food and Drug Administration (FDA) for the treatment of recurrent, BRCA-associated ovarian cancer. olaparib 21-29 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 30023007-3 2018 Drugs targeting DDR pathways taking advantage of clinical synthetic lethality have already shown therapeutic benefit - for example, the PARP inhibitor olaparib has shown benefit in BRCA-mutant ovarian and breast cancer. olaparib 151-159 poly(ADP-ribose) polymerase 1 Homo sapiens 136-140 29992957-5 2018 The approach illuminates cellular mechanisms of drug synergism and, through a targeted multivariate screen, could identify a functional interaction between PARPi olaparib and NEDD8/SCF inhibition, which we show is dependent on PARP1 and linked to PARP1 trapping. olaparib 162-170 poly(ADP-ribose) polymerase 1 Homo sapiens 247-252 30067621-3 2018 PARP inhibitors that have undergone clinical investigation in the treatment of breast cancer include olaparib, talazoparib, veliparib, niraparib, and rucaparib. olaparib 101-109 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 29750868-3 2018 The PARP inhibitor olaparib, approved as a monotherapy for patients with a germline BRCA mutation, has shown promising results in preclinical studies when combined with DNA damaging agents, such as carboplatin. olaparib 19-27 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 29867226-6 2018 Furthermore, phase II/III studies of single-agent PARP inhibitors (PARPi) have shown encouraging progression-free survival results in patients with BRCA1/2-mutated breast cancer, which led to the recent approval of olaparib, the first PARPi to be approved in breast cancer. olaparib 215-223 poly(ADP-ribose) polymerase 1 Homo sapiens 50-54 29870916-2 2018 Since the initial approval of olaparib, a mostly investigated PARP inhibitor (PARPi), the clinical development of PARPi in breast cancer treatment has been a major emphasis. olaparib 30-38 poly(ADP-ribose) polymerase 1 Homo sapiens 62-66 30067621-5 2018 In 2018, olaparib became the first oral PARP inhibitor to receive approval in the United States for the treatment of advanced BRCA-mutated breast cancer, an approval that represents a major change in the treatment paradigm for this subtype of breast cancer. olaparib 9-17 poly(ADP-ribose) polymerase 1 Homo sapiens 40-44 29973717-3 2018 To address the nature of such lesions and the cellular consequences of PARP trapping, we undertook three CRISPR (clustered regularly interspersed palindromic repeats) screens to identify genes and pathways that mediate cellular resistance to olaparib, a clinically approved PARP inhibitor1. olaparib 242-250 poly(ADP-ribose) polymerase 1 Homo sapiens 71-75 29973717-3 2018 To address the nature of such lesions and the cellular consequences of PARP trapping, we undertook three CRISPR (clustered regularly interspersed palindromic repeats) screens to identify genes and pathways that mediate cellular resistance to olaparib, a clinically approved PARP inhibitor1. olaparib 242-250 poly(ADP-ribose) polymerase 1 Homo sapiens 274-278 29765171-2 2018 Second, patients cannot benefit from targeted therapy, except for those with BRCA1/2 mutations, for whom poly (ADP-ribose) polymerase (PARP) inhibition therapy using olaparib has recently been approved. olaparib 166-174 poly(ADP-ribose) polymerase 1 Homo sapiens 105-133 29767248-0 2018 Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency. olaparib 65-73 poly(ADP-ribose) polymerase 1 Homo sapiens 50-54 29767248-7 2018 Taken together, these data suggest that the combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib may be a promising therapeutic regimen for the treatment of gastric cancer, and ARID1A deficiency could serve as a potential predictive therapeutic biomarker. olaparib 109-117 poly(ADP-ribose) polymerase 1 Homo sapiens 94-98 29954437-4 2018 Herein, we investigated whether a WEE1/ Polo-like kinase 1 (PLK1) dual inhibitor AZD1775 reported to impair HR augmented anticancer activity of a PARP inhibitor olaparib and its underlying mechanisms. olaparib 161-169 poly(ADP-ribose) polymerase 1 Homo sapiens 146-150 29954437-11 2018 CONCLUSIONS: PARP inhibitor olaparib combined with WEE1/PLK1 dual inhibitor AZD1775 elicited potentiated anticancer activity through disrupting DDR signaling and the DNA damage checkpoint. olaparib 28-36 poly(ADP-ribose) polymerase 1 Homo sapiens 13-17 29750420-3 2018 We review key trials that have led to the approval of three PARP inhibitors-olaparib, niraparib and rucaparib-as maintenance therapy for platinum-sensitive recurrent ovarian cancer. olaparib 76-84 poly(ADP-ribose) polymerase 1 Homo sapiens 60-64 29526801-8 2018 Collectively, our findings identify BCL2 status in PCa as a putative predictor of (i) radiotherapy response and (ii) response to treatment with PARP inhibitor olaparib as a radiosensitizing agent. olaparib 159-167 poly(ADP-ribose) polymerase 1 Homo sapiens 144-148 29765171-2 2018 Second, patients cannot benefit from targeted therapy, except for those with BRCA1/2 mutations, for whom poly (ADP-ribose) polymerase (PARP) inhibition therapy using olaparib has recently been approved. olaparib 166-174 poly(ADP-ribose) polymerase 1 Homo sapiens 135-139 29881257-5 2018 As a result of two positive clinical trials, Olaparib was approved in 2014 by U.S. Food and Drug Administration and European Medicines Agency as the first-in-class PARP inhibitor. olaparib 45-53 poly(ADP-ribose) polymerase 1 Homo sapiens 164-168 28657402-0 2018 In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450. olaparib 65-73 poly(ADP-ribose) polymerase 1 Homo sapiens 84-111 28657402-2 2018 In vitro studies were conducted to evaluate potential inhibitory and inductive effects of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, on cytochrome P450 (CYP) enzymes. olaparib 140-148 poly(ADP-ribose) polymerase 1 Homo sapiens 94-121 28657402-2 2018 In vitro studies were conducted to evaluate potential inhibitory and inductive effects of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, on cytochrome P450 (CYP) enzymes. olaparib 140-148 poly(ADP-ribose) polymerase 1 Homo sapiens 123-127 29855275-3 2018 The tumor presented a susceptibility to a combined chemotherapy and the PARP1-inhibitor olaparib. olaparib 88-96 poly(ADP-ribose) polymerase 1 Homo sapiens 72-77 29855275-10 2018 The treatment failure was the reason to induce an individualized therapeutic approach using combined chemotherapy of carboplatin, paclitaxel and the Poly (ADP-ribose) polymerase- (PARP)-inhibitor olaparib analogous to the treatment protocol of Oza et al. olaparib 196-204 poly(ADP-ribose) polymerase 1 Homo sapiens 149-178 29855275-10 2018 The treatment failure was the reason to induce an individualized therapeutic approach using combined chemotherapy of carboplatin, paclitaxel and the Poly (ADP-ribose) polymerase- (PARP)-inhibitor olaparib analogous to the treatment protocol of Oza et al. olaparib 196-204 poly(ADP-ribose) polymerase 1 Homo sapiens 180-184 29784019-0 2018 The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma. olaparib 19-27 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 29670134-6 2018 Importantly, we show that olaparib resistance is linked to missense mutations in the DNA binding regions of PARP1, but not in its catalytic domain. olaparib 26-34 poly(ADP-ribose) polymerase 1 Homo sapiens 108-113 29524880-8 2018 Furthermore, Iso markedly sensitized HB cells to the anti-proliferative effects of the poly ADP-ribose polymerase (PARP) inhibitor olaparib both in vivo and in vitro. olaparib 131-139 poly(ADP-ribose) polymerase 1 Homo sapiens 87-113 29524880-8 2018 Furthermore, Iso markedly sensitized HB cells to the anti-proliferative effects of the poly ADP-ribose polymerase (PARP) inhibitor olaparib both in vivo and in vitro. olaparib 131-139 poly(ADP-ribose) polymerase 1 Homo sapiens 115-119 29670134-7 2018 This provides experimental support to the concept of PARP1 trapping on DNA as the prime source of toxicity to PARP inhibitors, and points to a novel olaparib resistance mechanism with potential therapeutic implications. olaparib 149-157 poly(ADP-ribose) polymerase 1 Homo sapiens 53-58 29670134-7 2018 This provides experimental support to the concept of PARP1 trapping on DNA as the prime source of toxicity to PARP inhibitors, and points to a novel olaparib resistance mechanism with potential therapeutic implications. olaparib 149-157 poly(ADP-ribose) polymerase 1 Homo sapiens 53-57 29393407-1 2018 Poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib or rucaparib, have shown treatment efficacy in BRCA1/2-deficient tumors. olaparib 56-64 poly(ADP-ribose) polymerase 1 Homo sapiens 0-28 29774075-4 2018 About 10% of the patients who received Olaparib (PARP inhibitor) showed adverse side effects including neutropenia, thrombocytopenia and in some cases resulted in myelodysplastic syndrome, indicating that off-target effects were substantial in these patients. olaparib 39-47 poly(ADP-ribose) polymerase 1 Homo sapiens 49-53 29479816-0 2018 PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation. olaparib 15-23 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 29479816-2 2018 Olaparib, a highly potent poly(ADP-ribose) polymerase (PARP) inhibitor, has been shown to sensitize many types of tumor to radiotherapy. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 26-53 29479816-2 2018 Olaparib, a highly potent poly(ADP-ribose) polymerase (PARP) inhibitor, has been shown to sensitize many types of tumor to radiotherapy. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 55-59 29479816-10 2018 Olaparib was able to enhance the effect of radiation by inhibiting PARP1, inducing DNA lesions and apoptosis. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 67-72 29414021-0 2018 Development and validation of a high-performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells. olaparib 131-139 poly(ADP-ribose) polymerase 1 Homo sapiens 116-120 29414021-1 2018 Olaparib is a potent PARP inhibitor in clinical use for cancer therapy. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 21-25 29644451-4 2018 A single-arm phase 2 study of the PARP inhibitor olaparib demonstrated high response rates and more favorable progression-free and overall survival for men with metastatic castration-resistant prostate cancer and DNA repair defects treated with olaparib compared with men without DNA repair defects. olaparib 49-57 poly(ADP-ribose) polymerase 1 Homo sapiens 34-38 29644451-4 2018 A single-arm phase 2 study of the PARP inhibitor olaparib demonstrated high response rates and more favorable progression-free and overall survival for men with metastatic castration-resistant prostate cancer and DNA repair defects treated with olaparib compared with men without DNA repair defects. olaparib 245-253 poly(ADP-ribose) polymerase 1 Homo sapiens 34-38 29393407-1 2018 Poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib or rucaparib, have shown treatment efficacy in BRCA1/2-deficient tumors. olaparib 56-64 poly(ADP-ribose) polymerase 1 Homo sapiens 30-34 29392078-7 2018 The beneficial lifespan effect of Olaparib appeared to require both PARP-1 and TCF7L2, since treatment had no effect in hyperglycemic conditions in knock-out worm strains for either of these homologs. olaparib 34-42 poly(ADP-ribose) polymerase 1 Homo sapiens 68-74 29283581-4 2018 The present study explores the combination of a DNA damaging agent, doxorubicin (DOX), with the PARP inhibitor, olaparib (OLP), in order to achieve optimal synergy of both drugs in serous ovarian cancer. olaparib 112-120 poly(ADP-ribose) polymerase 1 Homo sapiens 96-100 29283581-4 2018 The present study explores the combination of a DNA damaging agent, doxorubicin (DOX), with the PARP inhibitor, olaparib (OLP), in order to achieve optimal synergy of both drugs in serous ovarian cancer. olaparib 122-125 poly(ADP-ribose) polymerase 1 Homo sapiens 96-100 29326071-7 2018 The effects of the clinical inhibitor olaparib on the activity of PARP1 was studied. olaparib 38-46 poly(ADP-ribose) polymerase 1 Homo sapiens 66-71 29326071-8 2018 It was shown that olaparib has no influence on the binding of PARP1 to the model DNA structures used, but it significantly inhibits the poly(ADP-ribosyl)ation of PARP1. olaparib 18-26 poly(ADP-ribose) polymerase 1 Homo sapiens 162-167 29895102-0 2018 The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others. olaparib 62-70 poly(ADP-ribose) polymerase 1 Homo sapiens 14-18 29895102-5 2018 PARP inhibitors, currently mainly including Olaparib, Niraparib, Velaparib, Rucaparib, and Talazoparib, have demonstrated promising activity in EOC treatment. olaparib 44-52 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 29902865-3 2018 We thus hypothesized that a HDACi (suberoylanilide hydroxamic acid (SAHA) or belinostat) could sensitize TNBC to the PARP inhibitor olaparib. olaparib 132-140 poly(ADP-ribose) polymerase 1 Homo sapiens 117-121 29150161-8 2018 Implemented in clinical radiotherapy combination Phase I trials, the REP-assay showed sensitive detection of PARP inhibition in patients treated with olaparib and establishes strong PARP inhibitory activities at low daily doses. olaparib 150-158 poly(ADP-ribose) polymerase 1 Homo sapiens 109-113 29150161-10 2018 This study shows the benefit and relevance of sensitive and adapted PD-assays for such combination purposes and provides proof of clinically relevant cellular PARP inhibitory activities at low daily olaparib doses. olaparib 199-207 poly(ADP-ribose) polymerase 1 Homo sapiens 159-163 29138344-4 2018 Targeting this pathway with AURKA inhibitor PHA739358 and PARP inhibitor olaparib generated therapeutic effects similar to those of gene knockdown in vitro and significantly suppressed tumor growth in both C4-2b4 and MDACC PDX144-13C subcutaneous models in vivoConclusions: Our results identify a novel MYCN-PARP-DDR pathway that is driven by N-MYC in a subset of CRPC-Adeno and in NEPC. olaparib 73-81 poly(ADP-ribose) polymerase 1 Homo sapiens 58-62 29138344-4 2018 Targeting this pathway with AURKA inhibitor PHA739358 and PARP inhibitor olaparib generated therapeutic effects similar to those of gene knockdown in vitro and significantly suppressed tumor growth in both C4-2b4 and MDACC PDX144-13C subcutaneous models in vivoConclusions: Our results identify a novel MYCN-PARP-DDR pathway that is driven by N-MYC in a subset of CRPC-Adeno and in NEPC. olaparib 73-81 poly(ADP-ribose) polymerase 1 Homo sapiens 308-312 29133592-9 2018 Taken together, these mechanistic data demonstrate that although nucleotide depletion is sufficient for radiosensitization by WEE1 inhibition alone, and inhibition of PARP catalytic activity is sufficient for radiosensitization by olaparib alone, PARP1 trapping is required for enhanced radiosensitization by the combination of WEE1 and PARP inhibitors.Implications: This study highlights DNA replication stress caused by nucleotide depletion and PARP1 trapping as an important mechanism of radiosensitization in KRAS-mutant tumors and supports further development of DNA replication as a therapeutic target. olaparib 231-239 poly(ADP-ribose) polymerase 1 Homo sapiens 167-171 29251678-1 2018 PURPOSE OF REVIEW: The recent United States Food and Drug Administration approvals of niraparib and olaparib as maintenance monotherapy for platinum-sensitive, high-grade ovarian cancers independent of BRCA status reflect a willingness to seek indications for poly-ADP-ribose polymerase (PARP) inhibitors beyond cancers with deleterious breast cancer 1 and breast cancer 2 mutations. olaparib 100-108 poly(ADP-ribose) polymerase 1 Homo sapiens 260-286 29251678-1 2018 PURPOSE OF REVIEW: The recent United States Food and Drug Administration approvals of niraparib and olaparib as maintenance monotherapy for platinum-sensitive, high-grade ovarian cancers independent of BRCA status reflect a willingness to seek indications for poly-ADP-ribose polymerase (PARP) inhibitors beyond cancers with deleterious breast cancer 1 and breast cancer 2 mutations. olaparib 100-108 poly(ADP-ribose) polymerase 1 Homo sapiens 288-292 29202431-5 2018 Key successes include that of the PARP inhibitor, olaparib, which prolonged progression-free survival in a trial of BRCA-mutated breast cancer and for which clinical approval (in this setting) appears imminent. olaparib 50-58 poly(ADP-ribose) polymerase 1 Homo sapiens 34-38 29327913-6 2018 Indeed, three PARP1 inhibitors (Olaparib, Rucaparib, and Niraparib) have recently been approved by the Food and Drug Administration for the treatment of ovarian cancer. olaparib 32-40 poly(ADP-ribose) polymerase 1 Homo sapiens 14-19 28806493-1 2018 BACKGROUND AND PURPOSE: Olaparib, rucaparib and niraparib, potent inhibitors of poly(ADP-ribose) polymerase (PARP) are approved as anti-cancer drugs in humans. olaparib 24-32 poly(ADP-ribose) polymerase 1 Homo sapiens 80-107 28806493-1 2018 BACKGROUND AND PURPOSE: Olaparib, rucaparib and niraparib, potent inhibitors of poly(ADP-ribose) polymerase (PARP) are approved as anti-cancer drugs in humans. olaparib 24-32 poly(ADP-ribose) polymerase 1 Homo sapiens 109-113 30024813-3 2018 In multiple mammary and ovarian cancer lines SRA737 synergized with the PARP1 inhibitors olaparib and niraparib to cause cell death. olaparib 89-97 poly(ADP-ribose) polymerase 1 Homo sapiens 72-77 29434894-3 2018 Olaparib was used to suppress the expression level of PARP-1 in PanC-1 cells. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 54-60 28213892-1 2018 The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. olaparib 55-63 poly(ADP-ribose) polymerase 1 Homo sapiens 40-44 31501807-2 2018 The PARP inhibitor (PARPi) olaparib received FDA breakthrough designation for treatment of metastatic castration-resistant prostate cancers (CRPC) carrying mutations in BRCA1/2 or ATM genes. olaparib 27-35 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 30595755-5 2018 The PARP inhibitor olaparib plus abiraterone provided a significant benefit in radiological progression-free survival compared with abiraterone alone, independent of homologous recombination repair (HRR) mutation status. olaparib 19-27 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 28790064-5 2017 Supporting this possibility, we found that the PARP inhibitor olaparib or ATR inhibitors reduced the viability of PDAC cells in vitro and in vivo associated with a genotype-selective increase in apoptosis. olaparib 62-70 poly(ADP-ribose) polymerase 1 Homo sapiens 47-51 30069770-1 2018 Olaparib (Lynparza [AstraZeneca, Cambridge, UK], formerly referred to as AZD2281 or KU0059436) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 106-133 30069770-1 2018 Olaparib (Lynparza [AstraZeneca, Cambridge, UK], formerly referred to as AZD2281 or KU0059436) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 135-139 30069770-1 2018 Olaparib (Lynparza [AstraZeneca, Cambridge, UK], formerly referred to as AZD2281 or KU0059436) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor. olaparib 73-80 poly(ADP-ribose) polymerase 1 Homo sapiens 106-133 30069770-1 2018 Olaparib (Lynparza [AstraZeneca, Cambridge, UK], formerly referred to as AZD2281 or KU0059436) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor. olaparib 73-80 poly(ADP-ribose) polymerase 1 Homo sapiens 135-139 30069770-1 2018 Olaparib (Lynparza [AstraZeneca, Cambridge, UK], formerly referred to as AZD2281 or KU0059436) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor. olaparib 84-93 poly(ADP-ribose) polymerase 1 Homo sapiens 106-133 30069770-1 2018 Olaparib (Lynparza [AstraZeneca, Cambridge, UK], formerly referred to as AZD2281 or KU0059436) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor. olaparib 84-93 poly(ADP-ribose) polymerase 1 Homo sapiens 135-139 30362859-12 2018 Finally, we demonstrated the value of combined treatments with luteolin and olaparib (PARP inhibitor) or ionizing radiation (IR). olaparib 76-84 poly(ADP-ribose) polymerase 1 Homo sapiens 86-90 29042365-3 2017 We show here that cell lines expressing JAK2(V617F), MPL(W515L), or CALR(del52) accumulated reactive oxygen species-induced DNA double-strand breaks (DSBs) and were modestly sensitive to poly-ADP-ribose polymerase (PARP) inhibitors olaparib and BMN673. olaparib 232-240 poly(ADP-ribose) polymerase 1 Homo sapiens 187-213 28394191-0 2017 The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells. olaparib 19-27 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 28394191-2 2017 To further improve the efficacy of [Gem + Bu + Mel], we added poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Ola). olaparib 107-115 poly(ADP-ribose) polymerase 1 Homo sapiens 91-95 29262611-5 2017 PARP1 and PARP2 depletion suppressed the phenotype while PARP2 overexpression enhanced it, suggesting that olaparib-bound PARP1 and PARP2 rather than the lack of catalytic activity causes this phenotype. olaparib 107-115 poly(ADP-ribose) polymerase 1 Homo sapiens 122-127 29262611-6 2017 Olaparib-induced mitotic chromatid scattering was observed in various cancer cell lines with increased protein levels of PARP1 and PARP2, but not in non-cancer or cancer cell lines that expressed lower levels of PARP1 or PARP2. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 121-126 29262611-6 2017 Olaparib-induced mitotic chromatid scattering was observed in various cancer cell lines with increased protein levels of PARP1 and PARP2, but not in non-cancer or cancer cell lines that expressed lower levels of PARP1 or PARP2. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 212-217 29262611-7 2017 Interestingly, the sister chromatid scattering phenotype occurred only when olaparib was added during the S-phase preceding mitosis, suggesting that PARP1 and PARP2 entrapment at replication forks impairs sister chromatid cohesion. olaparib 76-84 poly(ADP-ribose) polymerase 1 Homo sapiens 149-154 29254481-11 2017 This response also resulted in synthetic lethality to the PARP inhibitor olaparib. olaparib 73-81 poly(ADP-ribose) polymerase 1 Homo sapiens 58-62 29254481-12 2017 CONCLUSIONS: This unusual DNA damage response may be a more appropriate strategy for an aggressive and rapidly growing tumour like melanoma that enables it to better survive chemotherapy, but also results in increased sensitivity of cultured melanoma cells to the PARP inhibitor olaparib. olaparib 279-287 poly(ADP-ribose) polymerase 1 Homo sapiens 264-268 29121337-8 2017 Finally, we demonstrated that PARP inhibitor olaparib did not significantly alter the rate of PARP1 dissociation from DNA, but instead resulted in more motility of DNA-bound PARP1 molecules. olaparib 45-53 poly(ADP-ribose) polymerase 1 Homo sapiens 30-34 29121337-8 2017 Finally, we demonstrated that PARP inhibitor olaparib did not significantly alter the rate of PARP1 dissociation from DNA, but instead resulted in more motility of DNA-bound PARP1 molecules. olaparib 45-53 poly(ADP-ribose) polymerase 1 Homo sapiens 174-179 29037805-0 2017 Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. olaparib 45-53 poly(ADP-ribose) polymerase 1 Homo sapiens 30-34 28830922-3 2017 We assessed PARP inhibitor olaparib in combination with other chemotherapy medications using both in vitro and in vivo models.Results: We detected that ATM haploinsufficiency and ATM allelic variants are common genetic hallmarks of 11q-loss neuroblastomas. olaparib 27-35 poly(ADP-ribose) polymerase 1 Homo sapiens 12-16 29232464-11 2017 The presence of germline or somatic BRCA mutations allows platinum-responsive patients to optimize chemotherapy efficacy and prolonging PFS by the use of olaparib (PARP inhibitor) given as maintenance therapy until progression. olaparib 154-162 poly(ADP-ribose) polymerase 1 Homo sapiens 164-168 28895177-3 2017 Olaparib, a poly(adenosine 5"-diphosphate) ribose polymerase (PARP) inhibitor, received a U.S. Food and Drug Administration breakthrough therapy designation in January 2016 for the treatment of patients with BRCA1/2 or ATM gene-mutated mCRPC based on results of a compelling phase II trial of olaparib in patients with advanced castration-resistant prostate cancer (TOPARP-A). olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 62-66 29187880-5 2017 Our previous work showed that the PARP-1 inhibitor Olaparib causes both hypersensitivity of BRCA1+/- cells following exposure to gamma radiation due to the persistence of DNA strand breaks in cells, measured by the DNA damage biomarker gamma-H2AX. olaparib 51-59 poly(ADP-ribose) polymerase 1 Homo sapiens 34-40 29187880-7 2017 In this study we exposed two normal lymphoblastoid cell lines and three heterozygous BRCA1 lymphoblastoid cell lines to the PARP-1 inhibitor Olaparib and gamma radiation and after measured BRCA1 protein expression and apoptosis levels following treatment. olaparib 141-149 poly(ADP-ribose) polymerase 1 Homo sapiens 124-130 29262611-5 2017 PARP1 and PARP2 depletion suppressed the phenotype while PARP2 overexpression enhanced it, suggesting that olaparib-bound PARP1 and PARP2 rather than the lack of catalytic activity causes this phenotype. olaparib 107-115 poly(ADP-ribose) polymerase 1 Homo sapiens 0-5 28993682-6 2017 PARP inhibitor olaparib shows significant anti-proliferative effect on CC cells and drive loss of clonogenic survival and enhanced cell death in combination with cisplatin. olaparib 15-23 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 29207595-5 2017 Moreover, we show that compromised CDK1 activity dramatically increases the efficacy of chemotherapeutic agents that kill cancer cells through perturbing DNA replication, including Olaparib, an FDA approved PARP inhibitor. olaparib 181-189 poly(ADP-ribose) polymerase 1 Homo sapiens 207-211 29129088-10 2017 PARP inhibition with olaparib, warrants further investigation, possibly in combination with other targeted therapies or immune checkpoint inhibition and in a biomarker-selected population. olaparib 21-29 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 28759753-3 2017 Using BT549 breast cancer cells, we studied the roles of PTEN in DNA repair and in sensitization of breast cancer cells to olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor. olaparib 123-131 poly(ADP-ribose) polymerase 1 Homo sapiens 135-162 28759753-3 2017 Using BT549 breast cancer cells, we studied the roles of PTEN in DNA repair and in sensitization of breast cancer cells to olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor. olaparib 123-131 poly(ADP-ribose) polymerase 1 Homo sapiens 164-168 28759753-5 2017 PTEN-deficient BT549 cells are sensitive to olaparib, which shows the synthetic lethality between PTEN and PARP1. olaparib 44-52 poly(ADP-ribose) polymerase 1 Homo sapiens 107-112 28759753-11 2017 Consequently, these results demonstrate that inhibition of Rad51 can sensitize BT549 cells with wild type PTEN to olaparib, which would contribute to using PARP inhibitors in individual treatment of breast cancer patients with PTEN variations. olaparib 114-122 poly(ADP-ribose) polymerase 1 Homo sapiens 156-160 28692916-2 2017 In this study, with the help of molecular docking, we identified a novel series of 2,3-difluorophenyl-linker analogues (15-54) derived from olaparib (1) as PARP1 inhibitors. olaparib 140-148 poly(ADP-ribose) polymerase 1 Homo sapiens 156-161 29104487-7 2017 We also found that Olaparib, a PARP1 inhibitor, affected the stability of IER5. olaparib 19-27 poly(ADP-ribose) polymerase 1 Homo sapiens 31-36 29152107-1 2017 Clinical trials are studying the benefits of combining the PARP-1 inhibitor olaparib with chemotherapy and radiotherapy treatment in a variety of cancer increasing the therapeutic ratio for olaparib may come from its ability to modify the tumour microenvironment by targeting homologous recombination-deficient, hypoxic tumour clonogens, and/or increasing tumour-associated vasodilation to improve oxygenation. olaparib 76-84 poly(ADP-ribose) polymerase 1 Homo sapiens 59-65 29152107-1 2017 Clinical trials are studying the benefits of combining the PARP-1 inhibitor olaparib with chemotherapy and radiotherapy treatment in a variety of cancer increasing the therapeutic ratio for olaparib may come from its ability to modify the tumour microenvironment by targeting homologous recombination-deficient, hypoxic tumour clonogens, and/or increasing tumour-associated vasodilation to improve oxygenation. olaparib 190-198 poly(ADP-ribose) polymerase 1 Homo sapiens 59-65 28601509-1 2017 Olaparib was the first PARP inhibitor approved by the FDA for patients with BRCA-mutated ovarian cancer. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 23-27 28754483-1 2017 BACKGROUND: Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients with platinum-sensitive, relapsed high-grade serous ovarian cancer. olaparib 12-20 poly(ADP-ribose) polymerase 1 Homo sapiens 24-51 28754483-1 2017 BACKGROUND: Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients with platinum-sensitive, relapsed high-grade serous ovarian cancer. olaparib 12-20 poly(ADP-ribose) polymerase 1 Homo sapiens 53-57 28394338-8 2017 In this context, PARP inhibitors with high "PARP trapping" potency, such as olaparib or talazoparib, yield DNA damage and cell death preceded by intense signs of replication stress. olaparib 76-84 poly(ADP-ribose) polymerase 1 Homo sapiens 17-21 28394338-8 2017 In this context, PARP inhibitors with high "PARP trapping" potency, such as olaparib or talazoparib, yield DNA damage and cell death preceded by intense signs of replication stress. olaparib 76-84 poly(ADP-ribose) polymerase 1 Homo sapiens 44-48 28583909-1 2017 In the phase III OlympiAD study, tumors shrank in about 60% of women with BRCA mutation-associated metastatic breast cancer who received the PARP inhibitor olaparib compared with 29% who received chemotherapy; the median time to disease progression was 7 months compared with 4.2 months, respectively. olaparib 156-164 poly(ADP-ribose) polymerase 1 Homo sapiens 141-145 28601509-3 2017 Herein, based on rational drug design strategy, hydroxamic acid derivatives of olaparib were constructed as dual PARP and HDAC inhibitors. olaparib 79-87 poly(ADP-ribose) polymerase 1 Homo sapiens 113-117 29152062-0 2017 Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib. olaparib 77-85 poly(ADP-ribose) polymerase 1 Homo sapiens 62-66 28508305-2 2017 The PARP inhibitor, olaparib, has been clinically applied for treating certain recurrent ovarian cancer patients with BRCA1/2 mutations in Europe and the United States. olaparib 20-28 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 28389374-11 2017 MPM cell lines expressing more than 20% of BAP1Delta are more sensitive to olaparib (a PARP1 inhibitor) cytotoxicity, and this sensitivity is enhanced when olaparib treatment is combined with GDC0980 (a dual PI3K-mTOR inhibitor), which induces downregulation of BRCA1. olaparib 75-83 poly(ADP-ribose) polymerase 1 Homo sapiens 87-92 29152062-3 2017 The combination of the PARP inhibitor olaparib and rapamycin synergistically inhibited cell proliferation in non-small cell lung cancer (NSCLC) cells, and even in triple negative breast cancer (TNBC) cells with BRCA1 mutations. olaparib 38-46 poly(ADP-ribose) polymerase 1 Homo sapiens 23-27 28490518-4 2017 In SCLC models in vitro and in vivo, LY2606368 exhibited strong single-agent efficacy, augmented the effects of cisplatin or the PARP inhibitor olaparib, and improved the response of platinum-resistant models. olaparib 144-152 poly(ADP-ribose) polymerase 1 Homo sapiens 129-133 28363999-5 2017 Moreover, Atm-deficient cells and tumors were sensitive to the PARP inhibitor olaparib. olaparib 78-86 poly(ADP-ribose) polymerase 1 Homo sapiens 63-67 28672777-0 2017 Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin. olaparib 31-39 poly(ADP-ribose) polymerase 1 Homo sapiens 16-20 28498459-10 2017 In conclusion, AG014699, BSI-201 and AZD-2281 inhibitors of PARP-1 significantly inhibited the proliferation of HepG2 cells, however, AG014699 and BSI-201 demonstrated more sensitivity, induced apoptosis and inhibited migration of the hepatocellular carcinoma cells, which may be associated with alterations of the apoptosis signaling pathway and the expression of proteins associated with migration. olaparib 37-45 poly(ADP-ribose) polymerase 1 Homo sapiens 60-66 28600955-5 2017 The PARP inhibitors PJ34, TIQ-A and Olaparib were used as pharmacological tools. olaparib 36-44 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 28487110-6 2017 Finally, we demonstrated that NF90-depleted cells are sensitive to PARP inhibitor Olaparib (AZD2281) and DNA damage agents. olaparib 82-90 poly(ADP-ribose) polymerase 1 Homo sapiens 67-71 28487110-6 2017 Finally, we demonstrated that NF90-depleted cells are sensitive to PARP inhibitor Olaparib (AZD2281) and DNA damage agents. olaparib 92-99 poly(ADP-ribose) polymerase 1 Homo sapiens 67-71 28347815-6 2017 The PARP inhibitor, olaparib, sensitized tumor cells to a different sigma-2 receptor ligand SW43-induced apoptosis and cell death in human triple negative cell line, MDA-MB-231. olaparib 20-28 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 28347815-7 2017 Olaparib inhibited PARP activity and cell proliferation, and arrested cells in G2/M phase of the cell cycle in MDA-MB-231 cells. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 19-23 28415784-7 2017 In addition, we demonstrate that HPV-positive but interestingly more so HPV-negative OPSCC display increased radiosensitivity in combination with the PARP inhibitor olaparib. olaparib 165-173 poly(ADP-ribose) polymerase 1 Homo sapiens 150-154 27958297-2 2017 Olaparib is the first PARP inhibitor to be approved by the EMA and FDA for BRCA-mutated ovarian cancer. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 22-26 28346230-8 2017 Further, we observed that the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib synergizes with GLS1 inhibitors to suppress the growth of VHL-/- cells in vitro and in vivo. olaparib 75-83 poly(ADP-ribose) polymerase 1 Homo sapiens 30-57 28346230-8 2017 Further, we observed that the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib synergizes with GLS1 inhibitors to suppress the growth of VHL-/- cells in vitro and in vivo. olaparib 75-83 poly(ADP-ribose) polymerase 1 Homo sapiens 59-63 27831000-8 2017 Among new inhibitors under investigation are poly-ADP ribose polymerase (PARP) inhibitors (veliparib and olaparib) and phosphatidylinositol 3-kinase (PI3K) inhibitor (buparlisib). olaparib 105-113 poly(ADP-ribose) polymerase 1 Homo sapiens 45-71 28182994-0 2017 ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib. olaparib 74-82 poly(ADP-ribose) polymerase 1 Homo sapiens 59-63 28923217-3 2017 We review challenges in the management of BCBM, and potential treatment strategies, including novel agents such as poly-adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitors (olaparib, veliparib), cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (palbociclib, abemaciclib), and taxane derivatives (eg, ANG1005 and TPI-287). olaparib 185-193 poly(ADP-ribose) polymerase 1 Homo sapiens 167-171 28182994-5 2017 Here, we show that the colorectal cancer cell line SK-CO-1 lacks detectable ATM protein expression and is sensitive to the PARP inhibitor olaparib. olaparib 138-146 poly(ADP-ribose) polymerase 1 Homo sapiens 123-127 27663600-1 2017 Purpose: Our preclinical studies showed that the PARP inhibitor, olaparib, prior to carboplatin attenuated carboplatin cytotoxicity. olaparib 65-73 poly(ADP-ribose) polymerase 1 Homo sapiens 49-53 27993796-0 2017 Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. olaparib 131-139 poly(ADP-ribose) polymerase 1 Homo sapiens 85-113 27993796-0 2017 Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. olaparib 131-139 poly(ADP-ribose) polymerase 1 Homo sapiens 115-119 28034751-7 2017 Our results showed that combination MLN4924 and PARP inhibitor Olaparib impaired the DNA repair process in NSCLC cells. olaparib 63-71 poly(ADP-ribose) polymerase 1 Homo sapiens 48-52 27894958-9 2017 The PARP inhibitor olaparib was also effective in an in vivo xenograft model. olaparib 19-27 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 28280302-5 2017 Olaparib is an oral PARP inhibitor that blocks DNA repair pathway and coupled with BRCA mutated-disease results in tumor cell death. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 20-24 28069876-1 2017 Olaparib is an FDA-approved PARP inhibitor (PARPi) that has shown promise as a synthetic lethal treatment approach for BRCA-mutant castration-resistant prostate cancer (CRPC) in clinical use. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 28-32 28001384-4 2017 Veliparib and niraparib are selective inhibitors of PARP1 and PARP2; olaparib, rucaparib, and talazoparib are more potent inhibitors of PARP1 but are less selective. olaparib 69-77 poly(ADP-ribose) polymerase 1 Homo sapiens 136-141 28176879-2 2017 In this study, using miRNA microarray analysis of two BRCA1-mutated TNBC cell lines, we found that miR-664b-5p expression was increased after adding a PARP inhibitor, olaparib, to a carboplatin (CBP) plus gemcitabine (GEM) therapy regimen. olaparib 167-175 poly(ADP-ribose) polymerase 1 Homo sapiens 151-155 27267353-5 2017 The European Medicines Agency granted accelerated licensing approval for the first-in-class-drug that inhibits PARP, olaparib (Lynparza , AstraZeneca). olaparib 117-125 poly(ADP-ribose) polymerase 1 Homo sapiens 111-115 27902462-8 2016 We show that PARP1 silencing or inhibition (BMN673 or Olaparib) leads to selective killing within RAD54B-deficient cells relative to controls, and is accompanied by increases in gamma-H2AX (a surrogate marker of DNA double strand breaks) and cleaved Caspase-3 (an apoptotic indicator). olaparib 54-62 poly(ADP-ribose) polymerase 1 Homo sapiens 13-18 27440269-3 2017 EXPERIMENTAL DESIGN: Efficacy of PARP inhibitors olaparib, rucaparib, and veliparib, as well as etoposide and cisplatin in SCLC cell lines, and gene expression correlates, was analyzed using public datasets. olaparib 49-57 poly(ADP-ribose) polymerase 1 Homo sapiens 33-37 28055012-4 2017 ARPE-19 cells were resistant to H2O2 when PARP-1 was depleted using siRNA or inhibited by a pharmacological inhibitor of PARP-1, olaparib. olaparib 129-137 poly(ADP-ribose) polymerase 1 Homo sapiens 42-48 28055012-4 2017 ARPE-19 cells were resistant to H2O2 when PARP-1 was depleted using siRNA or inhibited by a pharmacological inhibitor of PARP-1, olaparib. olaparib 129-137 poly(ADP-ribose) polymerase 1 Homo sapiens 121-127 28695500-4 2017 Several pharmacological inhibitors of PARP moved toward clinical testing for a variety of indications, including cardioprotection and malignant tumors, and in late 2014, olaparib became the first PARP inhibitor approved for human use for the therapy of ovarian cancer. olaparib 170-178 poly(ADP-ribose) polymerase 1 Homo sapiens 38-42 28695500-4 2017 Several pharmacological inhibitors of PARP moved toward clinical testing for a variety of indications, including cardioprotection and malignant tumors, and in late 2014, olaparib became the first PARP inhibitor approved for human use for the therapy of ovarian cancer. olaparib 170-178 poly(ADP-ribose) polymerase 1 Homo sapiens 196-200 28695520-6 2017 However, most PARP-1 inhibitors, including olaparib, were developed as NAD+ analogs. olaparib 43-51 poly(ADP-ribose) polymerase 1 Homo sapiens 14-20 28082821-5 2016 Recent reports have shown that using the poly ADP ribose polymerase (PARP) inhibitor olaparib in patients with homologous repair enzyme deficiency gave positive clinical results in breast, ovarian and prostate cancers. olaparib 85-93 poly(ADP-ribose) polymerase 1 Homo sapiens 41-67 28082821-5 2016 Recent reports have shown that using the poly ADP ribose polymerase (PARP) inhibitor olaparib in patients with homologous repair enzyme deficiency gave positive clinical results in breast, ovarian and prostate cancers. olaparib 85-93 poly(ADP-ribose) polymerase 1 Homo sapiens 69-73 28117679-5 2017 The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib has been approved to treat women with defects in HR due to germline BRCA mutations. olaparib 50-58 poly(ADP-ribose) polymerase 1 Homo sapiens 4-32 28117679-5 2017 The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib has been approved to treat women with defects in HR due to germline BRCA mutations. olaparib 50-58 poly(ADP-ribose) polymerase 1 Homo sapiens 34-38 27995810-3 2017 Hence, the efficacy of PARP inhibitors in cancer therapy has been investigated and has progressed from the laboratory to clinics, with olaparib having already been approved by the US FDA for ovarian cancer treatment. olaparib 135-143 poly(ADP-ribose) polymerase 1 Homo sapiens 23-27 29250202-3 2017 In metastatic breast cancer patients harbouring BRCA germ-line mutations, the PARP(poly [ADP-ribose] polymerase)-inhibitor olaparib was superior to conventional chemotherapy defining a potential novel treatment standard in this high-risk population. olaparib 123-131 poly(ADP-ribose) polymerase 1 Homo sapiens 78-82 28033382-0 2016 Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts. olaparib 77-85 poly(ADP-ribose) polymerase 1 Homo sapiens 62-66 28004814-8 2016 Moreover, intravitreal injection of olaparib in rd1 animals diminished PARP activity and increased photoreceptor survival, confirming in vivo neuroprotection. olaparib 36-44 poly(ADP-ribose) polymerase 1 Homo sapiens 71-75 27742776-5 2016 Response to olaparib depended on a basal PARP enzymatic activity, but did not correlate with PARP1 expression. olaparib 12-20 poly(ADP-ribose) polymerase 1 Homo sapiens 41-45 27742776-0 2016 Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect. olaparib 143-151 poly(ADP-ribose) polymerase 1 Homo sapiens 128-132 27689388-6 2016 Further, while the roles of PARG and poly(ADP-ribose) polymerase (PARP) are closely intertwined, we demonstrate that the pharmacology of a PARG inhibitor differs from that observed with the more thoroughly studied PARP inhibitor olaparib. olaparib 229-237 poly(ADP-ribose) polymerase 1 Homo sapiens 214-218 27793035-3 2016 Testing tumor material for BRCA mutations is of increasing importance for therapeutic decision making as the poly ADP ribose polymerase (PARP) inhibitor, olaparib, is now available to treat patients with specific forms of ovarian cancer and BRCA mutations. olaparib 154-162 poly(ADP-ribose) polymerase 1 Homo sapiens 109-135 27793035-3 2016 Testing tumor material for BRCA mutations is of increasing importance for therapeutic decision making as the poly ADP ribose polymerase (PARP) inhibitor, olaparib, is now available to treat patients with specific forms of ovarian cancer and BRCA mutations. olaparib 154-162 poly(ADP-ribose) polymerase 1 Homo sapiens 137-141 27931843-1 2016 In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. olaparib 9-17 poly(ADP-ribose) polymerase 1 Homo sapiens 46-50 27931843-1 2016 In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. olaparib 9-17 poly(ADP-ribose) polymerase 1 Homo sapiens 52-80 27884198-5 2016 The PARP inhibitor Olaparib [AZD2281] has been approved by the FDA for use in pretreated ovarian cancer patients with defective BRCA1/2 genes, and by the EMEA for maintenance therapy in platinum sensitive ovarian cancer patients with defective BRCA1/2 genes. olaparib 19-27 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 27884198-5 2016 The PARP inhibitor Olaparib [AZD2281] has been approved by the FDA for use in pretreated ovarian cancer patients with defective BRCA1/2 genes, and by the EMEA for maintenance therapy in platinum sensitive ovarian cancer patients with defective BRCA1/2 genes. olaparib 29-36 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 27686740-0 2016 Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-kappaB interactions. olaparib 51-59 poly(ADP-ribose) polymerase 1 Homo sapiens 12-40 27736844-3 2016 Recently, olaparib was the first PARP inhibitor approved in the European Union and United States for the treatment of advanced BRCA-mutated OC. olaparib 10-18 poly(ADP-ribose) polymerase 1 Homo sapiens 33-37 27416328-4 2016 Specifically, the approval of olaparib in 2014 for the treatment of ovarian cancer with BRCA mutations validated PARP-1 as an anticancer target and established its clinical importance in cancer therapy. olaparib 30-38 poly(ADP-ribose) polymerase 1 Homo sapiens 113-119 27705909-0 2016 PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. olaparib 16-24 poly(ADP-ribose) polymerase 1 Homo sapiens 0-5 27705909-5 2016 We observed that PARP1 inhibitor olaparib sensitized melanomas with reduced expression of DNA ligase 4 (LIG4) to an alkylatimg agent dacarbazine (DTIC) treatment in vitro, while normal melanocytes remained intact. olaparib 33-41 poly(ADP-ribose) polymerase 1 Homo sapiens 17-22 27705909-9 2016 This work for the first time demonstrates the effectiveness of a combination of PARP1 inhibitor olaparib and alkylating agent DTIC for treating LIG4 deficient melanomas. olaparib 96-104 poly(ADP-ribose) polymerase 1 Homo sapiens 80-85 27736844-5 2016 Among the five key PARP inhibitors currently in clinical development, olaparib has undergone the most extensive clinical investigation. olaparib 70-78 poly(ADP-ribose) polymerase 1 Homo sapiens 19-23 27716873-6 2016 Olaparib, the first and most extensively investigated PARP inhibitor, is now licensed in Europe for maintenance treatment of patients with platinum-sensitive relapsed BRCA-mutated (germline or somatic) high-grade serous ovarian cancer who have responded to platinum-based chemotherapy. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 54-58 27745744-1 2016 PURPOSE: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with demonstrated efficacy in patients with BRCA-mutated ovarian cancer, is mediated by cytochrome P450 (CYP) enzymes (predominantly CYP3A4/5). olaparib 27-35 poly(ADP-ribose) polymerase 1 Homo sapiens 59-86 27869446-11 2016 Inhibitors of poly(ADP-ribose) polymerase (PARP) are the next generation of antitumor agents comprising olaparib which is implemented in clinical practice currently. olaparib 104-112 poly(ADP-ribose) polymerase 1 Homo sapiens 14-41 27869446-11 2016 Inhibitors of poly(ADP-ribose) polymerase (PARP) are the next generation of antitumor agents comprising olaparib which is implemented in clinical practice currently. olaparib 104-112 poly(ADP-ribose) polymerase 1 Homo sapiens 43-47 27745744-1 2016 PURPOSE: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with demonstrated efficacy in patients with BRCA-mutated ovarian cancer, is mediated by cytochrome P450 (CYP) enzymes (predominantly CYP3A4/5). olaparib 27-35 poly(ADP-ribose) polymerase 1 Homo sapiens 88-92 27673289-1 2016 Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have shown clinical activity in epithelial ovarian cancer, leading both the US Food and Drug Administration (FDA) and the European Medicines Agency to approve olaparib for tumors characterized by BRCA1 and BRCA2 mutations. olaparib 223-231 poly(ADP-ribose) polymerase 1 Homo sapiens 47-51 27425251-3 2016 We have demonstrated that the PARP inhibitor (PARPi) AZD2281 is also an effective radiosensitizer for carbon-ion radiation; thus, we speculated that the PARPi could be applied to a wide therapeutic range of linear energy transfer (LET) radiation as a radiosensitizer. olaparib 53-60 poly(ADP-ribose) polymerase 1 Homo sapiens 30-34 27673289-4 2016 In addition to olaparib, a number of other PARP inhibitors are in clinical development. olaparib 15-23 poly(ADP-ribose) polymerase 1 Homo sapiens 43-47 27426307-3 2016 The aim of this study was to evaluate the therapeutic effect of PI3K inhibitor BKM120 and PARP inhibitor Olaparib on ovarian cancer cell lines bearing wild-type PIK3CA genes. olaparib 105-113 poly(ADP-ribose) polymerase 1 Homo sapiens 90-94 27426307-10 2016 CONCLUSIONS: The combined use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib may be effective in ovarian cancers with a broader spectrum of cancer-associated genetic alterations but not limited to those with mutant PIK3CA or BRCA genes. olaparib 74-82 poly(ADP-ribose) polymerase 1 Homo sapiens 59-63 27426307-4 2016 METHODS: We exposed three wild-type PIK3CA ovarian cancer cell lines to a PI3K inhibitor BKM120 and/or a PARP inhibitor Olaparib. olaparib 120-128 poly(ADP-ribose) polymerase 1 Homo sapiens 105-109 27487106-0 2016 The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib. olaparib 105-113 poly(ADP-ribose) polymerase 1 Homo sapiens 61-65 27515310-5 2016 Therefore, our purpose was to determine whether the more specific PARP-1 inhibitors rucaparib and olaparib enhanced the efficacy of X-radiation or (131)I-MIBG. olaparib 98-106 poly(ADP-ribose) polymerase 1 Homo sapiens 66-72 27515310-10 2016 Rucaparib and olaparib were equally effective inhibitors of PARP-1 activity. olaparib 14-22 poly(ADP-ribose) polymerase 1 Homo sapiens 60-66 27037296-1 2016 The significant activity of poly(ADP-ribose)polymerase (PARP) inhibitors in the treatment of germline BRCA mutation-associated ovarian cancer, which represents ~15% of HGS cases, has recently led to European Medicines Agency and food and drug administration approval of olaparib. olaparib 270-278 poly(ADP-ribose) polymerase 1 Homo sapiens 28-54 27037296-1 2016 The significant activity of poly(ADP-ribose)polymerase (PARP) inhibitors in the treatment of germline BRCA mutation-associated ovarian cancer, which represents ~15% of HGS cases, has recently led to European Medicines Agency and food and drug administration approval of olaparib. olaparib 270-278 poly(ADP-ribose) polymerase 1 Homo sapiens 56-60 26979391-7 2016 MPN samples showed increased sensitivity to the PARP inhibitors veliparib and olaparib compared with normal myeloid progenitors. olaparib 78-86 poly(ADP-ribose) polymerase 1 Homo sapiens 48-52 27487106-5 2016 Olaparib is the best-studied PARP inhibitor to date, and a number of phase 3 trials with this agent are underway. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 29-33 27075016-1 2016 Background Olaparib is an orally available inhibitor of PARP-1. olaparib 11-19 poly(ADP-ribose) polymerase 1 Homo sapiens 56-62 27385701-2 2016 SUMMARY: Olaparib (Lynparza, AstraZeneca) is an oral inhibitor of poly(ADP-ribose) polymerase (PARP) proteins that play a key role in DNA repair and genomic stability. olaparib 9-17 poly(ADP-ribose) polymerase 1 Homo sapiens 95-99 27570553-0 2016 Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib. olaparib 76-84 poly(ADP-ribose) polymerase 1 Homo sapiens 61-65 27570553-8 2016 Therefore, we used the PARP-1 inhibitor Olaparib to increase the number of cytotoxic DSBs. olaparib 40-48 poly(ADP-ribose) polymerase 1 Homo sapiens 23-29 27385701-2 2016 SUMMARY: Olaparib (Lynparza, AstraZeneca) is an oral inhibitor of poly(ADP-ribose) polymerase (PARP) proteins that play a key role in DNA repair and genomic stability. olaparib 9-17 poly(ADP-ribose) polymerase 1 Homo sapiens 66-93 27256873-2 2016 Olaparib is the first of a new class of anticancer therapies, poly (ADP-ribose) polymerase (PARP) inhibitors that target tumors that have deficits in homologous recombination repair (such as BRCA mutations) by a process known as synthetic lethality. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 62-90 27256873-2 2016 Olaparib is the first of a new class of anticancer therapies, poly (ADP-ribose) polymerase (PARP) inhibitors that target tumors that have deficits in homologous recombination repair (such as BRCA mutations) by a process known as synthetic lethality. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 92-96 27385701-4 2016 In patients with BRCA-mutated cancers, olaparib blocks vital PARP-mediated tumor cell DNA repair mechanisms, leading to "synthetic lethality" and selective tumor cell death. olaparib 39-47 poly(ADP-ribose) polymerase 1 Homo sapiens 61-65 27385701-9 2016 CONCLUSION: Olaparib is a novel PARP inhibitor that is efficacious and well tolerated in patients with BRCA-mutated advanced ovarian cancers who have received three or more lines of prior treatment. olaparib 12-20 poly(ADP-ribose) polymerase 1 Homo sapiens 32-36 27336789-7 2016 Mesenchymal progenitor cells (MPCs) transformed with the signature EWS-FLI1 translocation, the hallmark of Ewing"s sarcoma family tumors, exhibited increased sensitivity to the PARP inhibitor olaparib as compared to MPCs transformed with a different translocation (Figure 4E). olaparib 192-200 poly(ADP-ribose) polymerase 1 Homo sapiens 177-181 26975633-0 2016 APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines. olaparib 48-55 poly(ADP-ribose) polymerase 1 Homo sapiens 75-79 27062051-1 2016 BACKGROUND: Maintenance treatment with the oral poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor olaparib (Lynparza) in Study 19 (study number, D0810C00019; ClinicalTrials.gov identifier, NCT00753545) significantly improved progression-free survival in comparison with a placebo for patients with platinum-sensitive, relapsed serous ovarian cancer with a BRCA1/2 mutation (BRCAm), but an interim analysis revealed no statistically significant overall survival (OS) benefit. olaparib 111-119 poly(ADP-ribose) polymerase 1 Homo sapiens 48-93 27062051-1 2016 BACKGROUND: Maintenance treatment with the oral poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor olaparib (Lynparza) in Study 19 (study number, D0810C00019; ClinicalTrials.gov identifier, NCT00753545) significantly improved progression-free survival in comparison with a placebo for patients with platinum-sensitive, relapsed serous ovarian cancer with a BRCA1/2 mutation (BRCAm), but an interim analysis revealed no statistically significant overall survival (OS) benefit. olaparib 111-119 poly(ADP-ribose) polymerase 1 Homo sapiens 95-99 26975633-0 2016 APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines. olaparib 57-65 poly(ADP-ribose) polymerase 1 Homo sapiens 75-79 26975633-4 2016 We hypothesize that by blocking this repair with the PARP-inhibitor AZD2281 (olaparib), DNA damage would accumulate in the cell leading to massive apoptosis. olaparib 68-75 poly(ADP-ribose) polymerase 1 Homo sapiens 53-57 26975633-4 2016 We hypothesize that by blocking this repair with the PARP-inhibitor AZD2281 (olaparib), DNA damage would accumulate in the cell leading to massive apoptosis. olaparib 77-85 poly(ADP-ribose) polymerase 1 Homo sapiens 53-57 27220325-5 2016 Consistent with our cellular data, isoeugenol did not inhibit Tdp1 enzymatic activity in vitro nor it sensitized cells to the PARP1 inhibitor olaparib. olaparib 142-150 poly(ADP-ribose) polymerase 1 Homo sapiens 126-131 27020103-3 2016 Herein, we investigated the impact of hypoxia on radiosensitization by the PARP inhibitor olaparib in human NSCLC xenograft models. olaparib 90-98 poly(ADP-ribose) polymerase 1 Homo sapiens 75-79 27087632-5 2016 Comparable to rucaparib development, other PARP inhibitors, such as olaparib, niraparib, veliparib and talazoparib, are developing CDx tests for targeted therapy. olaparib 68-76 poly(ADP-ribose) polymerase 1 Homo sapiens 43-47 27169564-0 2016 An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib. olaparib 96-104 poly(ADP-ribose) polymerase 1 Homo sapiens 81-85 29879343-2 2016 The PARP inhibitor olaparib (AZD2281) can be used as a sensitizer of radiotherapy and chemotherapy in the cancer treatment. olaparib 19-27 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 29879343-2 2016 The PARP inhibitor olaparib (AZD2281) can be used as a sensitizer of radiotherapy and chemotherapy in the cancer treatment. olaparib 29-36 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 29879343-6 2016 This study suggests that olaparib is a representative of the PARP inhibitor that can enhance Taxol"s antitumor effect in the 4T1 ectopic breast tumor model, which sets the foundation for future study of the mechanism of olaparib action. olaparib 25-33 poly(ADP-ribose) polymerase 1 Homo sapiens 61-65 27141070-4 2016 DESIGN: In the last decade, olaparib, the first and most-investigated oral PARP inhibitor, has undergone phase I-III trials as a single agent, in comparison with and in addition to chemotherapy, and as a maintenance therapy following chemotherapy. olaparib 28-36 poly(ADP-ribose) polymerase 1 Homo sapiens 75-79 26980768-7 2016 This sensitized cells to the cytotoxic DNA lesion O(6)-methylguanine and caused a synthetic lethal interaction with the PARP-1 inhibitor olaparib. olaparib 137-145 poly(ADP-ribose) polymerase 1 Homo sapiens 120-126 26984416-2 2016 Demonstration of anti-cancer activity has led to the European Medicines Agency (EMA) approval of the PARP inhibitor (PARPi) olaparib as maintenance therapy in women with BRCA-mutated (BRCAm) ovarian cancer with platinum-sensitive recurrence following response to platinum therapy and the US Food and Drug Administration (US FDA) approval of olaparib in relapsed germline BRCA-mutated (gBRCAm) ovarian cancer in women who have received at least three prior chemotherapy treatments, both occurring in 2014. olaparib 124-132 poly(ADP-ribose) polymerase 1 Homo sapiens 101-105 26984416-2 2016 Demonstration of anti-cancer activity has led to the European Medicines Agency (EMA) approval of the PARP inhibitor (PARPi) olaparib as maintenance therapy in women with BRCA-mutated (BRCAm) ovarian cancer with platinum-sensitive recurrence following response to platinum therapy and the US Food and Drug Administration (US FDA) approval of olaparib in relapsed germline BRCA-mutated (gBRCAm) ovarian cancer in women who have received at least three prior chemotherapy treatments, both occurring in 2014. olaparib 341-349 poly(ADP-ribose) polymerase 1 Homo sapiens 101-105 27022037-8 2016 IMPLICATIONS FOR PRACTICE: The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib has recently received approval from the Food and Drug Administration (FDA) and European Medicines Agency (EMA), with a second agent (rucaparib) likely to be approved in the near future. olaparib 76-84 poly(ADP-ribose) polymerase 1 Homo sapiens 31-58 27022037-8 2016 IMPLICATIONS FOR PRACTICE: The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib has recently received approval from the Food and Drug Administration (FDA) and European Medicines Agency (EMA), with a second agent (rucaparib) likely to be approved in the near future. olaparib 76-84 poly(ADP-ribose) polymerase 1 Homo sapiens 60-64 27117104-8 2016 To date, only one representative of the PARP1 inhibitors, called olaparib, has been approved for anti-cancer therapy in the EU and the USA. olaparib 65-73 poly(ADP-ribose) polymerase 1 Homo sapiens 40-45 27055253-5 2016 Using reverse-phase protein array, we found the proteins most significantly upregulated following treatment with the PARP inhibitors olaparib and rucaparib were in the PI3K/mTOR pathway (p-mTOR, p-AKT, and pS6) (p<=0.02). olaparib 133-141 poly(ADP-ribose) polymerase 1 Homo sapiens 117-121 26794465-4 2016 Our data show that SAHA, an HDAC class I + II inhibitor, in combination with olaparib (PARP inhibitor): i) enhanced inhibition of GBM cell survival, ii) induced apoptosis, and iii) impaired cell cycle progression. olaparib 77-85 poly(ADP-ribose) polymerase 1 Homo sapiens 87-91 26959114-2 2016 The PARP-1 inhibitor olaparib is approved for use in BRCA-mutated ovarian cancers but BRCA2-reversion mutations lead to functional homologous recombination repair (HRR) and olaparib resistance. olaparib 21-29 poly(ADP-ribose) polymerase 1 Homo sapiens 4-10 26959114-2 2016 The PARP-1 inhibitor olaparib is approved for use in BRCA-mutated ovarian cancers but BRCA2-reversion mutations lead to functional homologous recombination repair (HRR) and olaparib resistance. olaparib 173-181 poly(ADP-ribose) polymerase 1 Homo sapiens 4-10 26931795-2 2016 Olaparib, a potent PARP1 and PARP2 inhibitor, has been shown to significantly increase progression-free survival (PFS) in women with recurrent ovarian cancer related to a germline BRCA mutation and is currently approved fourth-line treatment in these patients. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 19-24 26073085-8 2016 Intriguingly, combined inhibition of beta1 integrin and PARP using Olaparib was significantly more effective than either treatment alone in non-irradiated and irradiated HNSCC cells. olaparib 67-75 poly(ADP-ribose) polymerase 1 Homo sapiens 56-60 26694829-6 2016 In December 2014, the first-in-human PARP inhibitor olaparib was approved for ovarian cancer patients with two different clinical indications in Europe and the United States. olaparib 52-60 poly(ADP-ribose) polymerase 1 Homo sapiens 37-41 26927065-0 2016 Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo. olaparib 37-44 poly(ADP-ribose) polymerase 1 Homo sapiens 22-26 26927065-7 2016 The PARP inhibitor AZD2281 (olaparib) showed synergetic effects with cisplatin in a dose-dependent manner. olaparib 19-26 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 26927065-7 2016 The PARP inhibitor AZD2281 (olaparib) showed synergetic effects with cisplatin in a dose-dependent manner. olaparib 28-36 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 26907257-6 2016 Molecular dynamics simulations suggested that the PARP1-ZINC67913374 complex was more stable than olaparib. olaparib 98-106 poly(ADP-ribose) polymerase 1 Homo sapiens 50-55 26723501-1 2016 OBJECTIVE: The efficacy and safety of olaparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, was investigated in a subgroup of patients with germline BRCA1/2 mutated (gBRCA1/2m) advanced ovarian cancer who had received >=3 prior lines of chemotherapy. olaparib 38-46 poly(ADP-ribose) polymerase 1 Homo sapiens 56-83 26723501-1 2016 OBJECTIVE: The efficacy and safety of olaparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, was investigated in a subgroup of patients with germline BRCA1/2 mutated (gBRCA1/2m) advanced ovarian cancer who had received >=3 prior lines of chemotherapy. olaparib 38-46 poly(ADP-ribose) polymerase 1 Homo sapiens 85-89 26941449-3 2016 Olaparib, licensed for use this year, is the best-studied PARP inhibitor used for treatment of high-grade serous ovarian carcinoma (HGSC). olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 58-62 26730949-7 2016 In fact, an anti-PAR antibody was able to co-immunoprecipitate p21 and PARP-1 from extracts of MNNG-treated cells, while blocking PAR synthesis with the PARP-1 inhibitor Olaparib, drastically reduced the amount of p21 co-immunoprecipitated by a PARP-1 antibody. olaparib 170-178 poly(ADP-ribose) polymerase 1 Homo sapiens 153-159 26811421-2 2016 Here, through an unbiased small interfering RNA screen, we identified and validated TOPBP1 as a novel determinant whose loss sensitized human cells to olaparib, an inhibitor of poly(ADP-ribose) polymerase. olaparib 151-159 poly(ADP-ribose) polymerase 1 Homo sapiens 177-204 26786262-18 2016 PARP inhibitors such as olaparib are most effective in tumors associated with inability to repair DNA damage. olaparib 24-32 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 26779812-2 2016 One PARP inhibitor, olaparib (Lynparza, AstraZeneca), was recently approved by the FDA to treat ovarian cancer with mutations in BRCA genes. olaparib 20-28 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 26730949-7 2016 In fact, an anti-PAR antibody was able to co-immunoprecipitate p21 and PARP-1 from extracts of MNNG-treated cells, while blocking PAR synthesis with the PARP-1 inhibitor Olaparib, drastically reduced the amount of p21 co-immunoprecipitated by a PARP-1 antibody. olaparib 170-178 poly(ADP-ribose) polymerase 1 Homo sapiens 153-159 26577420-1 2016 BACKGROUND: Poly(ADP)-ribose polymerase (PARP) inhibitors such as olaparib can induce cell death in cancer cells with homologous recombination (HR) DNA repair deficiencies, such as BRCA1/2 mutations. olaparib 66-74 poly(ADP-ribose) polymerase 1 Homo sapiens 12-39 26344419-2 2016 Olaparib inhibits poly(ADP-ribose) polymerase, thereby blocking the repair of single-strand DNA breaks. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 18-45 26650448-5 2016 In addition, we evaluated the efficacy of the PARP inhibitor AZD2281 (Olaparib) in MPNST cell lines. olaparib 61-68 poly(ADP-ribose) polymerase 1 Homo sapiens 46-50 26650448-5 2016 In addition, we evaluated the efficacy of the PARP inhibitor AZD2281 (Olaparib) in MPNST cell lines. olaparib 70-78 poly(ADP-ribose) polymerase 1 Homo sapiens 46-50 26658963-1 2016 In the phase II TOPARP-A clinical trial, patients with metastatic castrate-resistant prostate cancer who were treated with the PARP inhibitor olaparib lived nearly three times longer without their cancer worsening if their tumors had mutations in at least one of 12 DNA repair genes. olaparib 142-150 poly(ADP-ribose) polymerase 1 Homo sapiens 18-22 26577420-1 2016 BACKGROUND: Poly(ADP)-ribose polymerase (PARP) inhibitors such as olaparib can induce cell death in cancer cells with homologous recombination (HR) DNA repair deficiencies, such as BRCA1/2 mutations. olaparib 66-74 poly(ADP-ribose) polymerase 1 Homo sapiens 41-45 26937492-1 2016 Olaparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, is the first FDA-approved drug in its class for patients with ovarian cancer, specifically in a subset of patients with BRCA mutations and prior chemotherapy treatments. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 18-45 26937492-1 2016 Olaparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, is the first FDA-approved drug in its class for patients with ovarian cancer, specifically in a subset of patients with BRCA mutations and prior chemotherapy treatments. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 47-51 26967466-2 2016 Olaparib, a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor, has demonstrated antitumor activity in women with ovarian cancer, associated with homologous recombination deficiency. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 24-51 26967466-2 2016 Olaparib, a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor, has demonstrated antitumor activity in women with ovarian cancer, associated with homologous recombination deficiency. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 53-57 26370511-3 2015 We found that inhibition of PARP catalytic activity with olaparib resulted in global gene deregulation, affecting approximately 11% of the genes expressed. olaparib 57-65 poly(ADP-ribose) polymerase 1 Homo sapiens 28-32 26540566-4 2015 PARP1 inhibition by Olaparib or PARP1 siRNA could significantly attenuate growth and colony formation of gastric cancer cells, and which were mediated through induction of G2/M cell cycle arrest but not apoptosis. olaparib 20-28 poly(ADP-ribose) polymerase 1 Homo sapiens 0-5 26646960-6 2015 The PARP inhibitor olaparib is recommended as maintenance treatment of women with platinum sensitive relapsed BRCA mutated high-grade serous EOC who have responded to platinum-based chemotherapy. olaparib 19-27 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 26669450-5 2015 Studies of olaparib, the first PARP inhibitor to be approved in Europe and the USA, in patients with recurrent ovarian cancer have demonstrated clinical efficacy with improvements in progression-free survival. olaparib 11-19 poly(ADP-ribose) polymerase 1 Homo sapiens 31-35 26669452-2 2015 This article charts over 50 years of research from the discovery of the first PARP enzyme in 1963, to the approval and licensing in 2015 of the first PARP inhibitor, olaparib (Lynparza), in the treatment of BRCA-mutated ovarian cancer. olaparib 166-174 poly(ADP-ribose) polymerase 1 Homo sapiens 150-154 26205779-0 2015 PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice. olaparib 56-64 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 26205779-2 2015 To increase the clinical significance of our studies, it is imperative to demonstrate that PARP is actually activated in human asthma, to examine whether a PARP inhibitor approved for human testing such as olaparib blocks already-established chronic asthma traits in response to house dust mite (HDM), a true human allergen, in mice and to examine whether the drug modulates human cluster of differentiation type 4 (CD4(+)) T-cell function. olaparib 206-214 poly(ADP-ribose) polymerase 1 Homo sapiens 156-160 26242220-1 2015 BACKGROUND: The oral PARP inhibitor olaparib has shown efficacy in patients with BRCA-mutated cancer. olaparib 36-44 poly(ADP-ribose) polymerase 1 Homo sapiens 21-25 26513298-1 2015 Inhibition of Poly(ADP-ribose) Polymerase1 (PARP1) impairs DNA damage repair, and early generation PARP1/2 inhibitors (olaparib, niraparib, etc.) olaparib 119-127 poly(ADP-ribose) polymerase 1 Homo sapiens 99-104 26590714-4 2015 The recent approval of olaparib (Lynparza), the poly (ADP-ribose) polymerase (PARP) inhibitor for treating tumors harboring BRCA1 or BRCA2 mutations, represents the first medicine based on this principle, exploiting an underlying cause of tumor formation that also represents an Achilles" heel. olaparib 23-31 poly(ADP-ribose) polymerase 1 Homo sapiens 48-76 26590714-4 2015 The recent approval of olaparib (Lynparza), the poly (ADP-ribose) polymerase (PARP) inhibitor for treating tumors harboring BRCA1 or BRCA2 mutations, represents the first medicine based on this principle, exploiting an underlying cause of tumor formation that also represents an Achilles" heel. olaparib 23-31 poly(ADP-ribose) polymerase 1 Homo sapiens 78-82 26543375-8 2015 RESULTS: Olaparib changed the expression of gammaH2AX and PARP1, and increased the sensitivity of CRC cells to oxaliplatin. olaparib 9-17 poly(ADP-ribose) polymerase 1 Homo sapiens 58-63 26384693-6 2015 Several phase III clinical trials are in progress for the treatment of breast and ovarian cancers with BRCA mutations and the PARP inhibitor olaparib has just been approved for advanced ovarian cancers with germline BRCA mutation. olaparib 141-149 poly(ADP-ribose) polymerase 1 Homo sapiens 126-130 26056084-0 2015 The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin. olaparib 19-27 poly(ADP-ribose) polymerase 1 Homo sapiens 4-8 26309417-3 2015 Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, capitalizes on this concept and is the first drug in its class approved for patients with ovarian cancer. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 12-39 26309417-3 2015 Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, capitalizes on this concept and is the first drug in its class approved for patients with ovarian cancer. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 41-45 26211783-8 2015 PARP inhibitors, such as olaparib, are useful in BRCA mutated cancer cells and are also used in combination with other drug to enhance their efficacy. olaparib 25-33 poly(ADP-ribose) polymerase 1 Homo sapiens 0-4 26321255-6 2015 Furthermore, depletion of H3K9me2/3, inhibition of PARP activity by olaparib, or downregulation of PARP1 or CTCF expression counteracts both recruitment to the envelope and circadian transcription. olaparib 68-76 poly(ADP-ribose) polymerase 1 Homo sapiens 51-55 26169965-1 2015 The FDA approval of the PARP inhibitor olaparib for fourth-line therapy of germline BRCA1/2-mutated ovarian cancer represents the first registered indication for this class of drugs in any disease. olaparib 39-47 poly(ADP-ribose) polymerase 1 Homo sapiens 24-28 26277432-0 2015 In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio. olaparib 39-47 poly(ADP-ribose) polymerase 1 Homo sapiens 23-27 26277432-3 2015 MATERIAL AND METHODS: We tested the PARP inhibitor AZD-2281 as a radiosensitizing agent under oxic and hypoxic conditions for clonogenic survival in vitro and in vivo using the human prostate cancer cell line, 22Rv1. olaparib 51-59 poly(ADP-ribose) polymerase 1 Homo sapiens 36-40 26277432-5 2015 RESULTS: AZD-2281 inhibited cellular PARP activity under both oxic and hypoxic conditions. olaparib 9-17 poly(ADP-ribose) polymerase 1 Homo sapiens 37-41 26422459-5 2015 Erlotinib, PD98059 and olaparib were used to inhibit EGFR, MEK1/2 and PARP1, respectively. olaparib 23-31 poly(ADP-ribose) polymerase 1 Homo sapiens 70-75 26234720-2 2015 Inhibitors of poly(ADP-ribose) polymerase such as Olaparib could represent a promising targeted therapy but their sensitivity against Multidrug Resistance proteins (MDR), which causes resistance, is not well defined. olaparib 50-58 poly(ADP-ribose) polymerase 1 Homo sapiens 14-41 26124328-1 2015 The poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib has been reported as having preferential anti-proliferative effects on breast cancer 1 (BRCA1)-deficient breast and ovarian cancer cells and was recently approved by the US Food and Drug Administration (FDA) for advanced, BRCA1-mutated ovarian cancer. olaparib 50-58 poly(ADP-ribose) polymerase 1 Homo sapiens 4-31 26281686-4 2015 Olaparib, the first-in-class PARP inhibitor, was approved for treatment of BRCA-mutated ovarian cancer in Europe and the United States in 2014. olaparib 0-8 poly(ADP-ribose) polymerase 1 Homo sapiens 29-33 26183824-8 2015 Thieno[2,3-c]isoquinolin-5-one (TIQ-A) and olaparib (AZD2281) were used as potent inhibitors of PARP. olaparib 43-51 poly(ADP-ribose) polymerase 1 Homo sapiens 96-100 26183824-8 2015 Thieno[2,3-c]isoquinolin-5-one (TIQ-A) and olaparib (AZD2281) were used as potent inhibitors of PARP. olaparib 53-60 poly(ADP-ribose) polymerase 1 Homo sapiens 96-100 26183824-11 2015 Our results show that PARP inhibition pharmacologically by TIQ-A or olaparib or by PARP-1 knockdown blocked E2-dependent growth of MCF-7 cells. olaparib 68-76 poly(ADP-ribose) polymerase 1 Homo sapiens 22-26 26124328-1 2015 The poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib has been reported as having preferential anti-proliferative effects on breast cancer 1 (BRCA1)-deficient breast and ovarian cancer cells and was recently approved by the US Food and Drug Administration (FDA) for advanced, BRCA1-mutated ovarian cancer. olaparib 50-58 poly(ADP-ribose) polymerase 1 Homo sapiens 33-37 26124641-5 2015 In the current study, we investigated the mechanisms of erlotinib used alone or in combination with olaparib (AZD2281), a potent inhibitor of PARP, in an EGFR-overexpressing ovarian tumor xenograft model. olaparib 100-108 poly(ADP-ribose) polymerase 1 Homo sapiens 142-146 26124641-5 2015 In the current study, we investigated the mechanisms of erlotinib used alone or in combination with olaparib (AZD2281), a potent inhibitor of PARP, in an EGFR-overexpressing ovarian tumor xenograft model. olaparib 110-117 poly(ADP-ribose) polymerase 1 Homo sapiens 142-146 26048134-1 2015 BACKGROUND: The oral, potent poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, is well tolerated at doses of <=400 mg twice daily (BID) (administered as capsules), and has shown efficacy in patients with advanced BRCA-mutated ovarian and breast cancer. olaparib 75-83 poly(ADP-ribose) polymerase 1 Homo sapiens 29-56 26048134-1 2015 BACKGROUND: The oral, potent poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, is well tolerated at doses of <=400 mg twice daily (BID) (administered as capsules), and has shown efficacy in patients with advanced BRCA-mutated ovarian and breast cancer. olaparib 75-83 poly(ADP-ribose) polymerase 1 Homo sapiens 58-62 25904654-1 2015 Data from the phase II TOPARP-A clinical trial indicate that men with metastatic castration-resistant prostate cancer are more likely to respond to the PARP inhibitor olaparib if they have mutations in DNA damage repair genes. olaparib 167-175 poly(ADP-ribose) polymerase 1 Homo sapiens 25-29 25883215-1 2015 Based on a series of basic, preclinical and clinical studies, the Poly (ADP-ribose) Polymerase 1 (PARP1) inhibitor, olaparib, has recently been approved for use in ovarian cancer patients with BRCA1 or BRCA2 mutations. olaparib 116-124 poly(ADP-ribose) polymerase 1 Homo sapiens 66-96 25883215-1 2015 Based on a series of basic, preclinical and clinical studies, the Poly (ADP-ribose) Polymerase 1 (PARP1) inhibitor, olaparib, has recently been approved for use in ovarian cancer patients with BRCA1 or BRCA2 mutations. olaparib 116-124 poly(ADP-ribose) polymerase 1 Homo sapiens 98-103 25883215-2 2015 By identifying novel predictive biomarkers of tumour cell sensitivity to olaparib, it is possible that the utility of PARP inhibitors could be extended beyond this patient subgroup. olaparib 73-81 poly(ADP-ribose) polymerase 1 Homo sapiens 118-122 25767076-11 2015 PARP-1 inhibitor, olaparib, could significantly block oxaliplatin-induced cell death, thus confirming that PARP-1 activation is mainly responsible for the cytotoxicity of oxaliplatin. olaparib 18-26 poly(ADP-ribose) polymerase 1 Homo sapiens 0-6 25767076-11 2015 PARP-1 inhibitor, olaparib, could significantly block oxaliplatin-induced cell death, thus confirming that PARP-1 activation is mainly responsible for the cytotoxicity of oxaliplatin. olaparib 18-26 poly(ADP-ribose) polymerase 1 Homo sapiens 107-113